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Zusammenfassung 
Pannexine (Panx) sind eine Proteinfamilie mit drei Mitgliedern, i.e. Panx1, Panx2 und Panx3. Auf Gen-
Ebene zeigen die Pannexine Sequenzhomologie zu den Invertebraten Gap Junction Proteinen, den 
Innexinen. Im Gegensatz dazu weisen die Proteine eine vergleichbare Struktur- und Membran-
Topologie wie die Vertebraten Gap Junction Proteine, die Connexine, auf. Funktionell vermitteln 
Pannexin-Kanäle den Transport kleiner Moleküle (bis zu 1.5 kDa) zwischen Zytoplasma und 
Extrazellulärraum. Panx1 ist mit purinergen Rezeptoren assoziiert und hat besondere Bedeutung als 
Kanal für den Second Messenger ATP. 
Für den Zeitraum der postnatalen Neurogenese wurde festgestellt, dass Panx1 eine Rolle in der 
Proliferation und Migration der Zellen spielt und die Extension von Neuriten fördert. Dieses führte zu 
der Hypothese dieser Arbeit, dass Panx1 auch in früheren Stadien der Neurogenese (Embryonaltag (E) 
9.5 – E12.5) von Bedeutung sein könnte. Voraussetzung für funktionelle Analysen war jedoch die 
Darstellung der zeitlichen und räumlichen Expression von Panx1.   
Das erste Ziel dieser Arbeit war somit die Untersuchung der Expression von Panx1 in den 
Embryonalstadien E9.5 bis E12.5 der Maus. Die zeitliche Expression von Panx1 mRNA und Protein 
wurde mittels RT-PCR und Western Blot Analysen untersucht. Die Lokalisation der Panx1 Expression 
wurde ebenfalls auf mRNA und Protein Ebene analysiert und mittels Whole-Mount in situ 
Hybridisierung und Immunfluoreszenz dargestellt. Zudem wurde in Panx1-transgenen Mäusen die 
Expression des Reportergens ß-Gal analysiert.  
Während der frühen Entwicklungsstadien (E9.5, E10.5, E11.5, und E12.5) wurden Panx1 mRNA und 
Protein in Kopf und Körper der Embryonen nachgewiesen. Insbesondere das Nervensystem zeigte sehr 
früh die Expression von Panx1. Erstmalig konnten die Expression von Panx1 zu diesem Zeitpunkt der 
Entwicklung in Organen nachgewiesen werden, in denen die Expression erst in späteren 
Entwicklungsstufen beschrieben war. Zudem konnten neue Expressionsorte beschrieben werden: Die 
Expression von Panx1 im Rückenmark und in sensiblen Ganglien der Hirnnerven und des Rückenmarks 
war bis dato noch nicht bekannt. Für Panx1-positive Zellen konnte die Lokalisation in post-mitotischen 
Neuronen des Rückenmarks und sensiblen Ganglien beschrieben werden.  
Das zweite Ziel dieser Arbeit lag somit in der detaillierten Analyse des Rückenmarks und der sensiblen 
Ganglien in der Embryonalentwicklung sowie in postnatalen und adulten Stadien. Mögliche 
strukturelle Defizite aufgrund einer Panx1 Deletion wurden in Panx1-transgenen Tieren untersucht, 
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konnten im Rückenmark jedoch nicht identifiziert werden. Die Panx1 Expression wurde in den Stadien 
E18,5 und an Postnataltag (P) 9 und P12 sowie in adulten Tieren untersucht. Zu allen Stadien wurde 
Panx1 Expression im Rückenmark detektiert. Interessant war die Verteilung Panx1-positiver Zellen 
innerhalb der grauen Substanz des Rückenmarks: In embryonalen Stadien nahm die Anzahl Panx1-
positiver Zellen von dorsal nach ventral ab; postnatal war dieser Unterschied ebenfalls vorhanden und 
an P12 signifikant. Auf mRNA Ebene konnte eine vergleichbare Expression von Panx1 und der 
purinergen Rezeptoren P2X3 und P2X7 beobachtet werden, während Panx2 gegenläufig exprimiert 
war. Die Analyse der Expression von Panx1 in Spinalganglien zeigte eine differentielle Expression 
abhängig von der Segmenthöhe.  In Spinalganglien war die Expression der Panx1 mRNA mit der des 
purinergen Rezeptors P2X3 vergleichbar, nicht jedoch mit P2X7.  
Zusammenfassend konnte in dieser Arbeit erstmalig gezeigt werden, dass Panx1 bereits zu frühen 
Entwicklungsstadien im zentralen und peripheren Nervensystem exprimiert ist. Panx1 mRNA und 
Protein konnten in post-mitotischen Neuronen identifiziert werden. Insbesondere die sehr spezifische 
Verteilung von Panx1 im Rückenmark lässt eine funktionelle Bedeutung dieses Proteins vermuten, wie 
z.B. eine Rolle von Panx1 in der Entstehung des neuropathischen Schmerzes.   
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Summary 
Pannexins (Panx) are a protein family with three members, Panx1, Panx2 and Panx3. At gene level, 
these pannexins display sequential homology with invertebrate gap junction proteins, innexins. On the 
other hand, the proteins possess a structural and membrane topology similar to vertebrate gap 
junction proteins, connexins. Pannexin channels function as a mechanism for the transport of smaller 
molecules (up to 1.5 kDa) between cytoplasm and extracellular space. Panx1 is associated with 
purinergic receptors and is of particular importance as a channel for second messenger ATP. 
With regard to the period of postnatal neurogenesis, it has been determined that Panx1 plays a role in 
the proliferation and migration of cells and enhances neurite extension. This led to the hypothesis of 
this study that Panx1 may also be of importance in early stages of neurogenesis (embryonic day (E) 
9.5-E12.5). Functional analysis required, however, demonstration of the expression of Panx1 over time 
and its localization. 
The main aim of this study was thus the examination of the expression of Panx1 in the embryonic 
stages E9.5 to E12.5 in mice. Expression over time of Panx1 mRNA and protein was examined by means 
of RT-PCR and Western Blot analysis. Localization of Panx1 expression was also analyzed using whole 
mount in situ hybridization and immunofluorescence. Furthermore, the expression of reporter gene 
ß-Gal was analyzed. 
Panx1 mRNA and protein were detected in the heads and bodies of the embryos in the early stages of 
development (E9.5, E10.5, E11.5, E12.5). The nervous system in particular displayed expression of 
Panx1 at a very early stage. This was the first time that expression of Panx1 had been demonstrated in 
organs at this early point and not only at later stages of development. In addition, new expression 
locations were described: expression of Panx1 in the spinal cord and in afferent ganglia of brain nerves 
and spinal cord was hitherto unknown. Panx1-positive cells were also located in post-mitotic neurons 
of the spinal cord and in sensory ganglia. 
The second part of this study was thus directed at the detailed analysis of the spinal cord and of the 
sensory ganglia both in embryonic development as well as at post natal and adult stages. Possible 
structural deficits as a result of Panx1 deletion were examined in Panx1 transgenic animals but could 
not be identified in the spinal cord. Expression of Panx1 was examined on E18.5 and on postnatal days 
(P)9 and P12 as well as in adult animals. Panx1 expression was detected at all stages in the spinal cord. 
The distribution of Panx1-positive cells within the grey matter of the spinal cord was interesting: in 
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studied stages, the number of Panx1-positive cells decreased from dorsal to ventral, this reduction was 
significant at P12. At mRNA level a similar expression of Panx1 and the purinergic receptors P2X3 and 
P2X7 was detected, while in Panx2 it was diametrically opposed. Analysis of the expression of Panx1 
in spinal ganglia showed a differential expression, dependent on segment height. In spinal ganglia 
expression of Panx1 mRNA was comparable to that of purinergic receptor P2X3, however not with 
P2X7. 
In summary this study shows, for the first time, that Panx1 is already expressed in early developmental 
stages in the central and peripheral nervous system. Panx1 mRNA and protein were identified in post-
mitotic neurons. The highly specific distribution of Panx1 in spinal cord in particular suggests that this 
protein is of functional importance; that it, for example, might play a role in the generation of 
neuropathic pain.  
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1 Introduction 
1.1 Gap junction  
Cell communication in multicellular organisms is an essential process, where cells communicate with 
their environment and other cells. Via cell communication, cells exchange water, signal molecules, or 
metabolic molecules to be used in complex processes like development, differentiation, and function 
of whole organs. Cells contact with each other directly via specialized regions of membrane junctions 
e.g. tight junctions and gap junctions.  
Gap junctions are formed by linking two hemichannels at adjacent cells, resulting in a separation of 
junctional membranes with a gap of 3.5 nm (Perkins et al., 1997). These channels connect cells directly 
and allow the passage of cytoplasmic molecules between adjacent cells including ions (Na+, K+, Ca+, H+, 
Cl-), amino acids (glycine, glutamate), metabolites (glucose, glutathione, adenosine, adenosine 
monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP)), and short 
interfering RNA (Wong et al., 2008). The intercellular communication of gap junction is involved in 
various cellular mechanisms e.g. in electrical synchronization (Bennett and Zukin, 2004), cell growth 
and differentiation (Wei et al., 2004), in cell survival and cell death (Krysko et al., 2005), and in 
carcinogenesis (Mesnil et al., 2005).  
Gap junctions are very important intercellular channels even during the embryonic development 
(Houghton, 2005). They occur in all multicellular organisms, both in invertebrates and vertebrates. 
They consist of two species-specific types of integral membrane proteins named connexins (Cx) and 
innexins (Inx) (Phelan et al., 1998). Recently, a new family of vertebrates gap junctions has been 
discovered and was called pannexin (Panx) (Panchin et al., 2000).  
1.1.1 Connexins 
Vertebrate gap junctions are composed of proteins termed Connexins. The connexin family consists of 
20-21 members, 20 members in the mouse and 21 members in the human genome, 19 members of 
them are grouped as orthologous pairs (Sohl and Willecke, 2004). Most connexin genes contain two 
exons; the coding region is mostly located on the second exon as an uninterrupted reading frame 
Introduction 
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(Figure 1). A phylogenetic classification of connexins genes reveals six subfamily (α β γ δ ζ and ε). 
Subfamilies α and β are described as sister groups (Abascal and Zardoya, 2013). 
 
Figure 1.  An alignment of different connexin genes 
(A) Most connexin genes consist of two exons; the coding region (dark blue) is mostly located on the 
second exon as an uninterrupted reading frame. (B) Some connexin genes can be transcribed through 
different promoters in different tissues. (C) Other connexin genes (e.g. Cx45) contain different exons 
that can be present in the mature mRNA to generate alternatively spliced mRNA. (D) In some connexin 
genes (e.g. Cx36), the coding region is interrupted by an intron. Taken from Bosco et al. (2011). 
 
Individual proteins are different in size, they are named on the basis of the family name connexin (Cx) 
followed by the molecular mass (e.g. the connexin protein with a molecular mass of 43 kDa is named 
Cx43) (Bosco et al., 2011). All connexin proteins show similar membrane topology. The protein 
monomer integrates into the cell membrane forming four transmembrane domains, two extracellular 
loops, and one cytoplasmic loop. The N- and C- termini have a cytoplasmic localization (Bruzzone et 
al., 1996) (Figure 2). The amino acid sequence of extracellular loops is highly conserved between 
different connexins. There are three cysteine residues in each loop (except for Cx31) (Sohl and 
Willecke, 2004). In contrast, the intercellular loop is variable between connexin isoforms (Bosco et al., 
2011). Whereas the N-terminus is constant in length, the C-terminus is very variable in length and 
sequence between connexin isoforms (Bosco et al., 2011). Thus, the C-terminus part of the protein 
causes the difference in molecular weight between isoforms, is highly specific for each connexin 
protein and also leads to a specific interaction of individual connexins with other proteins (Herve et 
al., 2004). 
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Figure 2. Membrane topology of a vertebrate gap junction protein, connexin. 
Four transmembrane domains integrate into the cell membrane, forming two extracellular loops and 
one cytoplasmic loop. N- (H3N+) and C- (COO-) termini have a cytoplasmic localization. Three cysteine 
residues (C) are present in each extracellular loop and connected by disulfide bridges. Taken from Sohl 
et al. (2005). 
 
Six connexin monomers oligomerize to form one hemichannel named connexon. Connexons can be 
composed of one connexin isoform (homomeric) or by different isoforms (heteromeric). Two 
connexons of closely apposed cells link to each other and form a hydrophilic pore of 2.5-3 nm in 
diameter called gap junction (Bosco et al., 2011). Gap junctions are either of homotypic or of 
heterotypic form (Figure 3). Homotypic channels are composed of two homomeric connexons or of 
two identical heteromeric connexons. On the other hand, heterotypic channels are composed of two 
different homomeric connexons or of heteromeric connexons (Kumar and Gilula, 1996). 
 
  
Figure 3. Schematic representation of connexon types forming different gap junction channels 
The oligomerization of six connexin subunits forms either homomeric connexons (consisting of 
identical subunits) or heteromeric connexons (consisting of different subunits). Two connexons 
compose either homotypic channels (formed by two identical connexons) or heterotypic channels 
(formed by two different connexons). Taken from Kumar and Gilula (1996). 
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Connexins can also form non-junctional channels, when connexons do not link to each other, but form 
hemichannels between the cytoplasm and the extracellular space. Hemichannel formation has been 
reported for several connexin isoforms, particularly Cx43, with the possibility to release small 
molecules (e.g. ATP, glutamate and nicotinamide adenine dinucleotide (NAD+)) into the extracellular 
space (Evans et al., 2006, Lohman and Isakson, 2014).  
Connexins are expressed in all tissues of the vertebrate, for instance in the nervous system, liver, and 
heart. Connexin expression is highly specific, however, more than one connexin can be expressed in 
one cell. In the liver, hepatocytes communicate with each other through Cx32 and Cx26, whereas non-
parenchymal liver cells express Cx43. On the other hand, Cx37 and Cx40 are expressed in vascular cells 
in the liver (Maes et al., 2014). In the nervous system, connexins are expressed in neuronal and non-
neuronal cells. Cx29, Cx32, and Cx43 are expressed in myelinating Schwann cells (Li et al., 2007). In 
neurons, Cx36 is strongly expressed in different regions of the brain i.e. olfactory bulb, hippocampus 
and nuclei of brainstem (Condorelli et al., 1998). Many mutations in connexins are associated with 
diseases. Exemplarily, two diseases of the nervous system are highlighted here: mutations in Cx32 
cause a demyelination in the peripheral nervous system called X-linked Charcot-Marie-Tooth disease 
(CMTX) (Bergoffen et al., 1993). Mutations in Cx47 are associated with a dysmyelinating disease called 
Pelizaeus–Merzbacher-like disease (PMLD) (Orthmann-Murphy et al., 2007). 
1.1.2 Innexins 
Gap junctions are also present in invertebrates and formed by membrane proteins. Since they form 
functional junctions and are analogous to vertebrate connexins, they were given the functional name 
innexin (invertebrate analogues of the connexin) (Phelan et al., 1998). Innexins do not have any 
sequence homology to connexins (Bauer et al., 2005) but are similar to them in structure and function. 
The coding region of many innexins is located on multiple exons, which provides the possibility to 
encode more than one protein by differential splicing (Phelan, 2005). Innexins are named on the basis 
of the family name innexin (inx) which is prefixed two letters denoting the organism (Phelan and 
Starich, 2001). Innexins within an organism are numbered, but numbers do not imply any genetic 
relationship, e.g. Ce-inx-3 of C. elegans is not orthologous to Dm-inx3 of Drosophila melanogaster 
(Phelan and Starich, 2001). There are 25 innexin genes in C. elegans (Phelan and Starich, 2001). On the 
other hand, only 8 innexin genes have been identified in Drosophila melanogaster (Stebbings et al., 
2002). 
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The membrane topology of innexins is similar to that of connexins. Innexin protein also forms four 
transmembrane domains, two extracellular loops, and one intracellular loop in addition to the 
cytoplasmic localization of C- and N-termini (Figure 4) (Phelan et al., 1998). In contrast to connexins, 
in which three extracellular cysteine residues are conserved, innexins have only two cysteine residues 
in each of the extracellular loops. Like connexins, innexin monomers oligomerize into a hexameric 
structure of a hemichannel named innexon; two innexons of adjacent cells link to each other and form 
the invertebrate gap junction (Liu et al., 2013). Some innexins are able to form functional hemichannels 
as demonstrated by exogenous expression in Xenopus oocytes (Bao et al., 2007). These hemichannels 
are mechanosensitive (Bao et al., 2007); the activity of channels increases after applying mechanical 
stress using the membrane patch technique. Furthermore, innexin hemichannels can be activated by 
intracellular application of calcium in a micromolar range (Bao et al., 2007). The depolarization of these 
hemichannels with potassium solution induces channel opening and increases ATP release (Bao et al., 
2007). 
  
Figure 4. Membrane topology of an invertebrate gap junction protein, innexin. 
Four transmembrane domains (TM 1-4) integrate into the cell membrane, forming two extracellular 
loops and one cytoplasmic loop. N- and C- termini have an intracellular localization. Two cysteine 
residues (C) are present in each extracellular loop. Taken from Phelan et al. (1998). 
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1.1.3 Pannexins 
1.1.3.1 Pannexin discovery 
Connexins are specific vertebrate proteins; no sequence homolog of connexins was found in 
invertebrates (Phelan et al., 1998, Panchin et al., 2000). Fourteen years ago, Panchin et al. (2000) 
analyzed the genome of vertebrates for innexin homologs using innexin degenerate primers (Panchin 
et al., 2000). The similarity of these newly described sequences to innexins sequences was analyzed 
using PSI-BLAST database. Sequences homolog to innexins were found in different taxonomic groups 
including vertebrates, for instance in human and mouse genomes. This newly discovered gene was 
called pannexin (from the Latin pan; all, nexus; connection) (Panchin et al., 2000, Panchin, 2005). 
Sequence homology of the mammalian protein (pannexin) to invertebrate innexins was confirmed in 
other studies (Baranova et al., 2004). Genes encoding innexins were significantly similar to that of the 
putative mammalian protein MRS1 (Baranova et al., 2004). Sequence analysis of the newly discovered 
pannexin gene revealed two additional isoforms in mouse and human genomes. The three pannexin 
mouse genes were named Panx1, Panx2, and Panx3 (Bruzzone et al., 2003, Baranova et al., 2004). In 
this study, pannexin genes were abbreviated with italicized letters of PANX or Panx for human and 
mouse, respectively, whereas pannexin proteins were abbreviated with not italicized letters of PANX 
or Panx for human and mouse, respectively.  
1.1.3.2 Pannexin genes 
Pannexin-encoding genes are highly conserved in the vertebrate genome. They are orthologs to 
invertebrate innexins but do not have any sequence similarity to vertebrate connexins. Panx1 and 
Panx3 genes are located on the same chromosome in human and mouse genomes. This is similar to 
innexins, in which genes are often located in cluster of two or three, and can be related to evolution 
by local duplication (Baranova et al., 2004). Compared to connexin genes (see Chapter 1.1.1), pannexin 
genes have a higher number of exons (3, 4 or 5 exons), and the coding region is not restricted to one 
exon but located on all exons of the gene (Bruzzone et al., 2003). Panx1 and Panx3 genes are located 
on chromosome 9 of the mouse genome. The Panx1 gene includes five exons, whereas the Panx3 gene 
includes four exons (Figure 5). Unlike Panx1 and Panx3, the Panx2 gene is located on another 
chromosome (chromosome 15 of the mouse genome) and includes only three exons. 
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Figure 5. Mouse Pannexin genes 
Genomic regions of mouse Panx1, Panx2, and Panx3 are represented. Exons are presented by 
numbered boxes. Black regions point to coding regions. Taken from Bruzzone et al. (2003). 
 
1.1.3.3 Pannexin proteins 
Pannexin proteins have a similar topology as the gap junction proteins connexins and innexins 
(Ambrosi et al., 2010). Thus, the secondary structure of pannexin proteins also exhibits four 
transmembrane domains, two extracellular loops (EL), one intracellular loop (IL), and the cytoplasmic 
localization of N- and C-termini (Bruzzone et al., 2003) (Figure 6). Like innexins, pannexins display two 
conserved cysteine residues in extracellular loops, but there are also additional intracellular and 
transmembrane cysteine residues in Panx1 (Bunse et al., 2010). Panx1 and Panx3 proteins are homolog 
in sequence and size, they exhibit 41 % identity at the amino-acid level (Penuela et al., 2007). The 
Panx1 mRNA encodes a protein of 448 aminoacids (aa) with a molecular mass of 48.07 kDa. Panx3 
encodes a slightly shorter protein of 392 aa of with a molecular mass of 44.98 kDa. In contrast, Panx2 
is different in size and sequence. The Panx2 protein consists of 607 aa and has a molecular weight of 
73.27 kDa, which is higher than that of Panx1 and Panx3 (Bruzzone et al., 2003).  
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Figure 6. The membrane topology of pannexin family members 
(A) Secondary structures of Panx1, Panx2 and Panx3 proteins show four transmembrane domains, two 
extracellular loops (EL), one intracellular loop (IL), and the cytoplasmic localization of the amino 
terminus (NT) and carboxy terminus (CT). Extracellular loops are conserved and contain two cysteine 
residues (C). N-glycosylation sites (in red) locate at the first (Panx2, Panx3) or second (Panx1) 
extracellular loop. (B) The predicted hexameric structure of Panx1 forming membrane channels. Taken 
from Penuela et al. (2013). 
 
Pannexins differ from connexins and innexins by possessing N-glycosylation sites (Boassa et al., 2007, 
Penuela et al., 2007), which are located at the first (Panx2, Panx3) or second (Panx1) extracellular loop 
(Penuela et al., 2007, Penuela et al., 2014b). Pannexin proteins possess various glycosylation levels: 
Panx1 and Panx3 have a high-mannose and complex carbohydrate glycosylation. In contrast, 
glycosylation of Panx2 has a high-mannose content only (Penuela et al., 2009, Penuela et al., 2014b). 
The N-glycosylation of Panx1 and Panx3 at the extracellular loop probably prevents the formation of 
intercellular channels (Boassa et al., 2007). The de-glycosylation at the cell surface produces a higher 
junctional conductance in oocyte pairs, which express Panx1 (Boassa et al., 2008). On the other hand, 
glycosylation is required for trafficking of the protein from the endoplasmic reticulum into the plasma 
membrane in many cell types (Boassa et al., 2007, Penuela et al., 2007). Additional glycosylation sites 
were predicted in the intracellular loop and in the carboxy terminus of Panx1 and Panx3 (Penuela et 
al., 2007). These results were obtained using sequence analysis, since it is possible to predict post-
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translational glycosylation and phosphorylation sites of a protein from its amino acid sequences (Blom 
et al., 2004). 
Sequence analyses of pannexin proteins showed the presence of consensus sequences for several 
phosphorylation sites (Barbe et al., 2006, Penuela et al., 2007). Thus, pannexins might be 
phosphorylated at these sites via protein kinases in a post-translational event. Immunoprecipitation 
analysis of muscles fiber lysates confirmed that Panx1 is a phosphoprotein: Threonine and serine 
residues are phosphorylated in resting muscles fibers and the phosphorylation was enhanced in 
electrically stimulated fibers (Riquelme et al., 2013). In contrast, de-phosphorylation analysis of protein 
lysates did not support the finding of Panx1 and Panx3 phosphorylation as immunoblotting analysis 
did not exhibit fewer sizes of immunoreactive proteins after de-phosphorylation (Boassa et al., 2007, 
Penuela et al., 2007, Swayne et al., 2010).  
Further post-translational modification was observed in Panx2, which can be found in a palmitoylated 
or unpalmitoylated form. In neural stem and progenitor cell development, palmitoylated forms of 
Panx2 were cell type-specific and post-translational modification was associated with the subcellular 
localization of Panx2 (Swayne et al., 2010).  
As outlined above, pannexin monomers oligomerize to form a hemichannel named pannexon (Figure 
6). Pannexons, however, are differently composed within the family. Cross-linking analyses showed 
that Panx1 oligomerizes into a dimeric or hexameric pannexon (Boassa et al., 2007), whereas Panx2 
oligomerizes into an octameric pannexon (Ambrosi et al., 2010). However, most pannexins seem to 
form homomeric channels. The exogenous overexpression of Panx1 or Panx2 in mammalian cells 
showed the formation of homomeric channels, which were observed electron microscopically 
(Ambrosi et al., 2010). It was reported that homomeric pannexin channels appear similar to 
homomeric channels of the gap junction protein Cx26 (Ambrosi et al., 2010). Unlike connexins, 
heteromeric pannexons are unstable: exogenously overexpressed Panx1 and Panx2 form unstable 
heteromeric pannexons that disappear in a few hours. One hypothesis is that heteromeric pannexons 
disintegrate because of the different molecular weight of their protein components (Ambrosi et al., 
2010).  
1.1.3.4 Pannexin expression  
The three pannexin isoforms show different distribution in the vertebrate body. The first Northern blot 
analysis of pannexin expression (Bruzzone et al., 2003) revealed that Panx1 was expressed in a variety 
of tissues e.g. in brain, spinal cord, liver, bladder, thyroid gland, and eye, whereas Panx2 was more 
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restricted to the nervous system. Using the expressed sequence tags database (dbEST), Panx3 had 
been found in libraries of osteoblasts, synovial fibroblasts, cartilage, and the inner ear (Baranova et al., 
2004). 
In the adult mouse and rat, Panx1 was expressed in different regions of the brain, e.g. in neurons of 
the hippocampus, thalamus, olfactory bulb, cortex, and in the cerebellum (Bruzzone et al., 2003). 
Within the central nervous system (CNS), the hippocampus was shown to have higher expression levels 
than cortex and cerebellum (Hanstein et al., 2013). Many nuclei of the midbrain and hindbrain also 
expressed Panx1. Panx1 mRNA and protein were observed in motor nuclei of oculomotor, facial, vagus 
and hypoglossal nerves as well as in spinal trigeminal nucleus (Ray et al., 2005, Zappala et al., 2006). 
On the other hand, Panx1 mRNA and protein were absent in the mesencephalic trigeminal nucleus and 
motor trigeminal nucleus (Ray et al., 2005, Zappala et al., 2006). In spinal cord of adult mice, Panx1 
protein was detected in the ventral spinal cord in laminae VII, VIII, and IX, whereas in the dorsal region 
(laminae I-VI) no expression was observed. The protein showed a cytoplasmic localization in motor 
neurons (Zappala et al., 2006). 
On the other hand, conflicting observations have been reported for Panx1 expression in glia cells. 
Whereas Panx1 mRNA was absent in glial-like cells RT4-B5 (Ray et al., 2005) and in astrocytes of rat 
brain (Vogt et al., 2005), Panx1 mRNA was observed in the white matter of rat cerebellum and corpus 
callosum (Bruzzone et al., 2003). Furthermore, Panx1 protein was also observed in Bergmann glial cells 
of the cerebellar cortex (Zappala et al., 2006) and in cultured astrocytes (Iglesias et al., 2009) as well 
as in immature oligodendrocytes (Huang et al., 2007b). 
In the peripheral nervous system (PNS), Panx1 was detectable not only in the trigeminal ganglion but 
also in neurons of the nodose-petrosal-jugular complex (NPJc). In the trigeminal ganglion, Panx1 
expression was present in sensory neurons and in some satellite glial cells (SGCs) (Hanstein et al., 
2013). In contrast, Panx1 was present in the soma of NPJc neurons but not in SGCs (Retamal et al., 
2014). The protein showed a cytoplasmic localization and different expression levels within the 
neuronal soma. 
Recently, a quantitative analysis compared Panx1 expression between several tissues (Hanstein et al., 
2013). The highest expression level of Panx1 was found in the trigeminal ganglion followed by bladder 
and spleen. A lower expression was detected in the brain, calvaria, and heart. On the other hand, 
kidney and liver were shown to contain very low levels of Panx1.  
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In sensory organs, Panx1 mRNA and protein were also detected (Huang et al., 2007a, Romanov et al., 
2007). In taste buds, Panx1 showed a more abundant expression than connexin proteins Cx30 and 
Cx43. Expression sites included all taste receptor cells (type II) and only 50 % of other cell types as glial-
like (type I) and presynaptic cells (type III) (Huang et al., 2007a). In the retina, Panx1 mRNA was 
detectable in nearly all retinal layers (Ray et al., 2005). In the outer plexiform layer, immunolabeling 
and electron microscopy analyses revealed that Panx1 was mostly localized in dendritic and axonal 
terminals of horizontal cells (Kranz et al., 2013). 
Panx2 mRNA showed a similar distribution as Panx1 in many regions of rat CNS, for instance in olfactory 
bulb, hippocampus, dentate gyrus, and Purkinje cells of cerebellum (Vogt et al., 2005). In the PNS, 
Panx2 was also reported to be expressed in spiral ganglion neurons of the mammalian cochlea (Wang 
et al., 2009). In the retina, Panx2 was detectable in nearly all retinal layers of postnatal mice 
(Dvoriantchikova et al., 2006). Panx2 had higher expression levels than Panx1 in the whole retina and 
particularly in isolated retinal ganglion cells (Dvoriantchikova et al., 2006). 
Panx3 mRNA was detectable in human fetal hippocampal neurons and in adult rat brain (Baranova et 
al., 2004, Wang et al., 2009). In contrast, Panx3 was very weakly detectable in mouse brain (Penuela 
et al., 2007, Wang et al., 2009).  
On the other hand, Panx3 was predominantly expressed in the skin and cartilage, and was also 
detectable in other organs like liver, lung, and kidney (Penuela et al., 2007).  
In the skin, Panx1 and Panx3 exhibited coexpression, as shown in the epidermis of an E13.5 mouse 
embryo (Celetti et al., 2010). In the epidermis Panx3 displayed unchanged expression levels in 
embryonic and newborn mice. In the developing cartilage, Panx3 regulated chondrocyte proliferation 
and differentiation by promoting ATP release into the extracellular space (Iwamoto et al., 2010).  
1.1.3.5 Pannexin function 
The structural similarity of pannexins to the channel forming proteins connexins and innexins led to 
test the possibility whether pannexins form intercellular gap junctions. On way to investigate gap 
junction function of a protein is the paired oocyte assay (Dahl et al., 1987). In this experiment, no 
junctional currents were observed for Panx1 compared to the positive control using Cx43 mRNA (Dahl 
and Keane, 2012) when recording the transjunctional current 30 min after pairing and 48 hours after 
injection. Other studies observed a transjunctional current with Panx1 alone or with both Panx1 and 
Panx2 after pairing the oocytes for a longer time (24 - 48 hours) (Bruzzone et al., 2003). Panx2 alone 
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did not produce any current (Bruzzone et al., 2003). On the other hand, only Panx1, but not Panx2, 
formed functional hemichannels in the non-junctional membrane of single Xenopus oocytes (Bruzzone 
et al., 2003). These results and others supported the idea of a non-junctional function of Panx1. Lack 
of pairing might be due to the protein glycosylation at the extracellular loop, which might hinder the 
docking of two hemichannels (Boassa et al., 2007). Therefore, the functional pannexin oligomer was 
named `channel` to distinguish it from gap junction hemichannels (Sosinsky et al., 2011). 
Pannexin1 is the most studied and characterized member of the pannexin family (Ohbuchi et al., 2013). 
Panx1 channels transit ions and second messenger molecules up to a molecular weight of 1.5 kDa. 
These include positively and negatively charged molecules (e.g. ATP, UTP and Ca2+) (Dahl and Keane, 
2012). Furthermore, Panx1 channels mediate dye-take up, for instance of monomeric cyanine (Yo-PRO) 
(Chekeni et al., 2010) or carboxyfluorescein (Dahl and Locovei, 2006), from the extracellular space to 
the cytoplasm. On the other hand, no uptake of high-molecular-weight dyes (dextran rhodamine, 10 
kDa) was observed (Penuela et al., 2007). 
Panx1 is implicated in ATP release from the cytoplasm to the extracellular space. Cells release ATP as 
a signaling molecule into the extracellular space by two ways, either by vesicular release or through 
membrane channels. The first description of ATP release through Panx1 has been given by Bao et al. 
(2004) using luminometry analysis. Exogenously expressed Panx1 in Xenopus oocytes caused an efflux 
of ATP under depolarization conditions (high K+) (Bao et al., 2004). Erythrocytes express also Panx1, 
they show significant carboxyfluorescein uptake in the presence of high K+ concentration or upon ATP 
release under low oxygen conditions (Locovei et al., 2006a). 
In Xenopus oocytes, exogenously expressed Panx1 channels are closed at the resting membrane 
potential, and can be activated by a positive membrane potential (Bruzzone et al., 2003). Extracellular 
ATP also activates Panx1 channels via purinergic P2Y or P2X receptors (Locovei et al., 2006b). The 
extracellular application of ATP induced currents in Xenopus oocytes, which co-express Panx1 and 
P2Y1 or P2Y2 (Locovei et al., 2006b). Furthermore, after ATP stimulation, Panx1 induces also the pore 
formation and dye uptake in oocytes, which co-express Panx1 and P2X7R (Locovei et al., 2007). ATP-
receptor activation (P2Y or P2X) increases the cytoplasmic concentration of calcium, which induces 
ATP release via Panx1 channels (Figure 7). This process is achieved in several steps: By activation of G-
protein-linked receptors, the phospholipase C becomes active and produces IP3 protein, which leads 
to Ca2+ release from the endoplasmic reticulum (Scemes and Giaume, 2006). 
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Figure 7. Functions of Panx1 channels 
Panx1 channels (green) are closed at low intracellular pH (resting membrane potential). They become 
active by a positive membrane potential, stimulation of P2Y and P2X receptors, and an increase of 
cytoplasmic Ca2+. ATP stimulation via P2Y and P2X receptors leads to production of IP3 protein via 
phospholipase C. IP3, in turn, leads to the release of Ca2+ from the endoplasmic reticulum (ER). The 
cytoplasmic Ca2+ induces Panx1 channel activation and ATP release. Opened Panx1 channels allow the 
transit of small molecules including pro-inflamatory molecules, muramyl dipeptide (MDP), bacterial 
toxin and antigens. Panx1 is involved in several cellular mechanisms e.g. inflammasome activation, 
apoptosis, and wound healing. Taken from D'Hondt et al. (2009). 
 
ATP release via Panx1 channels is involved in different cellular mechanisms e.g. inflammasome 
activation and apoptosis. In macrophages, Panx1 induces caspase-1 activation (Figure 7) to convert the 
inactive interleukin-1β (pro-IL-1β) into the active form of mature IL-1β, in addition to the interaction 
between Panx1 and the inflammasome protein NLRP3 (Pelegrin and Surprenant, 2006, Wang et al., 
2013). Furthermore, in apoptotic cells (jurkat cells), Panx1 mediates “find-me” signals by releasing ATP 
from apoptotic cells (Chekeni et al., 2010). This signal is required to recruit phagocytes for quick 
removal of dying cells (Elliott et al., 2009). Panx1 is also permeable for specific dyes during apoptosis; 
the uptake of the apoptotic cell-indicator-dye YO-PRO-1 (monomeric cyanine) is Panx1-dependent 
(Chekeni et al., 2010).  
On the other hand, co-immuneprecipitation analysis revealed that Panx1 interacts with different 
proteins e.g. cytoskeletal proteins. Actin microfilaments regulate the distribution and the mobility of 
Panx1 on the cell surface (Bhalla-Gehi et al., 2010). The C-terminus of Panx1 interacts preferentially 
with actin and this might be a direct interaction (Bhalla-Gehi et al., 2010). Endogenous expression of 
Panx1 in Neuro-2a cells confirms the interaction of Panx1 with β-actin and with the actin-related 
protein3 (arp3) (Wicki-Stordeur and Swayne, 2013). 
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1.2 Gap junctions in development 
1.2.1 Connexins in development 
Gap junctions have been described in early phases of the embryogenesis. Cx32 mRNA is expressed in 
the zygote and remains present as an oogenetic protein product until the late morula stage (Barron et 
al., 1989). Nine connexin members are expressed in pre-implantation embryos (Wong et al., 2008). 
The expression of Cx43 begins at least at the 4-cells stage and was detected in gap junction-like plaques 
at the 8-cells stage (De Sousa et al., 1993). However, gap junctions in early stages can be required for 
intercellular communication after cell compaction (Barron et al., 1989). 
Studies on connexin knockout mice revealed that gap junction are very important in mammalian 
development. For example, there is no fertilization possible in Cx37-/- mice, as oocytes require Cx37 
gap junctions for signal transport between the oocyte and surrounding follicular cells (Simon et al., 
1997). Cx45 is also important for heart development in early embryonic stages. Cx45-/- mice die at E9 
(Kruger et al., 2000, Kumai et al., 2000, Alexander and Goldberg, 2003). Cx43-/- mice show heart defects 
in the development; they die shortly after the birth (Reaume et al., 1995).  
Gap junctions are present not only in embryonic stem cells but also in various somatic stem cells. They 
are involved in the proliferation, differentiation, and apoptosis of stem cells (Wong et al., 2008). In 
nervous system development, connexin gap junction proteins are present in neuronal and glial cells, 
they mediate cell communication and regulate neural progenitor cells proliferation and differentiation 
(Hartfield et al., 2011). During the proliferation in the cortical ventricular zone, radial glial cells require 
gap junction hemichannels for the propagation of calcium waves, which play a role in the regulation 
of neuronal proliferation (Weissman et al., 2004). In neurons, gap junctions are commonly regarded 
as electrical synapses and occur even during neurogenesis, whereas chemical synapses appear in the 
postnatal phase (Winterhager, 2005). 
1.2.2 Pannexins in development  
The expression of Panx1 was described in late stages of mouse and rat development. In the mouse 
embryo, Panx1 mRNA was detected by real time qPCR in embryonic (E14, E16, and E18) and postnatal 
development (P0, P3, P7 and P14) in the cortex, cerebellum and eye (Ray et al., 2005). The expression 
level of Panx1 peaks in late embryonic development at E18, is reduced thereafter in postnatal stages 
and shows further down-regulation in the adult mouse (Ray et al., 2005). In situ hybridization analysis 
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showed a high level of Panx1 in the cortical plate and subplate of an E18 embryo, in addition to a high 
expression levels in hippocampus (Ray et al., 2005). In rat embryos at E14 and E17, a high expression 
level of Panx1 was found in the brain and spinal cord, as observed using radioactive in situ hybridization 
(Vogt et al., 2005).  
In vitro, endogenous expression of Panx1 has also been reported during differentiation of many neural 
stem cell lines. In cell culture of RT4 cells, which are derived from a rat peripheral neurotumour and 
consist of multipotent stem cells, Panx1 mRNA was found in stem cells RT4-AC and neuron-like cells 
RT4-E5 and RT4-D8, but was absent in glial-like cells RT4-B5 (Ray et al., 2005). These results led the 
authors to suggest that Panx1 expression is restricted to neurons in the peripheral nervous system as 
well as in the CNS. Others reported Panx1 expression in Neuro-2a cells (N2a), a cell line which is derived 
from murine neuroblastoma and capable to differentiate into neuron-like cells (Wicki-Stordeur et al., 
2012, Wicki-Stordeur and Swayne, 2013).  
The expression of Panx1 in neural stem cells provides hints that Panx1 might play a role in the 
development of nervous system. The postnatal neurogenesis (Ming and Song, 2011) and N2a cells are 
ideal to investigate Panx1 function. In vivo, Panx1 is expressed in defined populations during postnatal 
neurogenesis, in neural stem and progenitor cells (NSC/NPCs) as well as in immature neurons. Whereas 
Panx1 was absent in neuroblasts (doublecortin-positive cells; Dcx) of immature mice (P15) (Wicki-
Stordeur et al., 2012), Panx1 was present in these cells of the adult mouse brain (Wicki-Stordeur and 
Swayne, 2013). Neuroblasts of the adult mouse brain exhibited lower expression level of Panx1 than 
NSC/NPCs, revealing that Panx1 expression decreases during differentiation of neural stem cells 
(Wicki-Stordeur and Swayne, 2013). 
During postnatal neurogenesis, Panx1 is involved in the regulation of NSC/NPC proliferation by 
mediating ATP release (Wicki-Stordeur et al., 2012). Furthermore, Panx1 influences cell migration and 
neurite extension; inhibition or knockdown of Panx1 induces the extension of neurites, while Panx1 
overexpression inhibits the outgrowth of neurites (Wicki-Stordeur and Swayne, 2013). 
During spinal cord development, Panx1 mRNA and protein expression were detected in isolated 
microglia cells, which were obtained from spinal cord of an E13.5 mouse embryo (Rigato et al., 2012). 
In contrast to P2X7R, Panx1 expression did not influence the proliferation of embryonic microglia cells 
(Rigato et al., 2012). 
Panx2 is also expressed at late stages of mouse and rat development. In contrast to Panx1, Panx2 
mRNA shows an extremely low expression in late embryonic stages during cerebellar development. 
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This expression level increases during postnatal development and the adult (Ray et al., 2006). Using 
radioactive in situ hybridization, Panx2 shows also low expression in the brain and spinal cord of rat 
embryos at E14 and E17 (Vogt et al., 2005).  
During the postnatal neurogenesis, Panx2 is expressed in early stem-like hippocampal neural 
progenitors, but it is absent in intermediate progenitor cells (doublecortin-positive cells) or in 
immature neurons. Interestingly, Panx2 is re-expressed in mature neurons of the hippocampus 
(Swayne et al., 2010).  
In vitro, Panx2 is endogenously expressed in N2a cells (Swayne et al., 2010). In these cells, the reduction 
of Panx2 expression to about 50 % accelerates morphological differentiation. Thereby, the expression 
of the marker of mature neuronal cells (NeuN) is increased, whereas the expression of the immature 
neuronal marker β-III-tubulin (Tuj1) in neurons was decreased (Swayne et al., 2010). Thus, 
investigation of neurogenesis suggests that Panx1 and Panx2 might have a specific function during the 
development. On the other hand, only limited data is available on both the embryonic expression and 
function in very early stages of embryogenesis. 
1.3 Development of the nervous system 
As this study focuses on the developmental and spatial expression of Panx1 in the nervous system, 
crucial steps of CNS and PNS development, particularly the development of spinal cord and sensory 
ganglia, are described. 
1.3.1 Cranial sensory ganglia development 
Cranial sensory ganglia develop from two cell structures: neural crest and sensory placodes (Lleras-
Forero and Streit, 2012). Placodes are ectodermal epithelium, outside the central nervous system, and 
originate from a pre-placodal region (PPR), a horseshoe-shaped ectodermal region surrounding the 
anterior part of the neural plate (Sato et al., 2010). In sensory cranial ganglia, neurons are derived from 
both neural crest cells and ectodermal placodes (Figure 8), whereas all satellite glial cells are derived 
from neural crest only. 
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1.3.1.1 Trigeminal ganglion 
In trigeminal ganglion development, mesenchymal cells begin to migrate from the trigeminal placode 
at E8.5 and this process ends at E10.5  (Nichols, 1986). At E9.5, the trigeminal placode appear as a 
thickened region of the ectodermal epithelium along the side of the embryonic head. Neurogenesis in 
the trigeminal ganglion occurs between E9.5 and E13.5 (Huang et al., 1999). 
The trigeminal ganglion complex itself develops by the fusion of two ganglia: the ophthalmic trigeminal 
ganglion in the anterior portion of the ganglion complex and maxillomandibular trigeminal ganglion 
(Figure 8). Neurons of ophthalmic branch innervate the head, including the nose and eyeballs. Neurons 
of maxillomandibular branch innervate the lower face, jaws, tongue and teeth. Trigeminal neurons 
transmit cutaneous information (touch, pain and temperature) from the skin and proprioceptive 
information from the muscles. Proprioceptive neurons seem to be derived from the neural crest (Rao 
and Jacobson, 2005). 
 
Figure 8. Illustration of placodes and neural crest forming cranial sensory ganglia in the head of 
chicken embryo 
Neurons in cranial sensory ganglia contribute to placode cells or neural crest cells. All satellite cells are 
derived from the neural crest. Fb, forebrain; G, ganglion; gen, geniculate; ln, lens; mb, midbrain; mmV, 
maxillomandibular trigeminal; nod, nodose; olf, olfactory; opV, ophtalamic trigeminal; pet, petrosal; 
prox, proximal; sup, superior; vest-coch, vestibulocochlear. Taken from Rao and Jacobson (2005). 
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1.3.1.2 Geniculate, vestibular and spiral ganglia 
The geniculate ganglion of cranial nerve VII, i.e the facial nerve, arises from the first epibranchial 
placode and neural crest, whereas the spiral and vestibular ganglia are derived from the otic placode 
and neural crest. At E9, neural progenitor cells of all of these ganglia migrate and coalesce into a single 
ganglion complex (facio-acoustic ganglion complex), which differentiates at E12.5 into the geniculate 
ganglion and the vestibulocochlear ganglion. The vestibulocochlear ganglion divides at E13.5-E14.5 
into a vestibular and a spiral ganglion primordial, whereas their physical separation occurs at E17.5 
(Wikstrom and Anniko, 1987, Huang et al., 2001, Rao and Jacobson, 2005).  
Neurons in the geniculate ganglion provide dendrites to innervate taste buds of the tongue, taste buds 
of the palate, and the skin of the external ear (Patel and Krimm, 2010). Neurons in the spiral ganglion 
locate inside the otic capsule, innervate the cochlea and transmit the information to the brain. The 
vestibular ganglion locates outside the otic capsule, innervates the vestibular organs and transmits 
information into the vestibular nuclei in the medulla oblongata. 
1.3.2 Spinal cord development 
At the dorsal site of an E9.5 mouse embryo appears the structure of the neural tube after closing of 
the neural plate along the anterior-posterior axis. The neural plate contains initially only one 
ectodermal cell layer, which via cell division becomes later a ticker tube consisting of three layers: the 
ependymal layer (ventricular zone), the mantle layer and the marginal layer. The ventricular zone 
surrounds the lumen of the neural tube and the central canal. This zone contains progenitor cells, 
which give rise to neurons during neurogenesis (~E9-E14) and oligodendrocytes during gliogenesis 
(~E13 to postnatal) (Battiste et al., 2007). Cells in the midline of the ventral part differentiate into 
epithelial-like cells called the “floor plate”. At the dorsal part, a tissue known as the “roof plate”, 
develops. Between dorsal and ventral parts appears a fissure called the sulcus limitans. 
Spinal progenitor cells are arrayed at dorsoventral positions along the midline and proliferate to give 
rise to post-mitotic neurons during temporally restricted periods (Arber, 2012). Generation of neurons 
is induced by signaling activity of the floor plate and the roof plate. The gradational expression of Sonic 
Hedgehog (SHH) protein from the notochord and the floor plate establishes five ventral progenitor 
domains (Jessell, 2000), while gradational expression of Wingless/Int (WNT) and bone morphogenic 
protein (BMP) from the roof plate establishes six dorsal progenitor domains (Luu et al., 2011). Neurons 
derived from different progenitor cells migrate radially to the target destination in the mantle layer 
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(gray matter) to form neuronal subpopulations, which are organized in laminae known as Rexed´s 
laminae (Rexed, 1952). Laminae I-VI form the dorsal horn. The lamina VI is present in cervical and 
lumbosacral segments, but not in thoracic segments. Lamina VII forms the intermediate gray matter, 
and laminae VIII and IX form the ventral horn, whereas the lamina X surrounds the central canal (Figure 
9) (Watson et al., 2012).  
Finally, the gray matter consists of motor neurons, interneurons, axons of neurons and glia cells. The 
marginal layer (white matter) contains axons of neurons and glia cells (astrocytes and 
oligodendrocytes). Microglia cells, which originated form mesoderm, begin to invade the spinal cord 
at early stages E11.5 of mouse development (Rigato et al., 2011). 
  
Figure 9. Laminar organization of the thoracic segment T7 from P4 mouse spinal cord 
The dorsal horn contains laminae (I-V). Lamina VII forms the intermediate gray matter. Laminae VIII 
and IX form the ventral horn, and lamina X surrounds the central canal. Lamina VI is absent in the 
thoracic region. Axial muscle motor neurons of lamina 9 (Ax9), central canal (cc), dorsal corticospinal 
tract (dcs), dorsal nucleus (D), dorsolateral fasciculus (dl), gracile fasciculus (gr), intercalated nucleus 
(ICl), intercostal muscle motor neurons of lamina 9 (ICo9), intermediolateral column (IML), 
intermediomedial column (IMM), lamina 1 (1Sp), inner part of lamina 2 (2SpI), outer part of lamina 2 
(2SpO), lamina 3 (3Sp), lamina 4 (4Sp), lamina 5 (5Sp), lateral part of lamina 5 (5SpL), lateral spinal 
nucleus in the white matter (LSp), medial part of lamina 5 (5SpM), lamina 7 (7Sp), lamina 8 (8Sp), 
lamina 9(9Sp), lamina 10 (10Sp), lateral funiculus (lf), postsynaptic dorsal column pathway (psdc), 
rubrospinal tract (rs), ventral funiculus (vf), ventral median fissure (vmf), ventral white commissure 
(vwc). Taken from Sengul et al. (2012). 
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1.3.3 Dorsal root ganglion development 
After closure of the neural plate, neural crest progenitor cells leave the neuroepithelium and migrate 
between the mesenchymal cells lateral of the neural tube. Neural crest cells (NCCs) are progenitors of 
different cell types, e.g. peripheral neurons, peripheral glia (Schwann cells) and melanocytes. Two 
types of NCCs are present during the development of DRG neurons, which occurs in three waves of 
neurogenesis (Figure 10). The first wave occurs between E9.5 and E11.5, generating large neurons 
from the first type of NCCs. In the second wave between E10.5 and E13.5, the second type of NCCs 
generates large and small neurons of DRG neurons. In the third wave, boundary cap cells, neural crest 
derivatives at the spinal cord entry points, generate small neurons that largely consist of nociceptive 
neurons. All types of NCCs and boundary cap cells are involved in generating glia cells of DRGs (Maro 
et al., 2004, Marmigere and Ernfors, 2007). 
 
Figure 10. Three neurogenesis waves of DRGs 
(A) The first type (red) of neural crest cells migrates laterally and generates large neurons in the first 
wave. (B and C) In the second wave, the second type (orange) of neural crest cells migrates later and 
generates large and small neurons of DRGs. (D) In the third wave, boundary cap cells (blue) generate 
small neurons. Neural crest cells and boundary cap cells generate glia cells of DRGs. Taken from 
Marmigere and Ernfors (2007). 
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1.3.3.1 Populations and projection of sensory neurons 
DRGs contain a heterogeneous population of sensory neurons that innervate different peripheral 
targets and transmit different types of sensory information (e.g. pain, touch, vibration, pressure, 
temperature) to the central nervous system. Different criteria can be used to classify DRG sensory 
neurons, for instance the size of the pericaryon, ultrastructure, and the expression of certain 
neurotrophin receptors e.g. members of the family of high-affinity neurotrophin receptors tyrosine 
kinase receptors (Trk). In general, neurons in DRGs are classified in four main classes (Figure 11). Large 
proprioceptive neurons express TrkC and innervate sensory organs in muscle and joints. Intermediate 
neurons express TrkB and innervate mechanoreceptors. Small nociceptive neurons are peptidergic 
neurons, expressing TrkA, and the fourth class consists of non-peptidergic neurons (Montano et al., 
2010).  
 
Figure 11. Schematic representation of DRG neuronal populations and their projection 
Four main classes of DRG sensory neurons (B) project fibers into the periphery and the dorsal horn of 
the spinal cord (A). Small neurons have afferent myelinated Aδ and unmyelinated C fibers from the 
epidermis (E) forming intraepidermic nerve fibers (IEF). These fibers end in spinal cord in laminae I, II, 
and V. Intermediate neurons have afferent myelinated Aβ fibers from mechanoreceptors like Meisner 
corpuscles (Mc) and Pacinian corpuscles (Pc) that reach the laminae III and V or to the central nervous 
system nuclei. Large neurons have afferent input via myelinated Aα fibers from the muscle spindels 
(MS). Taken from Montano et al. (2010). 
 
DRG sensory neurons extend peripheral processes (Aα, Aβ, Aδ, and C fibers), which innervate various 
parts of the body including the skin (e.g. sensory organs in the skin and free nerve ending in the 
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epidermis) (Figure 11). Nociceptive small neurons sense pain and temperature send the messages to 
laminae I and II through thinly myelinated Aδ and unmyelinated C fibers, in an intermediate or slow 
conducting form. Mechanoreceptors convey touch by moderately myelinated Aβ fibers from 
intermediate sized neurons to the laminae III and V or to central nervous system nuclei. The 
proprioception is mediated by large neurons, which project myelinated Aα fibers with a fast 
conduction velocity to the skeletal muscles. Fibers end in the lamina VII, and connect directly to the 
ventral motor neurons (Caspary and Anderson, 2003, Montano et al., 2010).  
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2 Aim of the study  
Previous studies have reported that Panx1 is expressed in vitro in neural stem cells (Ray et al., 2005). 
Other studies confirmed this finding in vivo (Wicki-Stordeur et al., 2012, Wicki-Stordeur and Swayne, 
2013). Panx1 expression was identified in a defined neuronal population during postnatal (Wicki-
Stordeur et al., 2012) and adult (Wicki-Stordeur and Swayne, 2013) neurogenesis of the mouse brain. 
In neural stem and progenitor cells, Panx1 was shown to regulate cell proliferation by mediating ATP 
release (Wicki-Stordeur et al., 2012) in addition to influencing on cell migration and neurite extension 
during neurogenesis (Wicki-Stordeur and Swayne, 2013). 
These data have led to hypothesize that Panx1 might be important for embryonic neurogenesis. 
However, Panx1 expression during early neurogenesis remained largely unknown. There were only 
some reports showing Panx1 mRNA expression at late stages of mouse and rat development. 
Therefore, the analysis of the temporal and spatial expression of Panx1 mRNA and protein at the 
beginning of neurogenesis (E9.5 – E12.5) is essential for understanding its functional implication. 
The first aim of the study was therefore to investigate the temporal expression of Panx1 mRNA and 
protein at early stages of mouse development (E9.5 – E12.5). In those stages expressing Panx1, the 
spatial distribution of Panx1 mRNA and protein was to be analyzed in whole mount samples or in 
histological sections of embryos. Panx1 protein expression has never been described before in 
embryonic stages. In the present study, the temporal protein expression was studied in E9.5 – E12.5 
stages. The spatial distribution of Panx1 protein was also investigated in defined regions, in spinal cord 
and sensory ganglia, to determine cell populations expressing Panx1. 
Given that Panx1 mRNA was shown to be abundantly expressed in spinal cord and sensory ganglia of 
studied embryonic stages, the second aim of the study was a detailed analysis of Panx1 expression in 
these particular regions. In spinal cord, the spatial distribution of Panx1 was investigated in prenatal 
(E18.5), postnatal (P9 and P12) and adult stages. Relative gene expression of Panx1 in adult spinal cord 
was also compared with other associated genes. Possible phenotypic changes due to Panx1 deletion 
were examined in transgenic animals. In dorsal root ganglia, cell populations expressing Panx1 were 
determined. Given that different sensory ganglia relay information from different regions of the body 
(dermatomes), relative gene expression of Panx1 and other related genes was compared between 
different regions of sensory ganglia i.e. trigeminal ganglion and dorsal root ganglia of cervical, thoracic 
and lumbar regions.  
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3 Materials and Methods 
3.1 Materials 
Devices 
Analytical Balance  Sartorius, Göttingen, Germany 
Autoclave Systec D-65 Labor-Systemtechnik, Wettenberg, Germany 
Camera AxioCam ERc 5s Carl Zeiss, Göttingen, Germany 
Camera AxioCam MRm Carl Zeiss, Göttingen, Germany 
Camera CC-12 Olympus, Hamburg, Germany 
Cold-light source CL 1500 ECO Carl Zeiss, Göttingen, Germany 
Cryostat, Leica CM 1950 Leica, Wetzlar, Germany 
Embedding Center, MPS/P1 and MPS/C  Slee, Mainz, Germany 
Filter Sets (43HE, 38HE, and 49) Carl Zeiss, Göttingen, Germany 
Fluorescent Lamp HXP 120 C Carl Zeiss, Göttingen, Germany 
FUSION-FX7/SL Advance System PEQLAB, Erlangen, Germany 
Gel Electrophoresis System  PEQLAB, Erlangen, Germany 
Glass Knives C335 Plano, Wetzlar, Germany 
Heraeus Megafuge 16 R Centrifuge Thermo Fisher Scientific, Heidelberg, Germany 
Heratherm Oven Thermo Fisher Scientific, Heidelberg, Germany 
Himac CT 15RE centrifuge Hitachi Koki, Tokyo, Japan 
Historange Microtome 2218 Lkb Bromma, Sollentuna, Sweden 
Hybridization Oven, HB-1000 Ultra-Violet Products Ltd, Cambridge, Uk 
KERN PLE Scale KERN & SOHN Gmbh, Balingen, Germany 
Life Touch Thermal Cycler Biozym, Hessisch Oldendorf, Germany 
Micro-Plate Reader Infinite M200  Tecan, Crailsheim, Germany 
Microscope, Observer.Z1 Carl Zeiss, Göttingen, Germany 
Microscope, Olympus BX51 TF Olympus, Hamburg, Germany 
Microtome, HM 350 Techno-Med Gmbh, Bielefeld, Germany 
Mini Rocker  PEQLAB, Erlangen, Germany 
Nano Drop ND-1000 Thermo Fisher Scientific, Heidelberg, Germany 
Orbital Incubator SI500 Bibby Scientific, Stone, UK 
Paraffin Tissue Floating Bath Medax , Neumünster, Germany 
Robust Carousel Tissue Processor, mtp Slee, Mainz, Germany 
Semi-Dry Electro Blotter System PEQLAB, Erlangen, Germany 
Sonoplus, Ultrasonic Homogenizer  Bandelin Electronic, Berlin, Germany 
StepOnePlus Real Time PCR system Applied Biosystems, Foster City, USA 
Stereo Microscope Discovery. V8 Carl Zeiss, Göttingen, Germany 
Stereo Microscope SZX12 Olympus, Hamburg, Germany 
Thriller Thermo Shaker Incubator PEQLAB, Erlangen, Germany 
Ultra-Turrax Ika T10 Ika, Staufen, Germany 
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Universal Oven Memmert, Schwabach, Germany 
UV- Transilluminators Vilber Lourmat,  Eberhardzell, Germany 
Vibratome, LEICA VT1000 S Leica, Wetzlar, Germany 
Water Purification System Q-Pod 
Merck Millipore, Darmstadt, Germany 
Chemicals 
Acetic Acid VWR, Darmstadt, Germany 
Acrylamid Mix (Rotiphorese Gel 30) Carl Roth, Karlsruhe, Germany 
Agar AppliChem, Darmstadt, Germany 
Agarose Biozym Scientific, Hessisch Oldendorf, Germany 
Ammonium Acetate Fisher Scientific, Nidderau, Germany 
Ammonium peroxodisulfate Carl Roth, Karlsruhe, Germany 
Ampicillin  Carl Roth, Karlsruhe, Germany 
BamHI New England Biolabs, Hitchin, UK 
BCA assay kit  Thermo Fisher Scientific, Heidelberg, Germany 
Bis-Tris AppliChem, Darmstadt, Germany 
Blocking Reagent Roche, Manheim, Germany 
Bovine Serum Albumin MP Biomedicals, Heidelberg, Germany 
Bromophenol Blue Dye Alfa Aesar, Karlsruhe, Germany 
cDNA synthesis reaction buffer Thermo Fisher Scientific, Heidelberg, Germany 
CHAPS Alfa Aesar, Karlsruhe, Germany 
Chloroform Sigma-Aldrich, München, Germany 
Chromogenic substrate, TMB Dako, Hamburg, Germany 
Complete, Protease Inhibitor Cocktail Tablets Roche, Manheim, Germany 
Cresyl violet staining Merck, Darmstadt, Germany 
DAPI-Fluoromount-G Southern Biotechnology, Birmingham, USA 
DEPC Sigma-Aldrich, München, Germany 
DIG RNA Labeling Kit Roche, Manheim, Germany 
DNA loading Dye Thermo Fisher Scientific, Heidelberg, Germany 
dNTPs New England Biolabs, Hitchin, UK 
EcoRI  New England Biolabs, Hitchin, UK 
EcoRV New England Biolabs, Hitchin, UK 
EDTA Carl Roth, Karlsruhe, Germany 
EGTA AppliChem, Darmstadt, Germany 
Ethanol Pure Sigma-Aldrich, München, Germany 
Formaldehyde VWR, Darmstadt, Germany 
Formamid AppliChem, Darmstadt, Germany 
Freund’s Adjuvant Sigma-Aldrich, München, Germany 
Gel Red Biotium, Hayward, USA 
Gene Ruler 1 kb Plus DNA Ladder Fermentas, Heidelberg, Germany 
Gene Ruler Low Range DNA Ladder Fermentas, Heidelberg, Germany 
Glutardialdehyde Merck, Darmstadt, Germany 
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Glycine Carl Roth, Karlsruhe, Germany 
Heparin Carl Roth, Karlsruhe, Germany 
Hydrogen Peroxide (H2O2) Thermo Fisher Scientific, Heidelberg, Germany 
kanamycin  Sigma-Aldrich, München, Germany 
Lamb Serum  Invitrogen, Darmstadt, Germany 
Lithium Carbonate Sigma-Aldrich, München, Germany 
Lumi-Light Western Blotting Substrate Roche, Manheim, Germany 
Luxol Fast Blue Fisher Scientific, Nidderau, Germany 
Magnesium Chloride Merck, Darmstadt, Germany 
Masson Goldner Trichrome Staining Kit Carl Roth, Karlsruhe, Germany 
NBT/BCIP Roche, Manheim, Germany 
Nonfat Milk  Carl Roth, Karlsruhe, Germany 
Normal Goat Serum Sigma-Aldrich, München, Germany 
NP-40 Alternative Merck, Darmstadt, Germany 
Nuclear Fast Red Sigma-Aldrich, München, Germany 
Oligo (dT) Thermo Fisher Scientific, Heidelberg, Germany 
Page Ruler Plus Prestained Protein Ladder Thermo Fisher Scientific, Heidelberg, Germany 
Paraffin Wax (mp. 44-46°C)  Sigma-Aldrich, München, Germany 
Paraffin Wax (mp. 55-57°C) Carl Roth, Karlsruhe, Germany 
Paraformaldehyde Electron Microscopy Sciences, Hatfield, USA 
PCR Reaction Buffer New England Biolabs, Hitchin, UK 
Picric Acid Solution AppliChem, Darmstadt, Germany 
Plasmid Midi Kit (25) QIAGEN, Erlangen, Germany 
Ponceau Red Carl Roth, Karlsruhe, Germany 
Potassium Ferricyanide Carl Roth, Karlsruhe, Germany 
Potassium Ferrocyanide Carl Roth, Karlsruhe, Germany 
Pre-stained protein marker broad range New England Biolabs, Hitchin, UK 
Proteinase K Roche, Manheim, Germany 
Restriction Endonuclease Buffer New England Biolabs, Hitchin, UK 
RevertAid-RT Thermo Fisher Scientific, Heidelberg, Germany 
RNase inhibitor Thermo Fisher Scientific, Heidelberg, Germany 
RNase-free DNase I set QIAGEN, Erlangen, Germany 
RNeasy Lipid Tissue Mini Kit QIAGEN, Erlangen, Germany 
Roti-Histokitt Carl Roth, Karlsruhe, Germany 
Roti-Histol Carl Roth, Karlsruhe, Germany 
Roti-Mount Aqua Carl Roth, Karlsruhe, Germany 
Sodium Chloride VWR, Darmstadt, Germany 
Sodium citrate tribasic dehydrate (S-4641) Sigma-Aldrich, München, Germany 
Sodium Deoxycholate AppliChem, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
T4 DNA Ligase Fermentas, Heidelberg, Germany 
TakyonTM Rox SYBR Master Mix dTTP Blue kit Eurogentec, Seraing, Belgium 
Taq DNA polymerase New England Biolabs, Hitchin, UK 
TEMED Carl Roth, Karlsruhe, Germany 
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Tissue Tek Sakura, Staufen, Germany 
Tris base Sigma-Aldrich, München, Germany 
Tris HCl   Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
tRNA Roche, Manheim, Germany 
Tryptone Sigma-Aldrich, München, Germany 
Tween 20 Sigma-Aldrich, München, Germany 
X-Gal Carbolution Chemicals, Germany 
Yeast – Extract Sigma-Aldrich, München, Germany 
β-mercaptoethanol 
Carl Roth, Karlsruhe, Germany 
Consumables 
12-well culture plate  SARSTEDT, Nümbrecht, Germany 
96-well-plate SARSTEDT, Nümbrecht, Germany 
Coverslips R. Langenbrinck, Emmendingen, Germany 
Filter papers (190 g/m2) A. Hartenstein, Würzburg, Germany 
Fixogum Marabu, Tamm, Germany 
Nitrocellulose membrane (0.45 µm) GE Healthcare, Freiburg, Germany 
Peel-a-way disposable embedding molds Polysciences Europe, Eppelheim, Germany 
Pipette tips and tubes  SARSTEDT, Nümbrecht, Germany 
Razor blades Electron Microscopy Sciences, Hatfield, USA 
Real time qPCR 96 well plate Applied Biosystems, Foster City, USA 
SuperFrost Plus slides 
R. Langenbrinck, Emmendingen, Germany 
Software 
Adobe Photoshop CS4 Adobe Systems Software, California, USA 
AxioVision v 4.8. Carl Zeiss Microscopy, Jena, Germany 
Cell^P imaging software Olympus, Hamburg, Germany 
EndNote X6 Thomson Reuters, New York, USA 
FUSION-CAPT software PEQLAB, Erlangen, Germany 
Magelan software  TECAN, Crailsheim, Germany 
Prism 5 GraphPad Software, San Diego, USA 
Slide digital virtual microscopy V 1.2 Olympus, Hamburg, Germany 
StepOne software V 2.2 Applied Biosystems, Foster City, USA 
ZEN 2011 Carl Zeiss Microscopy, Jena, Germany 
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3.1.1 Antibodies 
Table 1. Primary antibodies 
Antibody Host Dilution Code Number Manufacturer 
anti-Panx1 (antiserum) Rabbit, pAb 
1:200 IF 
1:1000 IB 
1307 Saarland University* 
pre-immune serum (PIS) Rabbit 
1:100 IF 
1:1000 IB 
1307 Saarland University* 
anti Panx1 Rabbit, mAb 1:10,000 IB ab124969 abcam 
anti Panx1 Rabbit, pAb 1:500 IB ab139715 abcam 
anti Panx1 Mouse, mAb 1:500 IB MAB7097 R&D 
anti Panx2 Rabbit, pAb 1:2000 IB ARP42778_T100 AVIVA 
anti P2X7R Rat, mAb 1:100 IF MCA4713 AbD Serotec 
anti-DIG-AP Sheep, pAb 1:2000 ISH 11093274910 Roche 
anti β-III-tubulin (Tuj1) Mouse, mAb 1:500 IF MMS-435P Covance 
Primary Antibodies used for IF (immunofluorescence), IB (immunoblotting) and ISH (in situ 
hybridization). mAb (monoclonal antibody), pAb (polyclonal antibody). *Prof. Zimmermann, Dr. Jung, 
Dept. Of Biochemistry, Saarland University. 
 
Table 2. Panx1 antibodies recognize different epitopes of the protein 
Anti-Panx1 Epitope region Caspase cleavage product Panx1 isoforms 
1307 (antiserum) C-terminus 6, 30 kDa Panx1 (a, c) 
ab124969 (abcam) C-terminus 6, 30 kDa Panx1 (a, c) 
ab139715 (abcam) 1EL and 2Td 19, 42 kDa Panx1 (a, c, d) 
MAB7097 (R&D) C-terminus 6, 30, 42 kDa Panx1 (a, c, d) 
Antibodies used for Panx1 detection recognize different regions of the protein. For the present study, 
the generated antiserum (1307) recognizes a short part of the C-terminus. The antibody ab124969 
recognizes the C-terminus of human Panx1 and only 45 % of its epitope sequence is alignment in mouse 
sequence. The antibody ab139715 recognize a large region of the first extracellular loop (1EL) and the 
second transmembrane domain (2Td). The antibody MAB7097 recognizes most C-terminus region (87 
aa). Different predicted fragments of caspase cleavage are detectable with these antibodies; 
detectable fragments are listed in size. Not all Panx1 isoforms are detectable with these antibodies, 
Panx1a (48 kDa), Panx1c (40 kDa), and Panx1d (34 kDa) (Li et al., 2011).  
Materials and Methods 
29 
 
Table 3. Secondary antibodies 
Antibody Host Dilution Code Number Manufacturer 
anti-rabbit HRP Goat 1:10000 IB A10547 Invitrogen 
anti-mouse HRP Goat 1:50000 IB 115-035-146 Jackson Immune Research 
anti-rabbit-Alexa488 Goat 1:3000 IF A11008 Invitrogen 
anti-rabbit-Alexa568 Goat 1:3000 IF A11011 Invitrogen 
anti-rat-Alexa594 Goat 1:3000 IF A-11007 Invitrogen 
Secondary antibodies used for IF (immunofluorescence) and IB (immunoblotting). 
3.2 Animal experiments 
3.2.1 Animal handling 
All animal experiments were performed with the approval of the governmental animal care committee 
of the Saarland, Germany. All mice were bred and housed under standard conditions in the animal 
core facility at the Institute for Clinical and Experimental Surgery, Medical faculty of Saarland 
University. Adult rabbits were housed under standard conditions at the Institute for Medical 
Biochemistry and Molecular Biology, Saarland University. 
3.2.2 Animals 
An adult rabbit (New Zealand White Rabbit) was used to generate polyclonal antibodies against Panx1. 
C57Bl/6N mice (Charles River Laboratories, Sulzfeld, Germany) were used as wildtype mice. 
Two transgenic strains, Panx1tg/tg and Panx2tg/tg, were provided by Prof. Dr. Hannah Monyer, 
Department of Clinical Neurobiology, University Hospital of Neurology, Heidelberg, Germany. 
Generation of transgenic mice Panx1tg/tg (Anselmi et al., 2008) and Panx2tg/tg (Bargiotas et al., 2011) 
was performed by inserting the LacZ gene into the exon1 of Panx1 and Panx2 of C57Bl/6 mice, 
respectively (Figure 12). For this generation, genomic Panx1 and Panx2 fragments, which were 
obtained after screening a 129/SvJ mouse genomic library, were modified by inserting the bacterial 
gene LacZ and a phosphoglycerate kinase-neomycin cassette flanked by loxP into exon1 of both 
fragments. The modified construct was linearized and transfected into R1 embryonic stem cells using 
electroporation to replace the target fragment via homologous recombination. Clones of transfected 
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embryonic stem cells were injected into blastocytes, which were implanted into foster mothers. 
Chimeric animals were bred to obtain stable transgenic animals. The neomycin cassette was removed 
from transgenic animals by breeding with Cre-deleter mice.  
 
 
Figure 12. Transgenic mice generation 
A scheme shows the location of the LacZ cassette within exon1 of the Panx1 (top) and Panx2 (bottom) 
allele in transgenic strains Panx1tg/tg and Panx2tg/tg. Restriction endonucleases: A, ApaI; B, BamHI and 
E, EcoRI. Taken from Bargiotas et al. (2011). 
3.2.3 Collection of mouse embryos 
Female mice were mated with males (2:1) for 15 hours. The vaginal plug was examined at the time of 
separation. The day, on which a vaginal plug was found, was designated embryonic day (E) 0.5. 
Pregnant mice were sacrificed by intra-peritoneal injection with Pentobarbital-Sodium “Narcoren” (4 
g/kg body weight) (Merial, Hallbergmoos, Germany) or with Phenobarbital-Sodium “Luminal” (500 
mg/kg body weight) (Destin, Hamburg, Germany) on day 9.5, 10.5, 11.5, 12.5 or 18.5 of gestation. 
Uterine horns were dissected from the mouse and were placed in a petri dish containing phosphate 
buffer (PB) or 0.1 % diethyl pyrocarbonate treated phosphate buffered saline (DEPC-PBS), according 
to the protocol of the experiment. Embryos were isolated from the decidua, yolk sac and the amniotic 
sac for staging as described in Chapter 3.2.4. Staged embryos were treated according to specific 
experimental conditions. 
3.2.4 Staging of embryos  
Embryos were staged according to the description in the Atlas of Mouse Development (Kaufman, 
2003), focussing on the morphological differentiation of limbs at each stage. At embryonic day (E) 9.5, 
only forelimb buds are visible in the truncal region (Figure 13). At E10.5, hindlimb buds appear at the 
caudal extremity in the tail region. At E11.5, only the forelimbs are clearly divided into proximal and 
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distal regions, whereas hindlimb buds do not show this differentiation yet. At E12.5, the handplate 
shows angular contour, which are future digits, and the footplate is to see in a polygonal shape. 
 
Figure 13. Staging of embryos 
A schematic representation of mouse embryos shows staging strategies of studied embryos. At E9.5, 
the forelimb buds are visible. At E10.5, the hindlimb buds appear at the caudal extremity of the tail 
region. At E11.5, forelimbs are divided into proximal and distal parts. At E12.5, the handplate shows 
angular contour and the footplate has a polygonal shape. Black lines indicate sections levels as shown 
in the original scheme. Taken from Kaufman (2003). 
3.2.5 Dissection of organs  
Spinal cord, trigeminal ganglia and dorsal root ganglia (DRG) were collected at different ages and 
studied in histological and molecular biological ways. 
 In spinal cord, the cranial thoracic region between T2 and T6 segments was dissected and 
investigated in different methods. For real time qPCR experiment, the cranial thoracic region was 
divided into dorsal and ventral parts using razor blades (Electron Microscopy Sciences, Hatfield, 
USA) and subjected to RNA extraction prior to the cDNA synthesis and real time qPCR.  
 Dorsal root ganglia were collected of determined regions. At first, spinal segments were identified 
according to the description of Harrison et al. (2013). For histological experiments, thoracic ganglia 
were dissected so that they remained attached to the spinal cord. For real time qPCR experiment, 
vertebral columns of 9 animals were divided at C1, T1, T7, T13 and L6 segments into four regions 
(Table 4) Within each region, ganglia were pooled from three animals. All regions were analyzed in 
triplicate (n=3 per group). 
 
Table 4. Groups of collected dorsal root ganglia 
Materials and Methods 
32 
 
Group Region Segments 
1 Cervical  C2 to C8 
2 Cranial thoracic  T2 to T6 
3 Caudal thoracic  T8 to T12 
4 Lumbar  L1 to L5 
 Dissection and identification of trigeminal ganglia was performed as described in the protocol of 
Malin et al. (2007). The brain and the brainstem were dissected from the skull. This way, the 
trigeminal nerve was identified at the income point to the brainstem (Figure 14). Branches of 
mandibular nerve, ophthalmic nerve and maxillary nerve were cut of the trigeminal nerve. 
Trigeminal ganglia including the trigeminal nerve were collected and treated as described in 
Chapter 3.2.6. 
 
Figure 14. The location of the trigeminal ganglion 
A view of the cranial cavity after dissection of the brain shows the location of the trigeminal ganglion 
(TG) on the trigeminal nerve (V) at the branching point of the mandibular nerve. Ophthalmic nerve 
(V1), maxillary nerve (V2), mandibular nerve (V3). 
3.2.6 Cryopreservation of tissues and cryosectioning 
For RNA and protein extraction experiments, 8±2 embryos of E9.5 were pooled prior to freezing. 
Embryos of E10.5, 11.5 and 12.5 were divided in two parts: head and body. Heads or bodies of litters 
from each stage were pooled also prior to freezing. The collected samples of embryos or other organs 
were snap frozen in liquid nitrogen and subjected to RNA or protein extraction. 
To cryopreserve samples for cryosectioning, unfixed samples were embedded in OCT medium (Tissue 
Tek, Sakura, Staufen, Germany) using peel-a-way disposable embedding molds (Polysciences Europe 
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GmbH, Eppelheim, Germany) and frozen in the gas phase of liquid nitrogen. The frozen samples were 
stored at -80°C until further use. 
Samples were cut on a cryostat, Leica CM 1950 (Leica, Wetzlar, Germany), in a thickness of 10 µm for 
immunofluorescence and 15 µm for β-Gal staining. Sections were mounted onto SuperFrost Plus slides 
(R. Langenbrinck, Emmendingen, Germany) and allowed to dry at 37°C for 30 min, before using in the 
experiment or storing at -80°C until further use. 
3.2.7 Genotyping of transgenic animals 
Genotyping of transgenic animals was performed using the PCR as described by Bargiotas et al. (2011). 
Tail tips of studied mice were digested in the genotyping lysis buffer including proteinase K (Roche, 
Manheim, Germany) at 55°C for 24 hours by mixing intensity of 60 rpm in a Thermoshaker Incubator 
(PEQLAB, Erlangen, Germany). After that, proteinase K was inactivated at 95°C for 20 min. 2 µl of this 
tissue extract was used as template for PCR reaction mixture. PCR reaction mixture included 1x PCR 
reaction buffer (New England Biolabs, Hitchin, UK), 0.2 µM specific primers (Table 5) (Sigma-Aldrich, 
München, Germany), 0.2 mM dNTPs (New England Biolabs), and 0.3 U Taq DNA polymerase (New 
England Biolabs). Double-distilled water (ddH2O) was added to the reaction mixture to make a final 
volume of 25 µl. ddH2O was purified using the purification system Q-Pod (Merck Millipore, Darmstadt, 
Germany). The amplification of the target DNA was performed using the cycler LifeTouch Thermal 
(Biozym, Hessisch Oldendorf, Germany) under following conditions: 
Heated lid 110°C   
Initial denaturation 95°C 5 min 
Denaturation 95°C 30 s 
35 Cycles Annealing 60°C 30 s 
Extension 72°C 40 s 
Final extension 72°C 5 min  
 10°C ∞ 
PCR product was separated and visualized using agarose gel electrophoresis as described in Chapter 
3.5.6. The amplified size of the PCR product was used to determine the genotype of samples. This 
experiment was performed and analyzed by Andrea Rabung. 
PCR buffer 10x 
KCl 500 mM 
Tris buffer 100 mM 
MgCl2 22.5 mM 
DMSO 5 % (v/v) 
in ddH2O  
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Genotyping lysis buffer 
PCR buffer (10x)  1x 
Proteinase K 0.2 µg/µl 
in ddH2O   
Table 5. Primers used for Genotyping of transgenic mice 
Primers Sequence 
Amplification 
product length 
Genotype 
Panx1 
Fwd: 5`GGAAAGTCAACAGAGGTACCC 3` 
330 bp Panx1wt/wt 
Rev: 5`CTTGGCCACGGAGTATGTGTT 3` 
Rev: 5`GTCCCTCTCACCACTTTTCTTACC 3` (lacZ region) 630 bp Panx1tg/tg 
Panx2 
Fwd: 5`TCCTGCTATGAAGCTGGCATCTCTG 3` 350 bp 
430 bp 
Panx2wt/wt 
Panx2tg/tg Rev: 5`CAAGAAGCCACCCTTGACTGGCAAA 3` 
 
 
Figure 15. Genotyping of transgenic mice 
A specific region of genomic DNA was amplified using standard PCR conditions and analyzed by agarose 
gel electrophoresis. The size of PCR products was used to determine the genotype of animals. One PCR 
product was present in homozygous animals Panx1wt/wt (334 bp), Panx1tg/tg (630 bp), Panx2wt/wt (350 
bp), and Panx2tg/tg (430 bp). Two PCR products were present in heterozygous animals Panx1wt/tg (334 
and 630 bp) and Panx2wt/tg (350 and 430 bp). Broad range DNA ladder (M).  
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3.3 Reverse transcriptase PCR (RT-PCR) 
The expression of a gene of interest was detected using the reverse transcriptase-polymerase chain 
reaction (RT-PCR) technique. The total RNA including mRNAs was extracted from a tissue to transcribe 
mRNAs into the complementary DNA (cDNA) using the enzyme reverse transcriptase. The target 
sequence of the cDNA can be amplified using polymerase chain reaction (PCR) technique in the 
presence of gene-specific primers. Amplification products can be separated and visualized using 
agarose gel electrophoresis. Observed specific amplification products on the gel indicate the presence 
of the mRNA and its gene expression. 
3.3.1 RNA extraction 
The total RNA was extracted from tissues of interest and embryos. Samples were collected as described 
in Chapter 3.2.6. Tissue homogenization was performed using the ultrasonic homogenizer Sonoplus 
(Bandelin Electronic, Berlin, Germany) or the ultra turrax, Ika T10 (Ika, Staufen, Germany). The 
extraction of RNA was performed using the RNeasy Lipid Tissue Mini Kit (QIAGEN, Erlangen, Germany), 
according to the manufacturer’s instructions. The extraction included an on-column DNase-digestion 
step using an RNase-free DNase I set (QIAGEN). The RNA of all samples was eluted in 30 µl RNase-free 
water, except the RNA of cerebellum and brainstem samples, which were eluted in 50 µl of RNase-free 
water. The RNA was quantified using the spectrophotometer nano drop ND-1000 (Thermo Fisher 
Scientific, Heidelberg, Germany). 
3.3.2 cDNA synthesis 
The cDNA was synthesized from total RNA extract (see Chapter 3.3.1) using the enzyme RevertAid 
Reverse Transcriptase (Thermo Fisher Scientific). Two reactions served as negative controls: one was 
performed in the absence of the template (NT) and the other without reverse transcriptase (NR). 1 µg 
of the total RNA was incubated with 0.5 µg Oligo (dT) primer (Thermo Fisher Scientific) and DEPC-H2O 
in a volume of 12.5 µl at 65°C for five min, to hybridize primers to the RNA. This reaction mix was 
supplemented with reaction buffer (Thermo Fisher Scientific), 20 U RNase inhibitor (Thermo Fisher 
Scientific), 1 mM dNTP (New England Biolabs, Hitchin, UK), 200 U RevertAid-RT (Thermo Fisher 
Scientific) in a final volume of 20 µl. cDNA synthesis was performed at 42°C for one hour, followed by 
an inactivation step at 70°C for 10 min.  
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3.3.3 Polymerase chain reaction (PCR) 
The third step of the RT-PCR technique is the amplification of the target cDNA sequence using the 
polymerase chain reaction (PCR) technique. PCR technique is based on the amplification of a target 
cDNA sequence using a cDNA polymerase enzyme, which synthesizes a new DNA strand in the 
presence of target-specific primers and deoxynucleotide triphosphates (dNTPs). PCR was performed 
at the same time for all samples of cDNA synthesis including negative controls of NT and NR. The PCR 
reaction mix included 2 µl cDNA as template in addition to 2.5 U Taq DNA polymerase (New England 
Biolabs), 10 µM Primers (Table 7) (Sigma-Aldrich), 10 mM dNTPs (New England Biolabs), 1x PCR 
reaction buffer (New England Biolabs) and DEPC-H2O in a final volume of 25 µl. All PCRs had an initial 
denaturation step of 30 s at 95°C and a final extension step of 10 min at 68°C. The amplification was 
performed using the LifeTouch Thermal Cycler (Biozym) under different PCR conditions for different 
primers (see Table 6). The PCR product was separated and visualized using agarose gel electrophoresis 
as described in Chapter 3.5.5.  
Table 6. PCR conditions 
Target Denaturation Annealing Extension Cycles (n) 
Panx1 Ct 95°C; 30 s 56°C, 30 s 68°C, 2 min 25 
Panx2 95°C; 30 s 57°C, 30 s 68°C, 2 min 30 
18S rRNA 95°C; 30 s 56°C, 30 s 68°C, 2 min 20 
All PCRs had an initial denaturation step of 30s at 95°C and final extension of 10 min at 68°C. Primers 
had different annealing temperatures and different number of cycles. 
 
Table 7. Primers used in RT-PCR 
Primers Sequence Amplification product length 
Panx1 Ct 
Fwd: 5` AGAGAGGAATTCTGCAAGCTCATCGCCGTG 3` 
443 bp 
Rev: 5` AGAGAGGGATCCTTTGCTGCAGCCTCGCTG 3` 
Panx2 
Fwd: 5` GAGAAAAAGCATACCCGCCAC 3` 
266 bp 
Rev: 5` GGTGAGCAGACATGGAATGA 3` 
18S rRNA 
Fwd: 5` AAACGGCTACCACATCCAAG 3` 
155 bp 
Rev: 5` CCTCCAATGGATCCTCGTTA 3` 
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3.4 Real time quantitative PCR 
The previously described RT-PCR was used to determine the qualitative expression of Panx1 mRNA in 
defined stages of mouse development. Here, real time quantitative PCR technique was used to 
quantify relative Panx1 mRNA expression in different tissues. This experiment was performed using 
the Rox SYBR Green system. SYBR Green is a fluorescent dye binding to the double-strand DNA and 
emits a fluorescent signal. Rox dye was used as internal passive reference dye to normalize the SYBR 
Green signal in samples. During the amplification process, the increased fluorescent signal was 
measured to evaluate the double-strand DNA concentration. Reference genes were used to normalize 
differences in total RNA between samples. 
Samples of spinal cord, trigeminal ganglia, and DRGs were collected as described in Chapter 3.2.5. 
Triplet samples (n=3) of the cranial thoracic region of spinal cord were collected from three animals 
(47±3 weeks-old). On the other hand, trigeminal ganglia and DRGs were collected from nine animals 
(27±3 weeks-old) to obtain enough quantity of RNA for cDNA synthesis. Ganglia from each studied 
region were pooled from three animals to obtain finally triplet ganglia samples (n=3). The cDNA 
synthesis was performed using 0.5 µg total RNA for spinal cord samples and 1 µg total RNA for 
trigeminal ganglia and DRGs samples in a final reaction volume of 20 µl as described in Chapter 3.3.2.  
Prior to use in the experiment, all cDNA templates were diluted 1:5 with DEPC-H2O. The experiment 
was carried out in a 20 µl reaction mix, including 2.5 µl diluted cDNA template, 300 nM primers (Table 
8) and 10 µl master mix of TakyonTM Rox SYBR Master Mix dTTP Blue kit (Eurogentec, Seraing, Belgium). 
The Takyon master mix contains Takyon DNA polymerase, MgCL2, SYBR Green, dNTPs, Rox passive 
reference and stabilizers. The measurement was performed in a 96 well plate (Applied Biosystems, 
Foster City, USA) using the StepOnePlus Real Time PCR system (Applied Biosystems) under the regular 
amplification conditions, as recommended in the manufacturer’s instructions of Takyon Kit 
(Eurogentec). These includes an initial Takyon activation at 95°C for 3 min followed by 40 cycles of 
denaturation at 95°C for 10 s and annealing /extension at 60°C for 1 min. 
Subsequently, melting curve analysis was performed to identify any primer-dimers or other artifacts. 
Melting curve analysis was performed under the following conditions: 15 s denaturation at 95°C, 1 min 
annealing at 60°C, and continued measurement by increasing the temperature in a ratio of 0.3 °C/s 
from 60°C to 95°C. StepOne™ Software v2.2 (Applied Biosystems) was used to readout data of real 
time qPCR and melting curve. 
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3.4.1 Relative quantification of real time qPCR data 
The relative quantification of real time qPCR data was used to describe the relative expression of a 
gene in target samples compared to another calibration sample. Firstly, a threshold was determined 
for each individual gene during the exponential phase of the reaction. This determination of a 
threshold was used to distinguish the significantly increased signal from the initial fluorescent signal 
(background). The threshold cycle (Ct) indicated the cycle number at which the fluorescence value 
crosses the threshold. In all samples, the mean of a gene of interest was normalized (ΔCt) to the mean 
of the reference gene 18S rRNA as follows: 
ΔCt target = Ct target - Ct reference  
ΔCt values of target samples were related to a calibration sample. In the spinal cord experiment, for 
instance, samples of the ventral region were used as calibration samples (see Chapter 4.6.3). 
Trigeminal ganglia samples were used as calibration samples for sensory ganglia samples (see Chapter 
4.6.6). The relation between samples was calculated by:  
ΔΔCt target = ΔCt target– ΔCt calibration sample 
The relative gene expression in the target sample was calculated by:  
Relative quantity = 2-ΔΔCt 
All regions were analyzed in triplicate (n=3 per group). Data were presented as means ± standard errors 
of the mean (SEM). The statistical analysis of data was performed as described in Chapter 3.14.  
Table 8. Primers used in real time qPCR 
Primers Sequence Amplification product length 
Panx1 
Fwd: 5` AGCCAGAGAGTGGAGTTCAAAGA 3`  
104 bp 
Rev: 5` CATTAGCAGGACGGATTCAGAA 3` 
Panx2 
Fwd: 5` GTCACCCTGGTCTTCACCAA 3`  
113 bp 
Rev: 5` AGCTCTGTCCAGCAGTAGCC 3` 
P2X3R 
Fwd: 5` CTGCCTAACCTCACCGACAAG 3` 
150 bp 
Rev: 5` AATACCCAGAACGCCACCC 3` 
P2X7R 
Fwd: 5` CCTCTGCTATGCCTTTGACC 3` 
148 bp 
Rev: 5` CAGAGCACGAATTATGGCAC 3` 
18S rRNA 
Fwd: 5` AAACGGCTACCACATCCAAG 3` 
155 bp 
Rev: 5` CCTCCAATGGATCCTCGTTA 3` 
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3.5 Cloning of DNA templates for the in vitro transcription 
For whole-mount in situ hybridization (WM-ISH), it was required to prepare recombinant plasmids 
carrying DNA fragments of Panx1. These plasmids are required for in vitro transcription of cRNA 
probes.  
The source of murine pannexin1 (mPanx1) DNA fragment was a recombinant plasmid, which was 
obtained as a gift from Prof. Dr. Georg Zoidl (Ruhr-University Bochum, Germany). In this recombinant 
plasmid, mPanx1 was inserted into the plasmid pEYFP-N1 (Figure 16) at the restriction site of EcoRI. 
Figure 16. The map of the pEYFP-N1 vector 
The full-length mPanx1 DNA fragment was inserted into the plasmid pEYFP-N1 at the restriction site 
of EcoRI. This recombinant plasmid was used as the source of mPanx1 DNA fragment. Taken from BD 
Biosciences (Heidelberg, Germany).  
 
For in vitro transcription, two DNA fragments of Panx1 (full-length and short-length) were inserted into 
appropriate plasmids, pSPT18 and pSPT19 (Figure 17). These plasmids contain T7 and SP6 RNA 
polymerase promoters. 
3.5.1 Preparation of the Panx1 short-length DNA fragment 
The recombinant plasmid pEYFP-N1-mPanx1 was used as a template to amplify a short DNA fragment 
of 443 base pairs (bp) (bases 1231 to 1673) encoding the carboxy-terminus of murine Panx1 (Panx1 
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Ct). Primers were designed using tools of the program NCBI Primer-BLAST. Sequences of restriction 
endonucleases were designed at the 5´-end of primers to allow insertion of the short fragment into 
vectors. The forward primer included an EcoRI sequence and the reverse primer included a BamHI 
sequence (Table 9). 
Table 9. Primers used for Panx1 Ct amplification 
Primers Sequence Amplification product length 
Panx1 Ct 
Fwd: 5` AGAGAGGAATTCTGCAAGCTCATCGCCGTG 3` 
443 bp 
Rev: 5` AGAGAGGGATCCTTTGCTGCAGCCTCGCTG 3` 
Primer included sequences of restriction endonucleases EcoRI (GAATTC) and BamHI (GGATCC). 
 
The short fragment (Panx1 Ct) was amplified by PCR using 0.3 µg purified plasmid pEYFP-N1-mPanx1 
in a reaction volume of 50 µl including 2.5 U Taq DNA polymerase (New England Biolabs), 10 µM 
Primers (Sigma-Aldrich) (Table 9), 10 mM dNTPs (New England Biolabs), 1x reaction buffer (New 
England Biolabs) and ddH2O. An additional reaction mix, which contained all reaction components 
without the template, served as negative control. The amplification was performed under cycling 
conditions of an initial denaturation step at 95°C for 30s followed by 30 cycles of denaturation at 95°C 
for 30s, annealing at 56°C for 30s, and extension at 68°C for 2 min. Finally, the reaction had an 
extension step at 68°C for 10 min. PCR amplification was performed using the LifeTouch Thermal Cycler 
(Biozym). 
PCR product was examined by agarose gel electrophoresis (see Chapter 3.5.6) to ensure the specificity 
of the amplified fragment according to its size and by comparing it to the negative control without 
template. The amplified fragment was separated from the template by cutting out the specific 
amplification product under UV light as a gel block using UV-transilluminators (Vilber Lourmat,  
Eberhardzell, Germany). This DNA fragment was purified from the isolated gel block using the method 
freeze-squeeze (Thuring et al., 1975). In this method, the isolated gel block was frozen at -20°C 
overnight. The frozen gel block was squished gently using a Parafilm section to extract an aqueous 
solution from the gel. The resulting liquid consists of solution of agarose gel and separated DNA. DNA 
was purified from the collected aqueous solution by isopropanol precipitation as described in Chapter 
3.5.5. After purification, the PCR product was eluted in 10 µl ddH2O. This purified DNA fragment (Panx1 
short-length) was joined to the linearized plasmid pSPT19 (Figure 17) using the enzyme T4 DNA ligase 
(Fermentas, Heidelberg, Germany) as described in Chapter 3.5.3.  
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3.5.2 Preparation of the Panx1 full-length DNA fragment 
The recombinant plasmid pEYFP-N1-mPanx1 contains the full-length fragment of mPanx1 (1280 bp), 
which is flanked by restriction sites of EcoRI at both termini. This recombinant plasmid does not allow 
in vitro transcription, as this plasmid does not contain any promoters for RNA polymerase. Therefore, 
it was required to transfer the Panx1 full-length fragment from pEYFP-N1-mPanx1 into appropriate 
plasmids, pSPT18 and pSPT19, which are flanked by T7 and SP6 RNA polymerase promoters. Firstly, 
the recombinant plasmid pEYFP-N1-mPanx1 was digested using the restriction endonuclease EcoRI. 3 
µg purified recombinant plasmid of pEYFP-N1-mPanx1 was digested in the presence of 10 units of the 
restriction endonuclease EcoRI (NEB), 1x restriction endonuclease buffer (NEB) and ddH2O in a final 
volume of 20 µl. Digestion was performed at 37°C for one hour. After digestion, Panx1 full-length 
fragment was separated from the plasmid pEYFP-N1 by agarose gel electrophoresis (see Chapter 
3.5.5). This fragment was also isolated from the gel using the method freeze-squeeze (see Chapter 
3.5.1), followed by isopropanol precipitation as described in Chapter 3.5.5. This purified DNA fragment 
(Panx1 full-length) was finally inserted into linearized plasmids pSPT18 and pSPT19 using the enzyme 
T4 DNA ligase (Fermentas) as described in Chapter 3.5.3. 
3.5.3 Ligation of fragments into Vectors 
The enzyme T4 DNA ligase binds 5’-phosphate to 3’-hydroxyl termini in double-strand DNA. Ligation of 
DNA was performed in a 20 µl reaction volume including 35 ng of linearized plasmid (see Table 10)  and 
0.3 µg of DNA insert in addition to 5 units T4 DNA Ligase (Fermentas), 1x T4 ligase buffer (Fermentas) 
and ddH2O. The mixture was incubated at 16°C for one hour. The resulting recombinant plasmid was 
amplified using competent bacteria as described in Chapter 3.5.4. 
Table 10. Linearization of plasmids prior to DNA insertion 
Plasmid linearization site of the plasmid DNA insert 
pSPT 19 EcoRI BamHI Panx1 short-length 
pSPT 19 EcoRI Panx1 full-length 
pSPT 18 EcoRI Panx1 full-length 
3.5.4 Bacterial transformation 
Bacterial transformation was performed in a S1 approved laboratory. All transformed organism were 
recorded at the governmental committee of the University of Saarland, Germany. Not required 
organisms were directly destroyed by autoclaving. 
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Bacteria take up DNA from their environment via transformation in a special physiological state called 
competent. This advantage is commonly used to amplify a large amount of plasmids. Escherichia coli 
XL1-blue cells had previously been made competent and were stored at -80°C. 0.5 µg plasmids were 
transferred to 200 µl competent bacteria. The mixture of bacteria and plasmids was placed on ice for 
30 min following a heat shock at 42°C for 45 seconds; a process which allows the DNA to enter into 
bacteria. Bacteria were returned to ice for 1-2 minutes. 800 µl LB-Medium was added to the 
transformation mixture and placed on a shaker incubator (PEQLAB) at 37°C with mixing intensity of 
700 rpm for one hour. This pre-culture was briefly centrifuged, and plated out on an agar plate. The 
agar plate contained the LB-Medium and 2 % agar (w/v) (AppliChem, Darmstadt, Germany) in addition 
to the appropriate selective antibiotic. All antibiotics were used in a concentration of 50 µg/ml. The 
plasmid pEYFP-N1 was selected using kanamycin (Sigma-Aldrich). Ampicillin (Carl Roth, Karlsruhe, 
Germany) was used to select plasmids of pSPT 18, pSPT 19, and pBS. The plasmid pBS included the 
DNA insert of mMyoD. This recombinant plasmid pBS mMyoD was obtained as a gift from Prof. Beate 
Brand-Saberi (Ruhr-University Bochum, Germany) and served as positive control for in situ 
hybridization and preparatory procedures.  
After plating transfected bacteria, plates were incubated at 37°C overnight. A single visible isolated 
colony was inoculated into a starter culture (3ml LB-Medium containing the selective antibiotic) and 
incubated at 37°C overnight with shaking at 200 rpm using the orbital incubator SI500 (Bibby Scientific, 
Stone, UK). The starter culture was used to increase the quantity of bacteria and to inoculate the main 
culture of 100 ml LB-Medium containing the selective antibiotic. Bacteria were harvested from the 
main culture by centrifugation at 4°C and 2857 xg for 15 min using the centrifuge Heraeus Megafuge 
16 R (Thermo Fisher Scientific). Plasmid isolation from the bacterial pellet was performed using a 
plasmid midi kit (QIAGEN) according to the manufacturer's protocol. Transformed DNA fragments 
were tested by restriction analysis and sequencing by Eurofins Genomics (Ebersberg, Germany). 
Sequencing results confirmed the sequence of Mus musculus pannexin 1 (mPanx1), NM_019482.2. 
LB-Medium pH 7.0 
Tryptone 1 % (w/v) 
Yeast – Extract 0.5 % (w/v) 
NaCl  1 % (w/v) 
in distilled water (dH2O)  
Autoclave at 120°C 20 min  
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3.5.5 Isopropanol precipitation of DNA 
DNA can be precipitated from an aqueous solution in the presence of alcohol and a high concentration 
of salt. In this study, DNA was precipitated by addition of salt and alcohol in final concentration of 0.3 
M sodium acetate and 30 % isopropanol (v/v). The precipitation mixture was incubated at -20°C 
overnight followed by centrifugation at 4°C and 215 xg for 30 minutes using the centrifuge Himac CT 
15RE (Hitachi Koki, Tokyo, Japan). The supernatant was removed and the DNA pellet was washed twice 
in 70 % ethanol in ddH2O (v/v) by centrifugation at 4°C and 215 xg for 10 min. Finally, the pellet was 
air-dried for 30 minutes and re-suspended in 10 µl ddH2O. DNA was quantified using the nano drop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). 
3.5.6 Agarose gel electrophoresis 
Agarose gels were prepared by boiling a solution of Tris-Acetate-EDTA buffer (TAE buffer) and 1.5 % 
agarose (w/v) (Biozym) in the microwave for 2 min. The solution was allowed to cool down to 60°C and 
supplemented with the fluorescent nucleic acid gel stain, Gel Red (Biotium, Hayward, USA). 1x DNA 
loading Dye (Thermo Fisher Scientific) was applied to DNA samples. The mixture of samples was loaded 
into gel wells. DNA Ladder of low range or broad range (Fermentas) was pipetted next to the samples. 
DNA samples were separated in a horizontal gel electrophoresis system (PEQLAB) at 120 V and 75 mA 
for 45 minutes. Amplification products of DNA were photographed using FUSION-FX7/SL Advance 
system (PEQLAB). 
Tris-Acetate-EDTA (TAE) buffer  
Tris base  40 mM  
Acetic acid 0.11 % (v/v) 
0.5 M EDTA (pH 8.0) 0.2 % (v/v) 
in dH2O  
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3.6 Probe synthesis for in situ hybridization 
Digoxigenin-labeled complementary RNA probes (DIG-labeled cRNA probes) were prepared by in vitro 
transcription for whole-mount in situ hybridization. Prior to the synthesis of cRNA probes, recombinant 
plasmids were linearized and utilized for in vitro transcription. After that, cRNA probes were 
precipitated with ammonium acetate and ethanol. The quality of cRNA probes was tested by Northern 
blot analysis. 
3.6.1 Linearization of plasmid DNA 
A RNA polymerase synthesizes a cRNA in the direction 3`→5` of the DNA template. To terminate the 
reaction “run off”, each recombinant plasmid was linearized by a restriction at the site downstream 
from the site of interest (Table 11). 3 µg of the purified recombinant plasmid was digested in the 
presence of 10 units restriction endonuclease (NEB), 1x restriction endonuclease buffer (NEB) and 
DEPC-H2O in a final volume of 20 µl. Digestion was performed at 37°C for one hour. The linearized 
plasmid was purified by isopropanol precipitation as described in Chapter 3.5.5. Prior to in vitro 
transcription, this plasmid was eluted in 13 µl DEPC-H2O. 
3.6.2 In vitro transcription 
RNA transcription can be performed in vitro using a bacteriophage RNA polymerase of T3, T7, or SP6 
(Schenborn, 1995). In contrast to DNA polymerase, RNA polymerase does not require primers to 
produce the single strand of RNA. Plasmids are commonly used tools for in vitro transcription, which 
include the cognate promoter of a RNA polymerase in the multiple cloning site (MCS). In this study, 
recombinant plasmids of pSPT18, pSPT19 and pBS mMyoD were used for in vitro transcription. These 
plasmids contain promoters of T7 and SP6 RNA polymerase. In vitro transcription was performed using 
the DIG RNA Labeling Kit (Roche) according to the manufacturer’s instructions. In vitro transcription 
reaction mixture of 20 µl included the whole volume of 13 µl of the linearized plasmid (see Chapter 
3.6.1) and the corresponding RNA polymerase (see Table 11 and Figure 17) in addition to a mixture of 
NTPs including Digoxigenin-UTP. RNA polymerase T7 was used to generate antisense probes, whereas 
RNA polymerase SP6 was used to generate DIG labeled sense cRNA probes. It was not required to 
remove the DNA template from the reaction mixture after the transcription. 
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Figure 17. Recombinant plasmids used for in vitro transcription 
(A) A part of each recombinant plasmid is represented to illustrate the location of the insert within the 
plasmid. Linearization sites are represented in Table 11. The promoter T7 served to generate antisense 
probes, whereas SP6 served to generate sense cRNA probes. (B) Maps of pSPT18 and pSPT19 vectors. 
Taken from Roche. 
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Table 11. In vitro transcription of cRNA probes 
DNA Template linearization site RNA polymerase cRNA probes Length in  bases 
pSPT 19 mPanx1 Ct EcoRI T7 antisense  Panx1 Ct 443 
pSPT 19 mPanx1 Ct BamHI SP6 sense Panx1 Ct 443 
pSPT 18 mPanx1 BamHI T7 antisense Panx1 1280 
pSPT 19 mPanx1 BamHI SP6 sense Panx1 1280 
pBS mMyoD EcoRV T7 antisense MyoD 1833 
The table shows DNA templates used for in vitro transcription, the linearization site of each 
recombinant plasmid, RNA polymerase used for each reaction, cRNA probe generated through each 
reaction, and the length of each cRNA probe in bases. 
 
3.6.3 Ammonium acetate precipitation 
Ammonium acetate precipitation is an alternative method to sodium acetate precipitation. It reduces 
co-precipitation of NTPs. Probes of cRNA were precipitated immediately after transcription. The 
precipitation mixture (20 µl) was supplemented with  ammonium acetate (Fisher Scientific, Nidderau, 
Germany) in a final concentration of 1M and with 82 % ethanol pure (v/v) (stored at -20°C). The 
precipitation mixture was immersed in liquid nitrogen for 3 min followed by centrifugation at room 
temperature at 162 xg for 10 minutes using a Himac CT 15RE centrifuge (Hitachi Koki). The supernatant 
was removed and the pellet was washed with 500 µl of 80 % ethanol pure in ddH2O (v/v) and 
centrifuged at 215 xg at RT for 10 min. The supernatant was removed; the pellet was air-dried at RT 
for 30 min. The pellet of cRNA was eluted in 100 µl DEPC-H2O. Aliquots of cRNA probes were stored at 
-20°C until use. The quality of cRNA probes was controlled by agarose gel electrophoresis using 10 µl 
of each probe as described in Chapter 3.5.6.  
3.7 Whole-mount in situ hybridization 
In mouse embryos, the distribution of Panx1 mRNA expression was analyzed using whole-mount in situ 
hybridization. The technique was based on the hybridization of a DIG-labeled cRNA probe 
complementary to the target mRNA. This cRNA probe was detected using anti-DIG antibodies 
conjugated to a reporter molecule alkaline phosphatase (AP). Antibody binding was made visible using 
the substrate Nitro Blue Tetrazolium Chlorid / 5-Bromo-4-Chloro-3-Indolyl Phosphate (NBT/BCIP), 
which reacts in the presence of alkaline phosphatase to a purple staining at sites of hybridization. 
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3.7.1 Material and reagents for in situ hybridization 
All in situ hybridization procedures were performed under RNase-free conditions. Operation 
instruments were rinsed using the cleaning unit Elmasonic S 10 (Elma Hans Schmidbauer, Singen, 
Germany). Glassware and metal instruments were baked at 200°C in an oven (Thermo Fisher) for four 
hours. Disposable plastic wares were used sterile and RNase-free. Unsterile plastic equipment, e.g. pH 
electrode, was rinsed in 70 % ethanol DEPC-H2O (v/v) for 30 s followed by washing in 1M NaOH for 5 
min and a final wash in DEPC-H2O. 
Diethyl pyrocarbonate (DEPC) (Sigma-Aldrich) was used to inactivate RNases in water and solutions. 
Solutions were treated with 0.1 % DEPC (v/v) by stirring at RT for 1 hour. After treatment, DEPC was 
inactivated by autoclaving. DEPC is highly unstable in the presence of Tris. It decomposes rapidly into 
ethanol and CO2 (Hilario and Mackay, 2007). Therefore, Tris was not treated directly with DEPC during 
the preparation of Tris buffer, but Tris was dissolved in DEPC-H2O. 
DEPC-H2O 
1 l ddH2O was treated with 1 ml DEPC by stirring the solution at RT for 1 hour. DEPC was inactivated 
by autoclaving the solution. 
Hybridization solution 
Formamid 50 % (v/v) 
20x SSC 5x SSC 
CHAPS    0.5 % (w/v) 
Triton X-100  0.1 % (v/v) 
0.5 M EDTA (pH 8.0) 5 mM 
Blocking reagent 2 % (w/v) 
DEPC 0.1 % (v/v) 
in ddH2O  
All components were mixed by stirring at 60-65°C in a water bath for 2 hours. The mixture was allowed 
to cool on ice. After cooling, the following components were added: 
Heparin 50 µg/ml 
tRNA 1 mg/ml 
The solution was again mixed by stirring, aliquoted in RNase free tubes, and stored at -20°C until use.  
 
 
Saline sodium citrate (SSC) pH 7.0 
NaCl 0.15 M 
Sodium citrate tribasic dihydrate 15 mM 
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DEPC 0.1 % (v/v) 
in ddH2O  
The solution was sterilized by autoclaving and stored at RT. 
10x Sodium potassium buffer (KTBT) 
NaCl  1.5 M 
KCl  20 mM 
Tris HCl 1 M (pH7.3) 25 % (v/v) 
Tween 20 1 % (v/v) 
The solution was prepared in DEPC-H2O, sterilized by autoclaving, and stored at RT. 
Alkaline phosphate buffer (AP-buffer) 
5 M NaCl 2 % (v/v) 
1 M MgCl2 5 % (v/v) 
1 M Tris HCl (pH 9.5)  10 % (v/v) (dissolved in DEPC-H2O) 
Triton X-100 0.1 % (v/v) 
AP-buffer was always made fresh using ddH2O. 
10x DEPC-PBS pH 7.4 
NaCl 0.136 M 
KCl 2.6 mM 
Na2HPO4 10.1 mM 
KH2PO4  1.76 mM 
DEPC 0.1 % (v/v) 
in ddH2O  
All components were mixed by stirring. The solution was sterilized by autoclaving. 
3.7.2 Whole-mount in situ hybridization procedure 
Whole-mount in situ hybridization was performed in the following steps: 
 Embryos of different stages were dissected as described in Chapter 3.2.3. After that, embryos were 
transferred into a 12-well culture plate containing 4 % PFA (v/v), RNase free, (Electron Microscopy 
Sciences, Hatfield, USA) diluted in PBS-Triton for fixation at 4°C for 4 hours. Fixation was followed 
by washing twice in DEPC-PBS-Triton (DEPC-PBS in 0.1 % Triton X-100 (v/v) (Carl Roth)) on ice.  
 Subsequently, embryos were treated with 20 µg/ml Proteinase K (Roche) for 20 min at RT. 
Proteinase K makes the tissue permeable and unmasks the target mRNA. This allows the cRNA 
probe to access its target mRNA. The same digestion duration was used for all stages. 
 The digestion was stopped by washing embryos in DEPC-PBS-Triton for 10 min on ice.  
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 Embryos were post-fixed in postfixation solution (0.2 % glutardialdehyde (v/v) (Merck, Darmstadt, 
Germany), 4 % PFA (v/v) in PBS-Triton) for 20 min by shaking on ice, followed by washing in PBS-
Triton for 10 min on ice. 
 Pre-hybridization of embryos was performed in a hybridization oven, HB-1000 (Ultra-Violet 
Products Ltd, Cambridge, UK), with pre-warmed hybridization solution at 65°C twice; at first for 2 
hours and then overnight. 
 Embryos were hybridized with 1 µl/ml DIG-labeled cRNA probes (Table 11) in fresh pre-warmed 
hybridization solution at 65°C overnight. 
 Non-bound cRNA probes were removed by washing at 65°C in the following steps: 
- In 2x saline sodium citrate (SSC) for 20 min. 
- In 2x SSC containing 0.1 % CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-propansulfonat) 
(w/v) twice for 30 min each. 
- In 0.2X SSC containing 0.1 % CHAPS (w/v) twice for 30 min each.  
 Embryos were rinsed in KTBT buffer three times at RT for 10 min.  
 Non-specific antibody binding sites were blocked with lamb serum solution (20 % lamb serum (v/v) 
(Invitrogen, Darmstadt, Germany) diluted in KTBT) at RT for 4 hours.  
 DIG labeled cRNA probes were detected with anti-DIG-AP (Table 1), diluted 1:2,000 in lamb serum 
solution, at 4°C overnight. 
 Non-bound antibodies were removed by washing in KTBT buffer in steps: firstly, three times at RT 
for 10 min each, secondly, six times at RT for 1 hour each, and finally one time at 4°C overnight. 
 Embryos were equilibrated with the alkaline phosphate buffer three times at RT for 10 min each.  
 The color reaction was carried out using the staining solution of alkaline phosphate buffer and 2 % 
NBT/BCIP (v/v) (Roche). The color was allowed to develop in the dark at RT for one hour or until the 
signal or the background become visible. 
 Staining solution was removed, and embryos were washed with KTBT buffer twice at RT for 10 min. 
Color reaction was terminated by washing in DEPC-PBS. 
 Embryos were photographed using a stereo microscope SZX12 (Olympus, Hamburg, Germany), 
equipped with a color camera CC-12 (Olympus) and the software Cell^P imaging (Olympus). 
3.7.3 Vibratome sectioning post in situ hybridization 
Post whole-mount in situ hybridization, embryos were embedded in warm agarose gel (3 % agarose 
(w/v) in TAE buffer) and cooled at 4°C. 50 µm transversal sections were immediately cut using the 
vibratome VT1000 S (Leica) equipped with a razor blade (Electron Microscopy Sciences). The agarose 
Materials and Methods 
50 
 
block containing the tissue was immersed in PBS in the bath of the vibratome. PBS was prepared as 
described in Chapter 3.9. The vibration amplitude, the speed, and the angle of the blade were 
controlled. Sections were mounted onto SuperFrost Plus slides (R. Langenbrinck) using the embedding 
medium of Roti-Mount Aqua (Carl Roth). After drying, sections were photographed using the stereo 
microscope SZX12 (Olympus).  
3.8 Generation of anti-Panx1 polyclonal antibodies 
A polyclonal antibody against mouse Panx1 was generated in an adult rabbit (New Zealand White 
Rabbit) (see Chapter 3.2.2). Immunization was performed using synthetic peptides, which were 
synthesized at the Institute for Medical Biochemistry and Molecular Biology of Saarland University. 
The amino acid (aa) sequence (QRVEFKDLDLSSEAA) was derived from the carboxy terminus (395-409 
aa) of mouse Panx1.  In a previous study, the sequence was used to generate a polyclonal antibody 
against Panx1 by Penuela et al. (2007).  
Immunization of animals and collection of serum was performed at the Institute for Medical 
Biochemistry and Molecular Biology of Saarland University. Firstly, the pre-immune serum (PIS) was 
collected prior to immunization. The animal was immunized subcutaneously with the antigen every 
two weeks for six times. Each injection contained 200 µg antigen dissolved in 250 µl complete Freund’s 
adjuvant. The antiserum was collected ten days after each immunization. Finally, the animal was 
sacrificed and the whole endserum was collected.  
3.8.1 Determination of antibody titer by ELISA 
The enzyme-linked immune-sorbent assay (ELISA) was used to determine the antibody titer of the first 
antiserum. An equal amount of peptides (80 ng) was coated onto a 96 well plate. Serial dilutions 
(1:1000 – 1:128,000) of Panx1 antibody (the first antiserum) and of the negative control of PIS were 
allowed to bind to coated peptides. The peptide-antibody complex was detected using a horseradish-
peroxidase (HRP)-conjugated goat anti-rabbit antibody (Table 3). The antibody detection was 
visualized using a chromogenic substrate of 3,3'-5,5' tetramethylbenzidine (TMB) (Dako, Hamburg, 
Germany) which catalyzes a color in the presence of HRP. The absorbance of color was measured using 
the micro-plate reader infinite M200 (TECAN, Crailsheim, Germany). This experiment was carried out 
in our laboratory by Dr. Anja Beckmann and Jessica Kilper according to the following protocol: 
 Peptides were dissolved in 50 mM sodium bicarbonate (coating-buffer). 
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 50 µl of peptide solution was pipetted in a 96 well plate so that all wells contained an equal quantity 
of peptides (80 ng). The plate was sealed with parafilm and incubated at 37°C for three hours. 
 Wells were washed three times with 200 µl washing buffer (0.1 % Tween (v/v) in PBS) 
 Wells were incubated with 200 µl blocking solution (5 % nonfat milk powder (w/v) and 0.1 % Tween 
(v/v) in PBS) at 4°C overnight.  
 Wells were washed three times with 200 µl washing buffer.  
 Serial dilutions (1:1,000 – 1:128,000) of the first antiserum and PIS (Table 1) in washing buffer were 
allowed to bind to coated peptides. Antibody detection was performed at RT for 30 min. 
 Wells were washed three times with 200 µl washing buffer.  
 Wells were incubated with 150 µl of the secondary antibody HRP goat anti-rabbit (Table 3) at RT 
for 30 min. The antibody was diluted 1:20,000 in washing buffer. 
 Wells were washed three times with 200 µl washing buffer.  
 Color detection was performed using 50 µl of the chromogenic substrate TMB, which produces a 
blue color, for 5 min. 
 The enzymatic reaction was stopped with 50 µl 1M sulfuric acid, which converts the blue color to a 
yellow color. 
 The developed yellow color was measured at 450 nm using the micro-plate reader infinite M200 
(TECAN). 
 As described by Liu et al. (2009), results were taken as positive if the ratio of the absorbance of 
analyzed sample to the absorbance of negative control is greater than 2.1. 
3.8.2 Serum neutralization assay 
Unpurified polyclonal antibodies are able to bind non-specifically to proteins. To determine whether 
antibody signals are specific, a peptide preabsorbtion experiment was performed. Prior to use in the 
experiment, peptides were diluted in PBS and incubated with the antiserum (Table 1) at 4°C for 48 
hours. Peptides were used in a ratio of w/w to the concentration of proteins in the antiserum. Serial 
dilutions of peptides were prepared to determine the optimal dilution of peptides required for a 
complete inhibition. 
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3.9 Immunoblotting 
The presence of a protein in a tissue was detected using immunoblotting analysis. This analysis was 
achieved in multiple steps. Initially, proteins were isolated from a tissue and denatured by heat. 
Proteins were separated by size in an electrical field using gel electrophoresis. These separated 
proteins were transferred onto a membrane for immunodetection of a specific protein via antibodies. 
The molecular weight of the detected protein was determined by comparing its molecular weight to 
that of proteins of known molecular weight included in a protein marker mixture. 
Reagents for immunoblotting 
Lysis buffer 
Tris HCl 0.5 M (pH 6.8) 6.2 % (v/v) 
SDS 2 % (w/v) 
Glycerol 10 % (v/v) 
β-mercaptoethanol 2 mM 
Protease inhibitor 4 % (v/v) 
in dH2O  
5x Laemmli buffer 
Tris HCl 0.5 M (pH 6.8) 31 % (v/v) 
SDS 10 % (w/v) 
Glycerol 50 % (v/v) 
Bromophenol blue dye 0.05 % (w/v) 
β-mercaptoethanol 10 mM (v/v) 
in dH2O  
10x PBS pH 7.4 
NaCl 0.136 M 
KCl 2.6 mM 
Na2HPO4 10.1 mM 
KH2PO4  1.76 mM 
in dH2O  
 
PBST 
Tween 20 0.1 % (v/v) 
in PBS   
5 % Stacking gel 
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1 M Tris HCl (pH 6.8) 12.7 % (v/v) 
30 % Acrylamid Mix (w/v) 16.7 % (v/v) 
10 % SDS in dH2O (w/v) 1 % (v/v) 
10 % Ammonium peroxodisulfate (APS) in dH2O (w/v) 1 % (v/v) 
TEMED 0.1 % (v/v) 
in dH2O  
12 % Resolving gel 
1.5 M Tris HCl (pH 8.8) 25 % (v/v) 
30 % Acrylamid Mix (w/v) 40 % (v/v) 
10 % SDS in dH2O (w/v) 1 % (v/v) 
10 % APS in dH2O (w/v) 1 % (v/v) 
TEMED 0.04 % (v/v) 
in dH2O  
10x Electrophoresis buffer 
Tris base 250 mM, pH 6.8 
Glycine 2 M 
SDS 1 % (w/v) 
in dH2O  
Transfer buffer pH 8.3 
Tris base 25 mM 
Glycin 192 mM 
Methanol 20 % (v/v) 
in dH2O  
Ponceau Red solution 
Ponceau Red 0.1 % (w/v) 
Acetic acid 5 % (v/v) 
in dH2O  
Blocking solution 
Nonfat milk powder 1 % or 5 % (w/v) 
Tween 20 0.1 % (v/v) 
in PBS   
 
Dissociation buffer 
Tris HCl 62.5 mM (pH 6.7) 
SDS 2 % (w/v) 
β-mercaptoethanol 100 mM 
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in dH2O  
 
Protein isolation 
Proteins were isolated from tissues using the lysis buffer. 4 % (v/v) of the protease inhibitor cocktail, 
Complete (Roche), were included in this buffer to protect proteins during protein isolation. The lysis 
buffer also included 2 mM β-mercaptoethanol (Carl Roth) to reduce disulfide bonds in proteins. 2 % 
(w/v) sodium dodecyl sulfate (SDS) (Carl Roth) was also included in the lysis buffer to charge protein 
molecules negatively so that all protein molecules migrate towards the anode in an electrical field. 
Collected samples for immunoblotting (see Chapter 3.2.6) were thawed on ice. Samples were 
homogenized in 300-800 µl of the lysis buffer. The amount of the lysis buffer needed for 
homogenization was determined so the protein extract was not too diluted and had a protein 
concentration of 2-4 µg/µl. Samples were homogenized using an electric ultra-homogenizer; Ultra-
Turrax T-10 (IKA, Staufen, Germany) and centrifuged at 215 xg using a Himac CT 15RE (Hitachi Koki) 
centrifuge at 4°C for 30 minutes. The supernatant of the lysate was transferred into a new tube. The 
lysate was placed on ice and served for determination of the protein concentration in the sample. 
Protein concentration determination 
The total protein concentration in the lysate was determined by a bicinchoninic acid (BCA) assay kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. In this assay, a cuprous ion Cu+ 
becomes reduced from Cu++ by proteins in an alkaline medium. This cuprous ion interacts with two 
molecules of bicinchoninic acid (BCA) to produce a purple color. The absorption of light through this 
color can be measured to determine the protein concentration. 
The reaction was carried out in 96-well-plate (Sarstedt, Nümbrecht, Germany). The absorbance was 
measured at 562 nm using the micro-plate reader; infinite M200 (TECAN). The protein concentration 
was calculated by comparison to known concentrations of the standard protein, bovine serum albumin 
(BSA). Data were analyzed using Magelan software (TECAN).  
 
Protein denaturation 
After determination of its protein concentration, the protein lysate was diluted with 5x Laemmli buffer 
to obtain an equal protein concentration of 1 µg/µl in all samples. 5x Laemmli buffer also included the 
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blue dye Bromophenol Blue (Alfa Aesar, Karlsruhe, Germany) to indicate samples on the gel. Proteins 
in diluted samples were denatured by boiling the mixture at 95°C for 5 min. After heating, samples 
were cooled and stored at -20°C until use. Through this denaturation step, proteins lose their 
secondary and tertiary structure. This helps proteins to be completely denatured and become 
separated only according to their molecular weight. 
SDS-PAGE electrophoresis 
Proteins were separated according to their molecular weight in an electrical field using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In the vertical Dual Gel Electrophoresis System 
(PEQLAB), the SDS-PAGE gel included two polyacrylamide gels: a 5 % stacking gel and a 12 % resolving 
gel. The stacking gel was poured over the resolving gel. Equal amounts of proteins (15 µg) were loaded 
into gel wells. Glycerol, which is included in Laemmli buffer, allowed protein samples to sink easily into 
gel wells. Either the page ruler plus prestained protein ladder (Thermo Fisher Scientific) or the pre-
stained protein marker broad range (New England Biolabs) was used in a volume of 8 µl to determine 
the molecular weight of immunoreactive proteins. The gel was allowed to run in the presence of the 
electrophoresis buffer at 300 V and 25 mA/gel for 1 hour. 
Semi-dry blotting 
Negatively charged proteins in the gel can migrate out of the gel into a nitrocellulose membrane in a 
horizontal electrical field. Migrated proteins bind to the membrane that can then be used for 
immunodetection of proteins. 
After proteins were separated by size in SDS-PAGE, proteins were transferred from the gel onto a 
nitrocellulose membrane (0.45 µm pore size) (GE Healthcare Europe GmbH, Freiburg, Germany) using 
a semi-dry electro blotter system (PEQLAB). A horizontal gel-membrane-sandwich was made as 
following. Firstly, the gel and the nitrocellulose membrane were soaked in transfer buffer for 10 
minutes. Six sheets of filter paper 190 g/m2 (A. Hartenstein, Würzburg, Germany) were saturated with 
the transfer buffer. Three sheets of these papers were placed on the anode plate of the system. The 
nitrocellulose membrane was placed onto these papers. Thereon, the gel was placed and covered with 
three filter papers. Finally, the gel-membrane-sandwich was covered with the cathode plate of the 
system. The electro blotting was performed at 14 Volt and 180 mA/gel for 30 minutes. After blotting, 
the membrane was incubated in Ponceau Red (Carl Roth) solution for 2 min.  This staining was used to 
control the efficiency of protein transfer to the membrane. After that, the membrane was discolored 
by washing in water. 
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Immunodetection of blotted proteins 
The immunological detection of proteins was performed using chemiluminescence technique. After 
electro blotting, the membrane was washed in dH2O for 3 min. Non-specific binding of antibodies was 
prevented by incubating the membrane in the blocking solution (5 % nonfat milk powder (w/v) in PBST) 
at RT for one hour. After that, the membrane was incubated with a primary antibody that was diluted 
in 1 % blocking solution (1 % nonfat milk powder (w/v) in PBST) as described in Table 1 at 4°C overnight. 
Thereafter, the membrane was washed three times in 1 % blocking solution for 10 minutes each.  The 
membrane was incubated with the HRP-conjugated secondary antibody that was diluted in 1 % 
blocking solution as described in Table 3 at RT for one hour. Finally, the membrane was washed in PBST 
twice for 10 minutes. The lumi-light substrate (Roche) was applied on the membrane for 1-5 min. The 
substrate was removed; signal imaging was performed using FUSION-FX7/SL Advance system 
(PEQLAB). The molecular weight of the immunoractive product was determined using the FUSION-
CAPT software (PEQLAB). 
Antibody removal 
For a second detection of proteins on the same membrane, the primary and secondary antibodies 
were removed from the membrane. This method was used often to detect the signal of the loading 
control actin. After the first detection, the membrane was incubated in the dissociation buffer at 50°C 
for 15 min. After that, the membrane was washed twice in PBST at RT for 10 min. After antibody 
removal, further proteins were detected on the membrane as described above. 
3.10 Immunolabeling 
The localization of an antigen in a histological section was detected using a specific antibody to the 
antigen. Detection sites of primary antibodies were visualized indirectly using secondary fluorescence-
labeled antibodies (Alexa Fluor-conjugated antibodies) (Table 3). Nuclear DNA was labeled using 4',6-
diamidino-2-phenylindole, dihydrochloride staining (DAPI) to visualize all cell nuclei in the section. The 
experiment was carried out in the following steps: 
 10 µm thick cryosections (see Chapter 3.2.6) were fixed in absolute ethanol at -20°C for 20 min, and 
washed in PBS three times for 10 min. PBS was prepared as described in Chapter 3.9. 
 Non-specific binding sites were blocked in blocking solution (10 % normal goat serum (NGS) (v/v), 
0.1 % Triton X-100 (v/v) in PBS) at RT for one hour. 
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 The primary antibody was diluted in the blocking solution as described in Table 1. Sections were 
incubated with the diluted primary antibody at 4°C overnight.  
 Thereafter, washing in PBS was performed three times at RT for 10 min to remove non-bound 
antibodies. 
 The second step of blocking was used to prevent the non-specific binding of secondary antibodies. 
Blocking was performed using 0.2 % bovine serum albumin (BSA) (v/v) (MP Biomedicals, Heidelberg, 
Germany) diluted in PBS at RT for 30 min.  
 The secondary antibody was diluted in BSA solution as described in Table 3. Sections were 
incubated with the diluted secondary antibody in the dark at RT for 2 hours. 
 Finally, sections were washed twice in PBS for 10 min. Mounting of sections was performed using 
the medium DAPI-Fluoromount-G (Southern Biotechnology, Birmingham, USA) which includes the 
nuclear staining DAPI. After mounting, sections were dried and stored in the dark at 4°C for 
microscopy. 
 Sections were photographed using the microscope Observer.Z1 (Carl Zeiss, Göttingen, Germany). 
The microscope was equipped with a fluorescent lamp, HXP 120 C (Carl Zeiss), and filter sets; 43HE 
for red, 38HE for green, and 49 for blue (Carl Zeiss). The photograph system was equipped with the 
digital camera AxioCam MRm (Carl Zeiss) and managed by AxioVision software (Carl Zeiss). 
3.10.1 Whole mount immunolabeling 
Whole mount immunolabeling of embryos was performed as described by De Bellard et al. (2002). 
 E9.5 embryos were fixed in 4 % formaldehyde (v/v) (VWR, Darmstadt, Germany) in PBS at 4°C for 4 
hours. PBS was prepared as described in Chapter 03.9. 
 Embryos were washed three times in PBS for one hour each. 
 Non-specific binding sites were blocked using 5 % BSA (v/v), 0.1 % H2O2 (v/v) (Thermo Fisher 
Scientific), 1 % Triton X-100 (v/v) in PBS at 4°C overnight. 
 Embryos were washed in 5 % BSA (v/v) and 1 % Triton X-100 (v/v) in PBS three times for one hour 
each. 
 Embryos were incubated with the primary antibody (Table 1) diluted in a solution of 10 % BSA, 1 % 
Triton X-100 in PBS at 4°C for two days. 
 The second step of blocking was performed three times using 1 % NGS (v/v), and 1 % Triton X-100 
(v/v) in PBS for one hour each. 
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 Embryos were incubated with the secondary antibody (Table 3) diluted 1:1,000 in 1 % NGS (v/v) 1 
% Triton X-100 (v/v) in PBS at 4°C overnight. 
 Embryos were washed three times in 1 % NGS (v/v) 1 % Triton X-100 (v/v) in PBS for one hour each. 
 Embryos were photographed using a stereo microscope SZX12 (Olympus), equipped with a color 
camera CC-12 (Olympus), a fluorescent lamp (Olympus), and the software Cell^P imaging 
(Olympus). 
3.11 β-Gal staining 
Transgenic mice of Panx1tg/tg and Panx2tg/tg express β-galactosidase under the control of Panx1 or 
Panx2 promoter, respectively, as described in Chapter 3.2.2. In β-Gal staining, β-galactosidase activity 
was used to determine expression of pannexin genes indirectly. Using the substrate of 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (Carbolution Chemicals, Germany), β–galactosidase 
cleaves X-Gal to produce a blue staining. In this study, β-Gal staining was performed as described by 
Kranz et al. (2013). 
Reagents for β-Gal staining 
Phosphate buffer (PB) 0.1 M pH 7.4 
Phosphate buffer was prepared by mixing 0.1M sodium phosphate monobasic (H2O free) and 0.1M 
sodium phosphate dibasic (H2O free), dissolved in dH2O, at a ratio of 2:8 to reach pH 7.4.  
Washing solution 
Phosphate Buffer pH 7.4 0.1 M 
EGTA 2 mM 
Sodium deoxycholate 0.01 % (w/v) 
NP-40 Alternative 0.02 % (v/v) 
MgCl2 2 mM 
in dH2O  
 
Staining solution 
Potassium Ferricyanide (K3[Fe(CN6)]) 5 mM  
Potassium Ferrocyanide (K4[Fe(CN6)]) 5 mM 
X-Gal 2 mg/ml 
in washing solution  
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3.11.1 Whole-mount β-Gal staining 
For whole-mount staining, embryos or organs were dissected in 0.1 M PB, pH 7.4, and transferred to 
15 ml tubes containing 0.2 % glutardialdehyd (Merck) diluted in PB for fixation at 4°C for 2 hours. Two 
rinses in washing solution followed. Embryos or organs were incubated in staining solution at 37°C 
overnight. Post staining, samples were washed twice in PB for 10 min.  Stained embryos or organs were 
photographed using the stereo microscope Discovery. V8 (Carl Zeiss). 
Post β-Gal staining, embryos were embedded in paraffin, and paraffin blocks were cut using a 
microtome to observe more details of stained sites. Firstly, embryos were dehydrated using a serial of 
ethanol dilutions as follows: one time in 50 % ethanol (v/v) in dH2O overnight, two times in 70 % and 
90 % ethanol for 30 min each, and three times in absolute ethanol for one hour each. After 
dehydration, embryos were embedded in paraffin using a low-melting-point paraffin wax (44-46°C) 
(Sigma-Aldrich). Embryos were incubated in paraffin at 49°C with three changes of the paraffin 
solution; a) after one hour, b) after an overnight incubation, and c) four hours, respectively. Finally, 
embryos were embedded in paraffin blocks and allowed to cool overnight. Paraffin blocks were cut 
using the microtome HM 350 (Techno-med GmbH, Bielefeld, Germany). At section levels of interest, 
the paraffin block was photographed using the microscope stereo Discovery. V8 (Carl Zeiss) equipped 
with the camera AxioCam ERc 5s (Carl Zeiss). The photograph system was managed by the software 
ZEN 2011 (Carl Zeiss). 
3.11.2 β-Gal staining of cryosections 
Cryosections from unfixed frozen tissue were prepared at a thickness of 15 µm and mounted onto 
SuperFrost-slides (R. Langenbrinck). Sections were allowed to dry and circled with a flexible mounting 
glue, Fixogum (Marabu, Tamm, Germany), to avoid leaking of solutions during the incubation. Sections 
were fixed in 0.2 % glutardialdehyd diluted in 0.1 M, PB pH 7.4, at RT for 10 min, followed by two 
washes in washing solution. Sections were stained in staining solution at 37°C overnight. Stained 
sections were washed for 10 min in 0.1 M PB. The Fixogum was removed and salt crystals were cleaned 
up by briefly washing in 70 % ethanol (v/v) in dH2O followed by a rehydration in dH2O. Post β-Gal 
staining, sections were stained with a red nuclear counterstain named nuclear fast red (Sigma-Aldrich). 
Sections were incubated in the histochemical reagent of nuclear fast red at RT for 7 min following by 
a wash in tap water and then in dH2O. After staining, sections were dehydrated in 70 % ethanol, 90 % 
ethanol and two changes in absolute ethanol for three min in each step. After dehydration, sections 
were treated for three changes in Roti-Histol (Carl Roth) for 3min in each. Finally, sections were 
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mounted in Roti-Histokitt (Carl Roth). Stained sections were scanned on the microscope Olympus BX51 
TF (Olympus). This system was managed by the software slide digital virtual microscopy V 1.2 
(Olympus). 
3.12 Preparation and staining of paraffin sections  
12-day-old mice (P12) of different strains were used to prepare paraffin sections. Trigeminal ganglia in 
addition to the thoracic part of the spinal cord attached to dorsal root ganglia were dissected and fixed 
in Bouin fixation solution (see below). Tissues were immersed in Bouin fixation solution and stored at 
RT until using. Paraffin infiltration was achieved post fixation using a robust carousel tissue processor; 
mtp (SLEE, Mainz, Germany). Tissues were dehydrated using a graded series of isopropanol, followed 
by washing steps in methyl benzoate to remove alcohol and water residues. Finally, tissues were 
infiltrated with a paraffin wax its melting point is 55-57 °C; Roti®-Plast (Carl Roth). 
Infiltration of paraffin was performed as follows: 
Isopropanol 70 % (v/v) 60 min 
Isopropanol 80 % (v/v) 90 min 
Isopropanol 90 % (v/v) 90 min 
Isopropanol 100 % 90 min 
Isopropanol 100 % 90 min 
Methyl benzoate 90 min 
Methyl benzoate 90 min 
Methyl benzoate 90 min 
Paraffin at 65°C 120 min 
Paraffin at 65°C 120 min 
After paraffin infiltration, samples were embedded in paraffin blocks using the embedding center of 
MPS/P1 and MPS/C (SLEE). Embedded samples were allowed to cool at RT until use. Paraffin sections 
were cut in a thickness of 6 µm using the historange microtome 2218 (LKB Bromma, Sollentuna, 
Sweden) which was equipped with a glass knives C335 (Plano, Wetzlar, Germany). Sections were 
collected on SuperFrost-Slides (R. Langenbrinck), dried at 37°C, and stored at RT until use.  
Bouin fixation solution 
Bouin fixation solution was prepared by mixing 1.2 % picric acid solution (v/v) (AppliChem) with 37 % 
formaldehyde (v/v) (VWR) in a ratio of 3:1. Prior to use, the mixture was supplemented with 5 % (v/v) 
of acetic acid (VWR). 
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3.12.1 Masson Goldner trichrome staining 
The morphology of spinal cord was illustrated using Masson Goldner Trichrome staining. The staining 
works with three different stains, Goldner`s stain I, II and III, which allow a differentiated visualization 
of tissue. In this staining, nuclei stain dark brown, cytoplasm and muscle fibers stain red, and 
connective tissue stain green. Paraffin sections were firstly deparaffinized in three changes of Roti-
Histol (Carl Roth) for three min each. After deparaffinization, sections were rehydrated using a graded 
series of ethanol, diluted in dH2O, as follows: 
Absolute ethanol 3 min 
Absolute ethanol 3 min 
90 % ethanol (v/v) 3 min 
70 % ethanol (v/v) 3 min 
dH2O 3 min 
The staining was carried out using Masson Goldner Trichrome staining kit (Carl Roth) according to the 
manufacturer’s instructions. Staining procedures were adapted to experimental conditions. After 
rehydration, nuclei were stained with iron hematoxylin solution according to Weigert for 5 min. 
Thereafter, sections were blued in flowing tap water for 10 min. Goldner’s stain I was applied for 5 min 
followed by washing in 1 % acetic acid (v/v) in dH2O for 30 seconds. Sections were stained with 
Goldner’s stain II until decolouration of connective tissue for 7 min followed by washing in 1 % acetic 
acid for 30 seconds. Counterstaining was performed using Goldner’s stain III for 10 min, which was 
followed by washing in 1 % acetic acid for 2 min. Finally, sections were dehydrated directly in absolute 
ethanol three times for 3 min each, followed by clearing for three changes in Roti-Histol (Carl Roth) for 
three min each. Sections were mounted in Roti-Histokitt (Carl Roth) and covered with coverslips (R. 
Langenbrinck). 
3.13 Histological image analysis  
Images of histological sections were analyzed using the software ZEN 2011 (Carl Zeiss). Measurements 
were performed in the unit of pixels and results were converted into the unit of millimeters. Converting 
of pixel into millimeter was calculated using a formula which was obtained from the imaging program 
for each image. The measurement of areas was obtained by outlining the region of interest using tools 
for the contour outline. Cell counting was used to estimate the cell density and the cell ratio in a 
definite area.  
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3.14 Statistical analysis  
Data of groups (n=3 per group) were presented as mean ± standard error of mean (SEM). Firstly, a 
normality test was performed for all data using Kolmogorov-Smirnov test. Normally distributed data 
were analyzed using one-way ANOVA test followed by a Bonferroni post-hoc test to compare means. 
Nonnormally distributed data were analyzed using Kruskal-Wallis test followed by Dunn's post test to 
compare means. The Mann-Whitney U test was used to compare differences between two 
independent groups. Statistical significance was set at the 95 % confidence level (p < 0.05). Results 
were considered statistically significant for *p < 0.05, **p < 0.01, and ***p < 0.001. Analyses were 
performed using the Prism 5 software (GraphPad Software, San Diego, USA). SEM = S / √n (SEM: 
standard error of the mean, S: sample standard deviation, n: number of samples). 
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4 Results 
4.1 Temporal expression of pannexin mRNA in mouse 
development 
A qualitative gene expression analysis was performed using reverse transcription polymerase chain 
reaction (RT-PCR) to determine whether pannexins are expressed in early stages of mouse 
development. Embryos were prepared as described in Chapter 3.2.6. Six embryos of E9.5 were pooled 
and RNA was isolated from whole embryos. Embryos of E10.5, E11.5 and E12.5 (four, three and one 
embryo(s), respectively) were analyzed in samples of heads and bodies separately. The total RNA was 
isolated and transcribed into cDNA. cDNA synthesis was controlled using negative controls without 
reverse transcriptase (NR) from each sample in addition to a negative control without template (NT). 
Resulting cDNA samples and negative control samples were used as template for the amplification of 
target genes Panx1 and Panx2 and the reference gene 18S rRNA using the polymerase chain reaction 
(PCR).  
 
Figure 18. Panx1 and Panx2 mRNA expression in mouse development 
Expression of Panx1 and Panx2 mRNAs was detectable in all investigated stages i.e. in E9.5 embryos as 
well as in heads and bodies of E10.5, E11.5 and E12.5 embryos. The transgenic embryo E11.5 Panx1tg/tg 
did not show any expression of Panx1 whereas it showed Panx2 expression. Negative controls without 
template (NT) or without reverse transcriptase (Panx1 NR, Panx2 NR and 18S NR) did not show any 
expression product for any primers. The reference gene 18S rRNA served as a loading control of equal 
cDNA template. Amplified products of Panx1, Panx2 and 18S were 500 bp, 300 bp and 200 bp in size, 
respectively.  
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In this experiment, the temporal expression of Panx1 and Panx2 was investigated in four early 
embryonic stages (E9.5, E10.5, E11.5 and E12.5). mRNA expression of Panx1 and Panx2 was detectable 
in all analyzed embryonic stages, in whole-mount of E9.5 as well as in heads and bodies of E10.5, E11.5 
and E12.5 (Figure 18). To determine the spatial distribution of mRNA expression, the three stages E9.5, 
E10.5 and E11.5 were investigated using the whole-mount in situ hybridization technique. 
4.2 Designing cRNA probes for in situ hybridization 
Whole-mount in situ hybridization provides information about the temporal and spatial distribution of 
gene expression and was applied during embryogenesis for a better understanding of their function 
during development. The technique is based on the complementary hybridization of a digoxigenin-
labeled cRNA probe with the target mRNA in whole embryos and detection of the cRNA probe using 
antibodies conjugated with a reporter enzyme of alkaline phosphatase (AP). Detection can be made 
visible using a NBT/BCIP substrate, which reacts in the presence of AP to produce a purple staining at 
sites of hybridization. Usually, the best results for in situ hybridization can be obtained using cRNA 
probes of 50-300 bp in length (Piette et al., 2008). As the full-length probe generated for Panx1 (full-
length) has ~1280 bp length, an additional shorter DNA fragment of 433 bp length was generated. This 
short DNA fragment was called Panx1 Ct. Thus, five types of cRNA probes were used: antisense Panx1 
(full-length), antisense Panx1 Ct (short-length), and antisense mMyoD (served as positive control) in 
addition to negative controls of sense Panx1 (full-length) and sense Panx1 Ct (short-length). 
4.2.1 Cloning of DNA template for the in vitro transcription 
Specific DNA fragments of Panx1 were inserted into vectors for in vitro transcription of cRNA probes. 
Firstly, the short DNA fragment of Panx1 Ct 443 bp (1231-1673 of the sequence NM_019482.2) 
corresponding to the carboxy-terminus of Panx1 was PCR-amplified and analyzed by agarose gel 
electrophoresis (Figure 19). Panx1 Ct (short-length) fragment was inserted subsequently into the 
plasmid pSPT19 (Figure 20). 
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Figure 19. PCR amplification of Panx1 Ct fragment 
Agarose gel electrophoresis analysis of Panx1 Ct amplification. The amplified product of Panx1 Ct was 
500 in size. The DNA template of pEYFP-N1-mPanx1 was very lightly present at the top of the gel 
(arrow). No product was present in the negative control without the template (NT). Low range DNA 
ladder (M). 
 
As mentioned above, it was required to transfer the Panx1 full-length fragment from the plasmid 
pEYFP-N1-mPanx1 into appropriate plasmids of pSPT18 and pSPT19, which are available for in vitro 
transcription (see Chapter 3.5.2). Recombinant plasmids pSPT18 Panx1, pSPT19 Panx1 and pSPT19 
Panx1 Ct were tested by restriction enzyme analysis to identify the correct insert according to the 
molecular weight of DNA insert (Figure 20). DNA fragments of interest were detected at ~1500 bp for 
Panx1 (full-length) and at 500 bp for Panx1 CT. Uncut plasmids of pSPT19 Panx1 and pSPT19 Panx1 Ct 
showed the supercoiled form. On the other hand, the plasmid of pSPT18 Panx1 showed two bands of 
linear and opencircular forms. After agarose gel analysis, DNA fragments of interest were analyzed by 
sequencing. Results confirmed the sequence of Mus musculus pannexin 1 (Panx1), NM_019482.2 (see 
Chapter 3.5.43.5.4). 
 
Figure 20. Restriction enzyme analysis of recombinant plasmids 
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(A) The recombinant plasmid pSPT19 Panx1 Ct was digested with two restriction enzymes EcoRI (E) 
and BamHI (B) (pSPT19 Panx1 Ct (E,B)). The insert of Panx1 Ct (short-length) appeared at 500 bp. The 
recombinant plasmid pSPT19 Panx1 was digested with EcoRI (pSPT19 Panx1 (E,E)) and showed the 
insert of Panx1 (full-length) at ~1500 bp. These recombinant plasmids (pSPT19 Panx1 Ct and pSPT19 
Panx1) showed the supercoiled form of uncut plasmids at 1500 bp. (B) The recombinant plasmid 
pSPT18 Panx1 was digested with EcoRI (pSPT18 Panx1 (E,E)) and showed the insert of Panx1 (full-
length) at ~1200 bp. pSPT18 Panx1 without digestion showed two bands of linear and opencircular 
forms. Broad range DNA ladder (M). 
4.2.2 Probe synthesis of DIG-labeled cRNA 
DIG-labeled cRNA probes were synthesized using the in vitro transcription processes in the presence 
of RNA polymerases (SP6 or T7). Northern blot analysis was used to evaluate the quality of cRNA 
probes, compared to a known probe of MyoD (Figure 21). cRNA was present in all samples on agarose 
gel electrophoresis. In both Panx1 and Panx1 Ct probes, probes equal in length (sense and antisense) 
appeared at the same level. 
 
Figure 21. Northern blot analysis of DIG labeled cRNA probes 
Antisense MyoD probe was used to control the quality of Panx1 (full-length) and Panx1 Ct (short-
length) cRNA probes. All cRNA probes were detected on the gel. Sense (s.) and antisense (as.) probes 
of Panx1 or Panx1 Ct, respectively, are equal in length. Panx1 Ct probes (443 bases) appeared lower 
than Panx1 probes (~1200 bases). However, DIG labeled probes did not appear at predicted sizes, as 
DIG retards the migration of labeled probes on the gel.  
4.3 Spatial distribution of Panx1 mRNA in the mouse embryo 
To date, there are a limited number of studies describing the expression pattern of pannexin family 
members in early stages of mouse development. In this study, the distribution of Panx1 mRNA 
expression was investigated using whole-mount in situ hybridization in early developmental stages 
(E9.5, E10.5 and E11.5). In all experimental steps, the antisense MyoD probe was used as positive 
control to check the quality of cRNA probes and to determine the optimal conditions for the in situ 
hybridization. MyoD is a myogenic regulatory factor, which is required for the formation of skeletal 
muscle in vertebrates (Rudnicki et al., 1993, Ishibashi et al., 2005). Normally, E9.5-E9.75 are the earliest 
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stages to observe MyoD expression by in situ hybridization in mouse embryos (Chen and Goldhamer, 
2004). In this study, MyoD expression was observed from E10.5 onwards, there was no staining visible 
in E9.5 embryos. In E10.5 embryos, MyoD hybridization resulted in a clear staining of interlimb somites 
(Figure 22). The expression level increased at E11.5 and appeared in several regions. It appeared as 
strongly stained parallel lines in interlimb somites and occipito-cervical somites. Further regions were 
also stained at this stage, i.e. in branchial arches, forelimb buds, hindlimb buds, and caudal somites. 
These expression sites were always observed by detecting of MyoD, which was used as a positive 
control in all in situ hybridization experiments.  
As mentioned above, two cRNA probes were used for the determination of Panx1 mRNA expression in 
situ: antisense Panx1 (full-length) and antisense Panx1 Ct (short-length), in addition to two sense cRNA 
probes as negative controls. In all studied stages, samples hybridized with antisense Panx1 Ct (short-
length) exhibited a more intense purple staining in several regions (Figure 22), which was in contrast 
to samples hybridized with antisense Panx1 (full-length), which showed a very light purple staining in 
restricted regions (e.g. ventricle walls) (Figure 23). In negative controls of both sense cRNA probes, no 
staining was observed.  
Panx1 Ct (short-length) showed the expression in all studied stages in both head and body (Figure 22), 
thereby confirming that confirms RT-PCR results (see Chapter 4.1). On the other hand, Panx1 (full-
length) probe did not detect any expression in the trunk, but only in the restricted regions of brain 
vesicles. At E9.5, the expression was detected lightly in the walls of forebrain, midbrain, and hindbrain 
vesicles, whereas at E10.5 and E11.5, the staining was observed only in the wall of telencephalic vesicle 
(Figure 23). Therefore, Panx1 mRNA expression pattern was determined in this project using the Panx1 
Ct (short-length) probe. The specificity of this probe was confirmed in negative controls using sense 
Panx1 Ct probe, which did not show any staining (Figure 22). 
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Figure 22. Overview of whole-mount in situ hybridization experiment 
Lateral views of studied stages E9.5, E10.5 and E11.5 hybridized with antisense Panx1 Ct, sense Panx1 
Ct (negative control), and antisense MyoD (positive control). Embryos hybridized with antisense Panx1 
Ct show the purple staining in all studied stages. No staining is present in the negative control using 
sense Panx1 Ct probe. Antisense MyoD probe shows the specific expression at E10.5 and E11.5 in 
interlimb somites (a), occipito-cervical and truncal somites (b), branchial arches (c), in forelimb buds 
(d), and in hindlimb buds (e). No MyoD expression was detected at E9.5. 
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Figure 23. Overview of whole-mount in situ hybridization using Panx1 (full-length) cRNA 
Samples hybridized with antisense Panx1 (full-length) probe exhibited a very light purple staining in 
the head of E9.5, E10.5 and E11.5 embryos, no staining was observed in the body at these stages. At 
E9.5, Panx1 was detected in the wall of brain vesicles; in forebrain (fb), midbrain (mb), and hindbrain 
(hb). At E10.5 and E11.5, the staining was restricted to the wall of telencephalic vesicle (t) (arrowhead). 
No staining was detectable in the negative control using sense Panx1 (full-length) probe (right panel).  
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4.3.1 Panx1 mRNA expression at E9.5 
For a better attribution of Panx1 expression sites at E9.5 to structures of the nervous system, whole-
mount immunolabeling was performed using the neuronal marker neuronal class III β-tubulin 
(monoclonal antibody Tuj1) to identify the localization of nervous system regions in this stage (Figure 
24). Panx1 mRNA expression at E9.5 was determined using antisense Panx1 Ct (short-length) and 
expression sites were observed in both head and body of the embryo (Figure 24). In cephalic regions, 
the wall of forebrain and the basal plate of the mesencephalic vesicle were Panx1-positive. In the 
maxillary region, the area of trigeminal ganglion tissue (V) was Panx1-positive. This signal appears 
dorsal of the first branchial arch. Likewise, the facio-acoustic ganglion complex (VII-VIII) exhibited the 
purple staining on the dorsal region of the second branchial arch. The otic pit, which appears on the 
caudal part of hindbrain vesicle, showed a less intense Panx1 expression signal. Panx1 expression was 
also observed in the first branchial arch. In the body, the occipito-cervical and truncal region of neural 
tube appeared to be Panx1-positive, as well as the forelimb buds. 
Figure 24. Panx1 mRNA expression in E9.5 embryo 
(A) Whole-mount immunolabeling of the neuronal marker β-III-tubulin in an E9.5 embryo used to 
present nervous system structures at this developmental stage. (B) Lateral view of mouse embryo E9.5 
shows Panx1 mRNA expression sites using DIG-labeled probes of antisense Panx1 Ct (short-length). 
Expression sites included telencephalic vesicle wall, basal plate of the mesencephalic vesicle 
(arrowhead), trigeminal ganglion (V), facio-acoustic (VII-VIII) ganglion complex, otic vesicle (ov), neural 
tube (nt), forelimb bud (bu), and the first branchial arch (b1), but not the second branchial arch (b2).  
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4.3.2 Panx1 mRNA expression at E10.5 
The E10.5 embryo shows an obvious differentiation in the cephalic region. The primitive forebrain 
(prosencephalon) becomes subdivided into the telencephalon, which will later form cerebral 
hemispheres, and the diencephalon, which will form thalamic and hypothalamic regions of the brain 
(Rao and Jacobson, 2005). The two telencephalic vesicles appear anterior on either side of the third 
ventricle. Panx1 expression was observed in the wall of the two telencephalic vesicles (Figure 25). In 
the midbrain region, the mesencephalic basal plate and the vesicle wall show a noticeable Panx1 
expression in lateral and dorsal view, respectively.  
Figure 25. Panx1 mRNA expression in E10.5 embryo 
(A) Lateral view of an E10.5 embryo showing Panx1 expression (arrowheads), in the telencephalic 
vesicle (te) and in the basal plate of the mesencephalic vesicle (me). More intense labeling appeared 
in the trigeminal ganglion (V), facio-acoustic ganglion complex (VII-VIII), and otic vesicle (ov). Panx1 is 
also present in neural tube (nt) and fore-/hindlimb buds (bu). (B) Dorsal view of E10.5 showing Panx1 
expression (arrowhead) in the mesencephalic vesicle wall (me), the rhombencephalic vesicle wall (rb), 
and in the neural ridge of neural tube (nt) in the occipito-cervical region. Rhombomeres (r1–r8) were 
numbered as described by Cordes (2001). 
 
At this stage of development, the hindbrain is subdivided into eight segments called rhombomeres (r1-
r8) (Cordes, 2001). Panx1 exhibited a homogenous staining in all rhombomere segments (r1–r8). Some 
cranial ganglia in particular the trigeminal ganglion and the facio-acoustic ganglion complex exhibited 
a higher expression level than other cephalic regions. At this stage, the facial ganglion (VII) can hardly 
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be distinguished from the acoustic component (VIII) in the facio-acoustic ganglion complex. However, 
it appears that the whole complex, and thereby both ganglia, are Panx1-positive. Further expression 
sites were observed in the otic vesicle, forelimb and hindlimb buds. In the neural tube, the expression 
is clearly present in the truncal region. Expression was also observed in the neural ridge of the occipito-
cervical region (Figure 25). 
4.3.3 Panx1 mRNA expression at E11.5 
Many morphological changes are observable in E11.5 embryos: the telencephalic vesicles increases 
dramatically in volume, and the lens vesicle becomes differentiated and separated from the ectoderm. 
The three branchial arches show an increasing volume, and the forelimb becomes subdivided into 
proximal and distal regions. Best results of whole-mount in situ hybridization were observed at this 
stage; the purple staining was more clearly visible than in previous stages (Figure 26).  
The observed Panx1 signal in the walls of telencephalic vesicles (Figure 26, A and B), as well as in the 
alar plate of the mesencephalon (Figure 26 B) was more intense than at earlier stages. The 
mesencephalon showed fewer changes than other regions of the brain during development, it does 
not become subdivided into more parts and gives later rise to the midbrain, which connects the 
hindbrain (pons and cerebellum) with the forebrain (cerebral hemispheres, thalamic and hypothalamic 
regions). Panx1 expression was clearly visible also in the mesencephalic basal plate (tegmentum) 
(Figure 27 A). Interestingly, motor neurons of the oculomotor cranial nerve (III) develop from the 
mesencephalic basal plate between E10 and E12 (Wurst and Bally-Cuif, 2001). The developed 
oculomotor nucleus (III) keeps the localization in the midbrain (Guthrie, 2007).  
The rhombencephalon is located posterior to the mesencephalon, which becomes subdivided into 
anterior region named the metencephalon (it gives rise to cerebellum), and posterior region is the 
myelencephalon (it will form the medulla oblongata). The basal plate of the metencephalon, which 
gives rise to motor neurons of the trochlear nucleus (IV) (Wurst and Bally-Cuif, 2001), exhibited Panx1 
mRNA expression (Figure 27, A). Panx1 expression was also observed at this stage on the whole lip of 
rhombencephalon as well as in the roof plate of fourth ventricle (ventricular zone) (Figure 26 C). Some 
cranial ganglia, the trigeminal ganglion (V) and the facio-acoustic ganglion complex (VII-VIII), exhibited 
very clearly Panx1 expression. At this stage, it is possible to distinguish the acoustic ganglion 
component (VIII) from the facial ganglion (VII) (Figure 27, A). The otic vesicle is still located caudal to 
the facio-acoustic ganglion complex and Panx1 expression was detected in the wall of the vesicle 
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(Figure 27, A) as well as the maxillary component of first branchial arch. Spinal cord displays a 
continuous Panx1 expression signal in all spinal cord segments (Figure 27 B). 
 
Figure 26. Panx1 mRNA expression in E11.5 embryo 
Different views of E11.5 mouse embryos show Panx1 mRNA expression sites using DIG-labeled probes 
of antisense Panx1 Ct (short-length). (A) Lateral view shows expression sites (arrowheads) in the 
telencephalic vesicle wall (te) and the basal plate of the mesencephalic vesicle (me). Other expression 
sites were observed in trigeminal ganglion (V), facio-acoustic (VII/VIII) ganglion complex, otic vesicle 
(ov), spinal cord (sc) as well as in DRGs (not labeled). (B) Top view of cephalic region shows expression 
sites (arrowheads) at the wall of telencephalon vesicles (te) and the alar plate of the mesencephalon 
(me). (C) Posterior view of the cephalic region represents expression sites at the whole lip of 
rhombencephalon region (rb) (arrowhead) and in the ventricular layer of the fourth ventricle (arrows). 
(a) the maxillary component of first branchial arch, (a’) mandibular component of the first branchial 
arch, (b) the second branchial arch. 
 
Whole-mount in situ hybridization revealed that Panx1 is expressed mainly in the nervous system in 
all studied stages. To confirm the results obtained from whole-mount in situ hybridization and to reveal 
more details about the expression, vibratome sectioning was performed on embryos after the whole-
mount in situ hybridization procedure.  
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Figure 27. Panx1 mRNA expression in the head and the body of an E11.5 embryo 
High magnification views of the head and the truncal part of spinal cord hybridized with the antisense 
Panx1 Ct (short-length) probe (whole-mount in situ hybridization). (A) Panx1 expression (arrowheads) 
was observed in the walls of telencephalic vesicles (te) and in the basal plate of mesencephalon (me). 
Characters III and IV indicate the origin of oculomotor and trochlear cranial nerves from the basal plate, 
respectively. Panx1 expression was clearly present in cranial ganglia, i.e. in trigeminal ganglion (V), 
facial ganglion (VII), and acoustic ganglion component (VIII). The wall of the otic vesicle (ov) exhibited 
also Panx1 expression as well as the maxillary component of the first branchial arch (a). (B) Panx1 
expression was also detectable in all spinal cord segments (sc) (arrowheads) and in the apical region 
of the forelimb plate (arrow). (a’) points to the mandibular component of the first branchial arch, (b) 
the second branchial arch, (rb) rhombencephalon.  
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4.3.4 Vibratome sectioning post WM-ISH 
Embryos from E11.5 revealed best results by whole-mount in situ hybridization analysis as compared 
to other early stages of embryonic development. The purple staining was more abundant at this stage. 
Therefore, vibratome sectioning of E11.5 embryos was performed after the whole-mount in situ 
hybridization to obtain more details of expression sites. Hybridized embryos with antisense Panx1 Ct 
probe were sectioned and compared to the negative control of embryos hybridized with sense Panx1 
Ct probe.  
In a transversal section of the head region, the purple staining was observed only on the inner side of 
telencephalic vesicle wall (apical surface) (Figure 28). The embryonic cortex at this stage consists of 
two components, the ventricular zone (VZ) at the apical surface and the subventricular zone (SVZ) at 
the basal side. The VZ is made up of progenitor cells, which divide constantly at the apical surface; 
some cells exit the cell cycle and migrate into the SVZ (Dehay and Kennedy, 2007). This suggests that 
Panx1 is expressed in progenitor cells of VZ at this stage.  
Another region of the section, the trigeminal ganglion, showed a clear staining in the whole tissue of 
the ganglion (Figure 28). The facial ganglion (VII) and acoustic ganglion component (VIII) were also 
Panx1-positive. These two ganglia were separated from each other and located ventral to the otic 
vesicle. An additional expression site was observed in the inferior ganglion of vagus nerve (not shown). 
This ganglion was invisible in whole-mount samples. 
The inner side of the otic vesicle wall showed a hybridization signal in form of a dark line of purple 
staining. Moreover, a very light staining was observed in a section of the maxillary component of the 
first branchial arch, which develops to form later the face including the upper jaw. No staining was 
observed at any of these described sites in the sense negative control (Figure 28). 
By whole-mount in situ hybridization, Panx1 expression was observed in the whole lip of 
rhombencephalon. This expression site was confirmed in a transversal section at the caudal level of 
the rhombencephalon. Panx1 expression was observed in the alar plate of the cranial myelencephalic 
part. A transversal section at the truncal level of the spinal cord showed a very light staining in the 
mantle layer of the developing spinal cord and in dorsal root ganglia (DRGs). The expression in DRGs 
was also observed in a sagittal section of tail region (Figure 29 F). 
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Figure 28. Cephalic transverse vibratome sections of an E11.5 embryo 
Vibratome sections of an E11.5 embryo post whole-mount in situ hybridization. Section levels (A, B 
and C) are shown on the right. The middle column shows expression sites, which were observed using 
antisense Panx1 Ct (short-length). The left column shows the negative control of each region using 
sense Panx1 CT. (A) Panx1 expression (arrowheads) was observed in trigeminal ganglion (V), facial 
ganglion (VII), acoustic ganglion component (VIII), and in the wall of the otic vesicle (ov). (B) The wall 
of the telencephalon vesicle (te) exhibited also Panx1 expression (arrowhead). (C) The first branchial 
arch (b1) showed Panx1 expression (arrowhead) in the apical part.  
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Figure 29. Truncal transverse vibratome sections of an E11.5 embryo 
Vibratome sections of an E11.5 embryo post whole-mount in situ hybridization showing the dorsal 
region. (A and B) Transversal sections at the caudal level of the rhombencephalon (1). Panx1 
(arrowhead) was detected in the alar plate of the myelencephalon, cranial part (A). Transversal (C and 
D) and sagittal (F) sections of spinal cord (2, 3), Panx1 was detectable in the mantle layer (mt) and 
dorsal root ganglia (DRGs) (C and F). No expression was detected in the negative control (B and D). 
Somites (so). 
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Table 12. Embryo structures expressing Panx1 mRNA 
Labeled embryo structures E9.5 E10.5 E11.5 
Telencephalon vesicle  + + ++ 
Mesencephalon    
Alar lamina + + ++ 
Basal plate + + ++ 
Rhombencephalon (r1–r8)    
Metencephalon - ++ +++ 
Myelencephalon - ++ +++ 
Cranial ganglia    
Oculomotor motor neurons (III) - + ++ 
Trochlear motor neurons (IV) - + ++ 
Trigeminal ganglion (V) + ++ +++ 
Facial ganglion (VII) + ++ +++ 
Acoustic ganglion (VIII) + ++ +++ 
Vagus ganglion (X) n.d. n.d. +++ 
Otic vesicle + ++ ++ 
Spinal cord + ++ +++ 
Dorsal root ganglia n.d. n.d. ++ 
Branchial arch 1 + + + 
Forelimb plate + + + 
(+) indicates the intensity of in situ hybridization staining in whole-mount embryos or in vibratome 
sections of studied stages. The intensity was determined according to the optical observation. (-) 
indicates the absence of the staining. In DRG, Panx1 was observed only in vibratome sections of E11.5 
embryo. No vibratome sections were made of E9.5 and E10.5 embryos. n.d. not determined.  
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4.4 Panx1-β-Gal expression in transgenic embryos 
The bacterial gene LacZ encodes β-galactosidase in Escherichia coli in order to cleave the disaccarid 
lactose into two monosaccharides, glucose and galactose. Histochemical staining (β-Gal staining) uses 
the fact that β-galactosidase hydrolyzes X-Gal molecules to release indole molecules and galactose. 
Two indole molecules dimerize and produce a visible blue/green staining (Juers et al., 2012). Thus, cells 
or tissues producing this staining reveal an endogenous or exogenous expression of beta-galactosidase 
(β-Gal) in active form. 
β-Gal is, in addition to bacteria, also expressed in different mammalian cells at low level. To avoid the 
detection of endogenous expression of β-Gal, pH dependency of staining was investigated. Weiss et 
al. (1999) revealed that the endogenous β-Gal was active in acidic pH and that endogenous β-Gal 
detection can therefore be avoided using an alkaline pH for β-Gal staining. In this study, no endogenous 
β-Gal signal was detected in wildtype mice using a pH of 7.4 (Figure 30). In Panx1 transgenic mice 
(Panx1tg/tg), the LacZ gene is inserted into the Panx1 gene to be under the control of the Panx1 
promoter. Hence, the β-Gal staining can be used to evaluate Panx1 expression indirectly in whole-
mount embryo. 
  
Figure 30. Signal specificity of β-Gal staining 
Whole-mount β-Gal staining of Panx1tg/tg (A) and Panx1wt/wt (B) embryos at E11.5 and E13.5, 
respectively. No staining was visible in the wildtype embryo (B) compared to the transgenic embryo 
(A) under similar conditions. 
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4.4.1 Panx1-β-Gal expression in E11.5 Panx1tg/tg mice 
Whole-mount β-Gal staining was used to detect β-Gal expression in the whole embryo, in order to 
evaluate sites expressing Panx1 indirectly. This method allowed comparing reporter gene expression 
of β-Gal with Panx1 mRNA expression by WM-ISH.  
Many expression sites observed by WM-ISH were confirmed with β-Gal staining (Figure 31). The 
expression of β-Gal was observed in telencephalon and mesencephalon with lower expression in the 
basal plate of the mesencephalon. In the rhombencephalon, β-Gal expression was absent from the 
whole lip of the rhombencephalon. However, the roof plate of the metencephalon exhibited a strong 
signal. On the other hand, β-Gal staining in cranial ganglia (V, VII, and VIII) was very weak and hardly 
allowed identification of ganglia. A very strong signal was detected in the head behind the otic vesicle, 
likely to be the primary head vein. The expression of β-Gal in spinal cord was continuous in all 
segments. β-Gal staining in the abdominal region appeared non-specific. 
 
Figure 31. Whole-mount β-Gal staining of a Panx1tg/tg embryo at E11.5 
(A) A lateral view of an E11.5 embryo shows β-Gal expression in different regions, in the basal plate of 
mesencephalon (arrowhead), in the trigeminal ganglion (V), in the facio-acoustic (VII/VIII) ganglion 
complex, in the optic cup (op), and in spinal cord (sc). Primary head vein (p) (B) Top view of the cephalic 
region shows the β-Gal staining (arrowheads) in the wall of telencephalic (te) and mesencephalic 
vesicles (me). (C) Dorsal-top view of the hindbrain region shows β-Gal expression in the roof plate of 
the metencephalon (mt). 
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For detailed analysis of whole-mount β-Gal staining, paraffin sectioning was carried out. Unfortunately, 
the remainder of the staining was not sufficient for microscopy. Hence, paraffin block photography 
was performed at different levels to show an overview of β-Gal expression sites. A block sectioned at 
the level of the cephalic region showed β-Gal staining in the roof plate of mesencephalic vesicle (Figure 
32). Another block sectioned at the level of the rhombencephalon, shows the staining in the roof and 
floor plate of the caudal myelencephalic part. In spinal cord, the staining was visible in the mantle layer 
of the developing spinal cord and a very low level in DRGs (Figure 32 C). 
 
Figure 32. Overview of paraffin blocks post β-Gal staining of E11.5 Panx1tg/tg embryo 
(A) Overview of paraffin blocks at the level of mesencephalon (me) shows β-Gal staining (arrowhead) 
in the roof plate. (B) At the caudal level of the myelencephalon (my), the staining is visible in roof and 
floor plates. (C) At spinal cord level, the mantle layer (m) of the developing spinal cord and dorsal root 
ganglia (DRGs) are β-Gal-positive. Block sections were obtained from the embryo in (D) at labeled 
levels.  
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4.5 Panx1 protein expression in mouse development 
As described above, Panx1 expression was investigated in early stages of mouse development. This 
was based on PCR, whole-mount in situ hybridization, and β-Gal staining results. All these techniques 
revealed that the Panx1 gene is expressed in early mouse development, in the head and the body with 
abundant expression during development of the nervous system. To date, there are limited data 
illustrating Panx1 protein distribution in mouse development. The aim of this part of the study was 
therefore to analyze the distribution of Panx1 protein during mouse development, as a key to 
understand its function during development. 
The detection of a protein in a tissue requires protein-specific antibodies. In this study, different 
commercial antibodies against Panx1 were used for immunoblotting and immunofluorescence 
analyses. Many antibodies, however, either gave no signal or reacted unspecifically. Therefore, 
polyclonal antibodies were generated using immunization peptides according to the sequence 
described by Penuela et al. (2007). 
4.5.1 Panx1 antibody generation 
In this study, a polyclonal antibody was generated in rabbit using synthetic immunization peptides 
corresponding to amino acids 395 to 409 (QRVEFKDLDLSSEAA), located in the carboxy-terminus of the 
mouse Panx1 protein (Penuela et al., 2007). The pre-immune serum was collected from the animal 
prior to immunization and served as negative control. The antiserum was used without further 
purification. The antibody titer was determined using ELISA assay, and the specificity was characterized 
using immunolabeling and immunoblotting analyses. In parallel, analyses were performed using the 
pre-immune serum and preabsorbed antibodies with synthetic peptides as negative controls. 
4.5.2 Panx1 antiserum reactivity determined by ELISA  
The amount of the specific antibody in the antiserum was defined as the antibody titer. The antibody 
titer was determined at the highest dilution of the first antiserum, at which the absorbance ratio 
(absorbance of an antiserum sample to absorbance of PIS) was greater than 2.1 (Liu, 2009). Equal 
quantities (80 ng) of peptides were coated to wells. Serial dilutions (1:1,000 – 1:128,000) of the first 
antiserum and of PIS were allowed to bind to coated peptides. After the enzymatic detection of 
peptide-antibody complex via HRP antibodies, the produced color was measured. The absorbance 
value of antiserum dilutions was reduced in high dilution samples. PIS samples exhibited a constant 
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absorbance value. In all antiserum dilutions, the absorbance ratio was greater than 2.1 (Figure 33). The 
highest dilution (1:128,000) was defined as the antibody titer. These data are represented without 
statistical analysis, as this experiment was performed only once (n = 1). 
 
Figure 33. Antiserum titer determination by ELISA 
Serial dilutions (1:1,000 – 1:128,000) of the first antiserum and PIS were applied to 80 ng of synthetic 
peptides. All diluted samples of the antiserum were taken as positive, as the absorbance ratio was 
greater than 2.1. The antibody titer was determined at the highest dilution of 1:128,000. 
4.5.3 Panx1 antibody specificity determined by peptide competition assay 
Polyclonal antibodies can react unspecific and exhibit unspecific signals. The peptide competition assay 
was used to determine the specific signal of the generated antibody. Prior to use in an immunoblot, 
the first antiserum was incubated with Panx1 synthetic peptides used for antibody generation. These 
peptides were used to bind Panx1 specific antibodies in the antiserum. Thus, peptide pre-incubation 
should result in the absence of any specific signal and all detected signals remaining were considered 
non-specific. 
In this experiment, the antibody was preabsorbed with serial dilutions of Panx1 peptides to determine 
the optimum dilution for a complete peptide blocking. The experiment was performed using a brain 
protein lysate, as Panx1 expression had been reported in brain previously (Ray et al., 2005, Zappala et 
al., 2006). In the absence of peptides, the protein was detected at a molecular weight of 50 kDa 
corresponding to the molecular weight of Panx1. Samples, which were detected using the preabsorbed 
antiserum, showed a reduction in the intensity of the immunoreaction with increasing peptide 
quantities until 40x. No complete disappearance of the immunoreactivity was observed at these 
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dilutions (Figure 34). On the other hand, the negative control serum (PIS) did not detect any protein 
on the membrane.  
In this experiment, peptides were incubated with the antiserum at 4°C only for two hours. However, a 
complete blocking was obtained by incubating the antiserum with peptides for 48 hours as described 
in the next section.  
Figure 34. Panx1 antibody specificity as determined by peptide competition assay 
The peptide competition assay was performed on brain protein lysate. The antiserum detected a 
protein at 50 kDa corresponding to the molecular weight of Panx1. The first antiserum in a dilution of 
1:1,000 was preabsorbed with serial dilutions of Panx1 peptides (1x, 10x, 20x, and 40x). The 
preabsorbed antiserum showed reduced labeling intensity without complete elimination compared to 
not preabsorbed antiserum (0) or in PBS diluted antiserum. No protein was detectable with PIS.  
4.5.4 Temporal expression of Panx1 protein in mouse development 
As described above, Panx1 mRNA was expressed in early stages of mouse embryonic development, in 
both the head and the body (see Chapter 4.1). To analyze whether Panx1 mRNA was translated into 
protein at these stages, immunoblotting analysis was performed using the same developmental stages 
as in RT-PCR experiments. Ten embryos of E9.5 were pooled and proteins were isolated from whole 
embryos. Embryos of E10.5, E11.5 and E12.5 (six, six, and one embryos, respectively) were analyzed in 
samples of pooled heads or bodies separately. For each sample, the first antiserum was applied in 
addition to controls: of PIS and neutralized serum with 10x peptides. This experiment was performed 
only once (n = 1). 
Panx1 antiserum reacted in all stages and exhibited multiple immunoreactive proteins. A protein was 
detected at a molecular weight of 55 kDa in addition to other proteins in most samples. 
Immunoreactivity at 46 and 55 kDa disappeared completely in E12.5 samples and partly in E9.5, E10.5, 
and E11.5 samples after peptide preabsorption (Figure 35).  
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Figure 35. Temporal expression of Panx1 protein in mouse development 
Protein lysates of whole-mount E9.5, heads and bodies of E10.5, E11.5 and E12.5 were examined using 
Panx1 antiserum, preabsorbed serum with 10x peptides, and PIS. Panx1 antiserum detected multiple 
immunoreactive proteins at 55, 46 and 32 kDa. Intensity of immunoreactions was decreased or absent 
using preabsorbed antiserum. Immunoreactivty was present at a molecular weight of 17 kDa in E9.5 
and body samples or at 20 kDa in head samples incubated with Panx1 antiserum. This protein 
disappeared completely using the neutralized serum. No proteins were detected using the pre-
immune serum (PIS) except an unspecific detection in the head of E10.5. The loading control of actin 
appeared at 46 kDa in all samples. 
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The immunoreactivity at a molecular weight of 32 kDa was restricted to E9.5 (whole embryo) and to 
body samples of all stages. Immunoreaction to this protein disappeared completely after peptide 
preabsorption. Further immunoreactivity was clearly present in all samples at a molecular weight of 
17 kDa in E9.5 and body samples or at 20 kDa in head samples. This signal disappeared completely in 
all samples after peptide preabsorption. In the head of E10.5, an immunoreactive protein was visible 
using PIS, thus, it was considered non-specific. All other samples were negative using PIS. These results 
indicate that Panx1 protein is present in all studied stages in both the head and the body and exhibits 
multiple immunoreactive proteins. 
4.5.5 Specificity of Panx1 antibody in the retina and cerebellum 
The localization of Panx1 protein in tissues was determined using indirect immunolabeling detection. 
Firstly, the antiserum specificity was tested on tissues of cerebellum and retina, for which Panx1 
expression had been reported previously. In the cerebellum, Panx1 expression was detected in 
Purkinje cells and in the granule cell layer. Additional immunopositive cells were also detected in the 
molecular cell layer (Figure 36). In the retina, Panx1 was observed in the ganglion cell layer (GCL), the 
inner nuclear layer (INL), and at the outer border of the outer nuclear layer (ONL). Some 
immunepositive cells appeared also in the outer plexiform layer (OPL) adjacent to the INL (Figure 36). 
In both regions investigated, no signal was observed in the negative control using PIS except an 
unspecific signal within the GCL. 
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Figure 36. Panx1 antiserum specificity in the retina and cerebellum 
(A) In the cerebellum, Panx1 immunoreactivity (red) was present in cerebellar Purkinje cells layer (PC) 
(arrows) and in the granule cell layer (GL) (arrowhead). Some immunepositive cells were present in the 
molecular layer (Mo) (arrowheads). (B) No labeling was detectable in the cerebellum using PIS. (C) In 
the retina, Panx1 immunopositive cells (arrowheads) were present in ganglion cells (arrowheads in 
GCL), in the inner nuclear layer (INL) and at the outer border of the outer nuclear layer (ONL). Barbed 
arrowheads indicate immunepositive cells in the outer plexiform layer (OPL) adjacent to the INL. (D) 
The staining observed in the GCL using PIS was considered non-specific. DAPI was used as nuclear dye 
(blue). 
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4.5.6 Panx1 protein distribution in spinal cord and sensory ganglia of E11.5 
As described above, Panx1 mRNA expression was observed in early stages of mouse development. 
Immunoblotting analysis showed also the protein expression in all of these stages. To determine the 
localization of Panx1 protein in early stages, immunolabeling analysis was performed on E11.5 
embryos. At this stage, Panx1 mRNA was more abundantly expressed than in other early stages and 
especially observed in trigeminal ganglion and spinal cord (see Chapter 4.3.3).  
Panx1 was detected using the antiserum, in addition, negative controls using PIS and neutralized serum 
(preabsorbed with 60x peptides) were performed (see Chapter 3.8.2). An abundant expression of Panx1 
was observed in the trigeminal ganglion, dorsal root ganglia, as well as in the mantle layer of the spinal 
cord (Figure 37). No expression was detectable in the dorsal horn and in the ventricular zone as well 
as in the floor plate. Labeling was considered specific, since no labeling was observed in negative 
controls using the neutralized serum or PIS.  
For further determination of the cell types expressing Panx1 in DRGs and spinal cord, double 
immunolabeling was performed using Panx1 antiserum and NeuN antibody on spinal cord cryosections 
of E11.5 embryos. The neuronal marker NeuN (neuron-specific nuclear protein) is firstly detectable 
when neurons become post-mitotic and initiate the neuronal differentiation (Mullen et al., 1992). At 
E11.5, NeuN was expressed in the mantle layer but not in the ventricular zone or the floor plate. Panx1-
immunopositive cells, which were found at the site of developing motor neurons in the mantle layer, 
were also NeuN-positive. However, the number of NeuN-positive cells in the mantle layer and DRGs 
exceeded the number of Panx1-positive cells (Figure 38). 
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Figure 37. Panx1 expression in spinal cord and sensory ganglia at E11.5 
Transversal sections of E11.5 embryos, located at the level of trigeminal ganglion and spinal cord, 
respectively, were used for immunofluorescence. Many positive cells were visible using the antiserum 
of Panx1. The signal was visible in trigeminal ganglion (Tri), dorsal root ganglion (DRG) and in the 
mantle layer of the neural tube (ML). No labeling was observed in these regions using neutralized 
serum (+ 60x peptide) or PIS (pre-immune serum).   
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Figure 38. Co-localization of Panx1 and NeuN in an E11.5 embryo 
Double immunolabeling using Panx1 antiserum and NeuN antibody was performed on cryosections of 
E11.5 embryos. Transversal spinal cord cryosection at low (left planel) and high (right panel) 
magnification showing Panx1 and NeuN expression (arrowheads) in the mantle layer (ML) and in DRG. 
(left). At high magnification, DRGs labeled with anti-Panx1 and anti-NeuN antibodies revealed the co-
localization of Panx1 and NeuN (arrowheads). DAPI was used as nuclear dye (blue).  
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4.5.7 Panx1 mRNA and protein expression investigated in transgenic mice 
To validate that primers used for further analysis did not detect any transcript in Panx1- or Panx2-
transgenic mice, RT-PCR analysis was performed. The experiment was performed using tissues from 
wildtype animals and transgenic animals of Panx1tg/tg, Panx2tg/tg, and Panx1wt/tg / Panx2tg/tg. Primers 
were tested on a total RNA extract of cerebellum and brainstem. An internal control was applied using 
the reference gene 18S rRNA.  
Panx1 and Panx2 expression in cerebellum and brainstem was previously described in many reports 
(Baranova et al., 2004, Ray et al., 2006, Zappala et al., 2006). Samples of wildtype and heterozygous 
Panx1-transgenic animals (Panx1wt/tg) showed a specific PCR product at the predicted size (Figure 39). 
No detectable products were visible in samples of homozygote transgenic mice Panx1tg/tg and Panx2tg/tg 
or in the absence of reverse transcriptase (NR) during cDNA syntheses.  
Figure 39. Panx mRNAs expression in transgenic mice 
PCR analysis of wildtype and Panx1 / Panx2 transgenic tissues cerebellum and brainstem using primers 
amplifying Panx1, Panx2 or 18S. PCR product were present in both wildtype and heterozygous animal 
of Panx1tg/wt in the present of reverse transcriptase (RT) at the predicted size (443 bp Panx1, 266 bp 
Panx2 and 155 bp 18S). No PCR products were detectable in samples of homozygote transgenic animals 
and in the negative control without reverse transcriptase (NR). 18S rRNA amplification served as a 
reference for equal cDNA template. 
 
This experiment revealed that the primers used were specific and that Panx1 and Panx2 were not 
present in the particular homozygote transgenic animals. This also allowed to use transgenic animals 
to examine the specificity of Panx1 antiserum using immunolabeling and immunoblotting analyses. 
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Immunohistochemically, Panx1 antiserum labeled cells in the ganglion cell layer and in the inner 
nuclear layer of wildtype animals (Figure 40). No labeling was detected in the inner plexiform layer. On 
the other hand, Panx1 antiserum did not exhibit any signal in transgenic animals. This revealed that 
Panx1 antiserum detected Panx1 protein specifically. 
 
Figure 40. Panx1 expression in the retina of transgenic mice 
Cryosections of the retina from Panx1wt/wt and Panx1tg/tg mice were labeled using Panx1 antiserum 
(red). (A) In the wildtype, Panx1 antiserum detected positive cells in ganglion cell layer (GCL) (arrow) 
and in the inner nuclear layer (INL) (arrowheads). No positive cells were detected in the inner plexiform 
layer (IPL). (B) In transgenic animal Panx1tg/tg, no labeling was detected in the retina. (C and D) Same 
images as in A and B, respectively, are represented including the nuclear dye DAPI (blue). 
 
For further determination, the antiserum was tested using immunoblotting analysis on brain and 
cerebellum protein lysates of wildtype and transgenic animals. Using Panx1 antiserum, 
immunoreactive proteins were detected in the wildtype as well as in transgenic tissues, in both brain 
and cerebellum samples (Figure 41 A). Two immunoreactive proteins at 32 kDa and 35 kDa were 
present in transgenic animals whereas only one protein was detectable in wildtype tissues. An 
additional protein was detected at a molecular weight of 14 kDa in all samples. This experiment was 
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performed using the first antiserum; the same antiserum was used on embryonic lysates in previously 
described experiments (see Chapter 4.5.4). 
Furthermore, three commercial antibodies were tested by immunoblotting. The monoclonal Panx1 
antibody (ab124969) detected an immunoreactive protein at 48 kDa in wildtype as well as in transgenic 
animals using a dilution of 1:10,000. The polyclonal Panx1 antibody (ab139715) displayed two 
immunoreactive proteins at a molecular weight of 34 and 40 kDa; labeling was more intense in 
transgenic animals than in wildtype tissues. The monoclonal Panx1 antibody (MAB7097, R&D) 
detected a protein at 46 kDa in all samples with similar intensity (Figure 41). Immunoblotting analysis 
of each antibody was performed only once by investigating protein lysates of two organs, i.e. brain and 
cerebellum. 
 
Figure 41. Panx1 protein expression in transgenic tissues 
Panx1 antibodies were analyzed by Immunoblotting using protein lysates of brain (Br.) and cerebellum 
(Cer.) from Panx1wt/wt and Panx1tg/tg animals. (A) Panx1 antiserum showed two proteins at 32 and 35 
kDa in transgenic animal Panx1tg/tg whereas only one protein was detectable in the wildtype Panx1wt/wt. 
An additional protein was also visible at 14 kDa in all samples. (B) Anti Panx1 (ab124969) detected a 
protein at 48 kDa in both Panx1wt/wt and Panx1tg/tg of Br. and Cer. (C) A protein was detected very weakly 
at 40 kDa using anti Panx1 (ab139715) in both Panx1wt/wt and Panx1tg/tg. An additional protein was 
strongly apparent in Panx1tg/tg and very weakly in Panx1wt/wt at 34 kDa. (D) No difference was apparent 
between Panx1wt/wt and Panx1tg/tg using anti Panx1 (MAB7097, R&D). This antibody detected a protein 
at 46 kDa in all samples.  
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The polyclonal Panx2 antibody (ARP42778_T100, AVIVA) was also tested on protein lysates of brain 
and cerebellum. The antibody detected a protein at 66 kDa corresponding to the molecular weight of 
Panx2. This detection was similar in wildtype and Panx2tg/tg transgenic animal (Figure 42). 
 
Figure 42. Panx2 protein expression in transgenic tissues 
The specificity of the Panx2 antibody (AVIVA) was examined by immunoblotting using protein lysates 
of brain (Br.) and cerebellum (Cer.) from Panx2wt/wt and Panx2tg/tg animals. The antibody detected a 
protein at 66 kDa in both Panx2wt/wt and Panx2tg/tg tissues. 
 
In immunoblot analysis, Panx1 and Panx2 antibodies employed in this study revealed similar 
immunoreactivities in both wildtype and transgenic Panx1tg/tg or Panx2tg/tg animals, respectively. The 
analysis of Panx protein expression therefore requires further analysis and the use of additional 
antibodies. In the course of this project, alternative methods were used for the detection of Panx1 
expression with focus on spinal cord and sensory ganglia.   
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4.6 Panx1 expression in spinal cord and sensory ganglia 
In situ hybridization and PCR analysis revealed that Panx1 mRNA is expressed in spinal cord and sensory 
ganglia during development. To investigate the cellular and regional distribution further, expression 
was investigated in adult spinal cord and sensory ganglia using β-Gal staining. This analysis was 
quantifiable from E18.5 onwards. To obtain an overview about Panx1 expression in spinal cord, whole-
mount β-Gal staining was performed on spinal cord and sensory ganglia from a 4-week-old Panx1tg/tg 
mouse (Figure 43). The β-Gal staining was observed in all spinal segments of the posterolateral tract. 
No staining was observed in the dorsal funiculus or in the ventral funiculus. On the other hand, all DRGs 
and trigeminal ganglia exhibited clearly the β-Gal staining. This experiment revealed that Panx1 is 
expressed in all spinal segments as well as in DRGs and trigeminal ganglion. For further determination 
of signals, β-Gal staining was performed on cryosections of these regions.  
 
Figure 43. Whole-mount β-Gal staining of spinal cord and sensory ganglia 
The whole-mount spinal cord attached to the dorsal root ganglia (DRGs) and sensory trigeminal ganglia 
was prepared from a 4-week-old Panx1tg/tg mouse. The preparation was stained whole mount with β-
Gal. (A) A dorsal view shows the positive β-Gal staining at all segments of the posterolateral tract (plt) 
in spinal cord and brain stem. No staining was observed in the dorsal funiculus (dfu) and in the ventral 
funiculus (vfu). Trigeminal ganglion (Tri) and DRGs were stained also with β-Gal. (B) The ventral region 
of spinal cord did not show the staining product.  
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4.6.1 β-Gal staining on cryosections 
In Panx1-transgenic animals, the reporter gene LacZ is under control of the Panx1 promoter. Panx1 
promoter activity was evaluated indirectly using β-Gal staining. This method indirectly allows the 
determination of cells expressing Panx1 in tissues. On cryosections, best results were observed by 
fixation of the tissue prior to staining with 0.2 % glutardialdehyde. The signal was absent when using 
acetone or 4 % formaldehyde, and very light after ethanol fixation (not shown). Therefore, 
glutardialdehyde fixation was used in all β-Gal staining experiments on sections. The specificity of this 
staining was tested in studied tissues by comparing the positive signal in transgenic tissues with tissues 
of wildtype animals as negative control. No staining was observed in the negative control (Figure 44). 
 
Figure 44. The specificity of β-Gal staining on cryosections 
Cryosections of spinal cords from 9-day-old mice (P9) were stained with β-Gal staining. The staining 
(blue; arrowheads) was present in transgenic animals Panx1tg/tg (left) and absent in the wildtype 
Panx1wt/wt (right). Fast red staining (red) was used as nuclear stain.  
4.6.2 Panx1-β-Gal expression in spinal cord development 
Panx1 mRNA expression in spinal cord is already described using RT-PCR analysis but little is known 
about its distribution. Panx1 protein distribution has been described only in adult mice using 
immunolabeling (Zappala et al., 2006). The observed β-Gal signal on cryosections allowed studying the 
distribution of Panx1 during the development of spinal cord.  An overview of spinal cord sections 
showed a variation in the distribution of β-Gal-positive cells during the development (Figure 46).  
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To determine how numbers of Panx1-positive cells changed during the development, a direct optical 
quantitative analysis was performed by counting β-Gal-positive cells. The quantification was 
performed on sections of thoracic spinal segments. β-Gal-positive cells were generally observed in the 
gray matter of spinal cord. The density of positive cells was determined at E18.5, P9, P12 and adult 
stages. A higher density of positive cells was observed in embryonic and postnatal stages than in adult 
animals (Figure 45). During early postnatal stages, the density increased significantly from P9 to P12. 
This increase was followed by a significant reduction in adult animals. This result revealed that Panx1 
expression is temporally regulated in spinal cord development.  
Figure 45. Panx1 expression in spinal cord development 
This diagram shows the density of β-Gal-positive cells in spinal cord gray matter. The quantification 
was performed on sections of Panx1tg/tg animals from different stages (E18.5, P9, P12, and adult). The 
number of β-Gal-positive cells increased significantly at postnatal stage P12 and decreased largely in 
the adult. Asterisks indicate a significant difference between groups (*p <0.05, ***p <0.001). Shown 
are mean values ± SEM.  
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Figure 46. Panx1 distribution in spinal cord development 
Cryosections of thoracic spinal segments were stained with β-Gal staining (blue). Sections were 
obtained from different stages E18.5, P9, P12, and adult. Fast red staining (red) was used as nuclear 
stain. In all stages, β-Gal-positive cells were restricted to the gray matter. The highest number of 
positive cells was observed at P12. A gradational distribution appears from dorsal to ventral within 
most stages. The apparently inverse distribution (ventral to dorsal) at E18.5 was not confirmed by 
quantification (see Figure 47). 
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β-Gal-positive cells did not appear to show a homogeneous distribution in the gray matter. Optical 
observation of the overview revealed a graded distribution of positive cells from dorsal to ventral in 
most stages, however, at E18.5 it seemed inverse from ventral to dorsal (Figure 46). To examine this 
observation quantitatively, it was necessary to differentiate between the dorsal region (laminae I-V) 
and the ventral region (laminae VII-X) of the spinal cord at all stages. Determination of the density of 
β-Gal-positive revealed that the dorsal region exhibited more positive cells per area than the ventral 
region at all stages investigated (Figure 47). Within each stage, only P12 spinal cord showed a 
significant reduction from the dorsal region to the ventral region. The dorsal region of P12 spinal cord 
exhibited a significant increase in the number of β-Gal-positive cells compared to other regions and 
stages. On the other hand, both dorsal and ventral regions of adult spinal cord showed the lowest 
number of positive cells compared to all other regions and stages. In contrast, no significant difference 
in cell number was observed within E18.5 and P9 spinal cord or between these two stages.  
Figure 47. Gradational distribution of Panx1 in spinal cord 
The density of β-Gal-positive cells was compared between the dorsal region (laminae I-V) and the 
ventral region (laminae VII-X) of spinal cord. P12 spinal cord exhibited a significant difference between 
dorsal and ventral regions. The number of β-Gal-positive cells was significantly increased in the dorsal 
region of P12 spinal cord compared to all regions of other stages. In contrast, a significant reduction of 
β-Gal-positive cells was exhibited in regions of adult spinal cord. Number of positive cells was not 
significantly different at E18.5 and P9 spinal cord. Asterisks indicate a significant difference between 
groups (*p < 0.05, **p < 0.01, and ***p < 0.001). Shown are mean values ± SEM. 
 
The difference between dorsal and ventral regions was determined from the areal density of β-Gal-
positive cells. Nevertheless, it is unknown whether the areas investigated (dorsal and ventral) have the 
same density of cells. Therefore, the ratio of β-Gal-positive cells to the total number of cells was 
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determined in these regions. This determination was performed on sections of P12 animals, as this 
stage exhibited a significant difference in the density of β-Gal-positive cells between dorsal and ventral 
regions. 
β-Gal staining was performed to determine lacZ expressing cells and nuclear fast red stain was used to 
identify other cells. All cells were counted and the ratio of β-Gal-positive cells was calculated. This 
quantification revealed that the percentage of β-Gal-positive cells was reduced in the ventral area v1 
compared to the dorsal area d1. Only the ventral area v2 (laminae VIII and IX) showed a significantly 
reduction in the percentage of β-Gal-positive cells comparing to other areas (Figure 48, B). For a more 
detailed analysis, the gray matter of P12 spinal cord was subdivided into four areas d1 (laminae I-II), 
d2 (laminae III-V), v1 (laminae VII, and X), and v2 (laminae VIII and IX). The percentage of β-Gal-positive 
cells in the dorsal region (laminae I-V) was significantly higher than in the ventral region (laminae VII-
X) (Figure 48, A). This confirmed the results that the number of β-Gal-positive cells per area was higher 
in the dorsal region than in the ventral part of the spinal cord. 
These results demonstrate that Panx1 expression in spinal cord displays a graded distribution from 
dorsal to ventral at P12. The dorsal region, d1, of lamina (I-III) had the highest number of Panx1-positive 
cells. In contrast, the ventral region, v2, of lamina (VIII and IX) had the lowest number of positive cells. 
 
Figure 48. The ratio of β-Gal-positive cells in the gray matter of P12 spinal cord 
(A) The ratio of β-Gal-positive cells in the dorsal region (laminae I-V) was significantly higher than the 
ventral region (laminae VII-X). (B) Within spinal cord laminae, the percentage of β-Gal-positive cells 
significantly declined from dorsal to ventral. d1 (laminae I-II), d2 (laminae III-V), v1 (laminae VII, and 
X), v2 (laminae VIII and IX). Asterisks indicate a significant difference between groups (***p <0.001). 
Shown are mean values ± SEM.  
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4.6.3 Relative gene expression in adult spinal cord 
The graded distribution of Panx1 protein was analyzed by light microscopy based on β-Gal staining as 
described in the previous section. Another quantitative analysis was performed to compare the 
relative expression of Panx1 mRNA between the dorsal and the ventral region of adult spinal cord. 
Given that Panx1 can associate with several purinergic receptors (Li et al., 2011), the relative gene 
expression of the receptors P2X3R and P2X7R was also analyzed in spinal cord samples. Based on the 
evidence that Panx2 showed co-expression with Panx1 in several regions of adult rat brain (Vogt et al., 
2005), the association of Panx1 with Panx2 expression was also investigated in studied regions of spinal 
cord. The reference gene 18S rRNA was used as an internal calibrator. 
The cranial thoracic region of spinal cord was sagittally divided into two parts, the dorsal region (lamina 
I-V) and the ventral region (lamina VII-X). As described above, lamina VI is absent in the thoracic region 
of mouse spinal cord. RNA was extracted from these parts. This experiment was performed using 
samples of three adult animals (n=3). Samples were analyzed at the same time using a 96-well PCR 
plate.  
In terms of Panx1 expression, results were different from the quantitative results of β-Gal-positive cells 
as described above. Panx1 expression in the dorsal region was significantly lower than in the ventral 
region (Figure 49). This expression pattern was also reflected by purinergic receptors P2X3R and 
P2X7R. In contrast, Panx2 expression in the dorsal region was significantly higher than in the ventral 
region. 
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Figure 49. Relative gene expression in adult spinal cord 
In the thoracic region of adult spinal cord, the relative mRNA expression of Panx1, Panx2, P2X3R, and 
P2X7R in the dorsal region was compared with the ventral region using real time qPCR analysis. Panx1 
mRNA expression level in the ventral region was significantly higher than in the dorsal region. P2X3R 
mRNA and P2X7R mRNA exhibited a similar expression pattern; mRNA expression in the dorsal region 
shows significantly lower expression than in the ventral region. In contrast, the highest expression level 
of Panx2 mRNA was in the dorsal region. 18S rRNA was used as reference gene. The asterisk indicated 
a significant difference between groups (**p < 0.01). Shown are mean values ± SEM. 
4.6.4 Histological analysis of transgenic spinal cord 
Panx1 expression during development of the spinal cord led to examine whether the lack of Panx1 also 
caused a phenotypic change. As quantitative analyses of β-Gal staining showed the highest number of 
Panx1-positive cells in postnatal stage P12, the thoracic region of this stage was histologically analyzed.  
This analysis was performed on two groups of animals: wildtype and Panx1tg/tg. Each group included 
samples of three P12 animals (n=3). Paraffin sections of spinal cord were stained using Masson Goldner 
staining which allows a differentiated visualization of tissues. Nuclei were stained dark brown, 
cytoplasm and muscle fibers were stained red, and connective tissue appeared in green (Figure 50). 
Using light microscopic analysis on sections of three animals from each group, no morphologic 
alterations were observed in transgenic animals compared to wildtype animals. In all sections, cells 
exhibited similar distribution in the gray and white matter. Cytoplasm appeared more dark red in the 
gray matter than in the white matter. The spinal cord was surrounded by a connective tissue shown in 
green. This analysis did not give any indication of a morphological changes in spinal cord caused by 
Panx1 deficiency. 
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Figure 50. Histological analysis of transgenic spinal cord 
Paraffin sections of the thoracic region of spinal cord were obtained from P12 animals: Panx1wt/wt (A) 
and Panx1tg/tg (C). Insets in A and C are shown at higher magnification in B and D, respectively. Sections 
were stained using Masson Goldner staining. The microscopic analysis did not show any obvious 
morphologic changes in transgenic animals compared to wildtype tissues. *The asterisk indicated a 
sectioning artifact. Nuclei (dark brown), cytoplasm (red) and connective tissue (green).  
4.6.5 Panx1 expression in dorsal root ganglia 
Panx1 expression in DRGs has not been described previously. In this study, Panx1 in DRGs was firstly 
observed in sections of E11.5 embryos; vibratome sections post whole-mount in situ hybridization 
showed a very light signal. β-Gal staining confirmed Panx1 expression in DRGs from this stage. Sections 
of paraffin blocks after whole mount β-Gal staining exhibited β-Gal signal in DRGs. For further 
determination of Panx1 expression in DRGs, a quantitative analysis was performed on stained 
cryosections of DRGs. Analyzed ganglia were obtained from the thoracic region of P9 transgenic 
animals Panx1tg/tg (Figure 51). Cryosections were stained with β-Gal staining. The size of β-Gal-positive 
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and -negative neurons was measured in all neurons whose nuclei were visible in the section. Positive 
neurons were sorted and grouped by size in increments of 50 µm. The same was done for all neurons 
(positive and negative neurons). The number of neurons in each group was determined. β-Gal-positive 
neurons were observed in all groups (Figure 52). This made 40 % of all neurons in each group (± 10 %) 
(not shown). In most sections, some satellite glia cells (3 ± 1) were identified as β-Gal-positive. Panx1 
was expressed in all types of neurons in DRGs. The percentage of Panx1-positive cells was similar in all 
neuronal cell types.  
 
Figure 51. Panx1 expression in DRG of P9 mice 
β-Gal staining was performed on cryosections of DRG from P9 Panx1tg/tg animals. β-Gal staining (blue) 
was observed in many neuronal cells (arrowhead) and some satellite glia cells (arrow). Three glia cells 
(± 1) were β-Gal-positive per section. Positive neurons showed different signal intensity. 
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Figure 52. Size-frequency distribution of Panx1-positive neurons in DRGs of P9 mice 
A diagram shows β-Gal-positive neurons and their size-frequency distributions comparing to all 
neurons in DRG of P9 transgenic animals Panx1tg/tg. β-Gal-positive cells were present in all groups of 
neurons except one group (951-1000). Asterisks indicated a significant difference between β-Gal-
positive neurons (black columns) and all neurons (gray columns) within a group (*p < 0.05 and **p < 
0.01). Shown are mean values ± SEM. 
4.6.6 Relative Panx1 expression in sensory ganglia 
As described above, Panx1 was observed in trigeminal ganglion and in all DRGs using whole mount β-
Gal staining. Based on the fact that neurons in each sensory ganglia relay information from a discrete 
dermatome, the relative gene expression of Panx1 was compared between sensory ganglia of different 
regions. This included the trigeminal ganglion and dorsal root ganglia of cervical, thoracic and lumbar 
regions. Nine mice were used for this experiment. Ganglia of each region were pooled from three mice 
to obtain enough RNA. These groups were used to replicate experiments three times (n=3). Using an 
equal quantity of RNA, cDNA syntheses of all regions were performed in one preparation for all 
samples. The relative expression of Panx1 was determined in all regions of ganglia at one time. 18S 
rRNA expression was used as reference gene in all experiments. 
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Panx1 showed different expression levels within sensory ganglia of different spinal cord regions (Figure 
53). Cervical and thoracic ganglia exhibited significantly higher expression levels than trigeminal 
ganglia. Within DRGs, the expression level increased in cervical and thoracic ganglia and was reduced 
in lumbar ganglia. 
Figure 53. The relative expression of Panx1 in sensory ganglia 
Panx1 expression increased significantly in cervical and thoracic ganglia and a reduced thereafter in 
the lumbar ganglia. The lowest expression level appeared in trigeminal ganglia. 18S rRNA was used as 
reference gene. Asterisks indicate a significant difference between groups (**p < 0.01, and ***p < 
0.001). Shown are mean values ± SEM. 
4.6.7 Relative P2X3R expression in sensory ganglia 
Panx1 can associate with several purinergic receptors (Li et al., 2011). P2X3R is the major purinergic 
receptor expressed in the soma of sensory ganglia (Huang, Gu and Chen 2013). It has higher expression 
levels in trigeminal ganglia and DRGs than other purinergic family members (Xiang et al., 1998). P2X3R 
immunoreactivity exhibits more intensity in small-diameter than large- diameter neurons (Xiang et al., 
1998). In this context, the relative expression of P2X3R was investigated in studied regions (see Chapter 
4.6.6) of sensory ganglia to compare its expression with that of Panx1. P2X3R showed diverse 
expression levels within sensory ganglia. A significantly lower expression level of P2X3R was observed 
in trigeminal ganglia compared to cervical and thoracic DRGs (Figure 54). Within DRGs, the thoracic 
region exhibited the highest expression level of P2X3R, which was decreased significantly in the lumbar 
region. These results revealed that relative expression levels of Panx1 and P2X3R are very similar within 
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sensory ganglia of different spinal areas. This provided hints that these genes might be associated in 
sensory ganglia. 
Figure 54. The relative expression of P2X3R in sensory ganglia 
P2X3R exhibited the lowest expression level in trigeminal ganglia. This expression level increased 
significantly in cervical and thoracic ganglia and reduced significantly in lumbar ganglia. 18S rRNA was 
used as reference gene. Asterisks indicate a significant difference between groups (*p < 0.05, and ***p 
< 0.001). Shown are mean values ± SEM. 
4.6.8 Relative P2X7R expression in sensory ganglia 
In contrast to P2X3R, the purinergic receptor P2X7 was abundantly expressed in satellite glia cells 
(Figure 55), whereas a limited P2X7R expression was found in neurons (Chen et al., 2008). As described 
above, Panx1 can be associated with P2X7R and activated by ATP stimulation of P2X7R. Therefore, 
P2X7R expression in sensory ganglia was investigated to determine its expression, as it was done for 
Panx1 and P2X3R. Within studied regions of sensory ganglia, P2X7R showed a different expression 
pattern than Panx1 and P2X3R. The highest expression level of P2X7R was observed in trigeminal 
ganglion, followed by decreasing expression in cervical, thoracic and lumbar ganglia (Figure 56). 
Lumbar ganglia exhibited a significantly lower expression level than other ganglia. This experiment 
revealed that P2X7R showed reduced expression compared to P2X3R and Panx1 in sensory ganglia.  
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Figure 55. P2X7R expression in sensory ganglia 
Immunolabeling of P2X7R in DRGs of an adult mouse showed a specific signal (red staining) in satellite 
glia cells (arrowheads). Neurons (N) did not exhibit P2X7R immunoreactivity. The erd staining observed 
in the the negative control without the primary antibody was considered non-specific. DAPI was used 
as nuclear dye (blue). 
 
Figure 56. The relative expression of P2X7R in sensory ganglia 
The relative expression of P2X7R was higher in trigeminal ganglia than in DRGs. Within DRGs, the 
expression level declined significantly from cervical to lumbar ganglia. 18S rRNA was used as reference 
gene. Asterisks indicate a significant difference between groups (**p < 0.01, and ***p < 0.001). Shown 
are mean values ± SEM.  
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5 Discussion 
Panx1, one member of the gap junction protein family, forms transmembrane channels. Panx1 protein 
has a similar topology as connexins and innexins (Ambrosi et al., 2010) by forming four transmembrane 
domains and by oligomerization into hexameric channels (Boassa et al., 2007). Topologically, Panx1 
channels differ from connexins and innexins by possessing N-glycosylation sites on the second 
extracellular loop (Boassa et al., 2007, Penuela et al., 2007). Panx1 channels can also be 
pharmacologically distinguished from connexin hemichannels using probenecid (Silverman et al., 
2008), a Panx1 inhibitor, or the connexin and Panx1 blocker carbenoxolone (Bruzzone et al., 2005)  
Panx1 channels, however, allow the passage of ions and small molecules between the cytoplasm and 
the extracellular space (Dahl and Keane, 2012). The purine nucleotide (ATP) is the major molecule 
released via Panx1 channels (Dahl et al., 2013). This molecule was found to be released from neural 
progenitor cells of mouse fetal neurospheres in episodic burst events (Lin et al., 2007). ATP mediates 
purinergic signaling, which regulates neural progenitor cells expansion and neurogenesis (Lin et al., 
2007). Extracellular ATP, on the other hand, showed a mitotic effect on cells of the subventricular zone 
after ATP infusion into the lateral ventricle of an adult mouse brain (Suyama et al., 2012). 
These data have led to the suggestion that Panx1 might be implicated in the neurogenesis by ATP 
releases. In this context, Panx1 protein was found to be expressed in a variety of tissues including the 
nervous system, for instance, in the subventricular zone of the lateral ventricles during postnatal 
(Wicki-Stordeur et al., 2012) and adult neurogenesis (Wicki-Stordeur and Swayne, 2013). During 
postnatal neurogenesis, Panx1 showed regulation in the proliferation of neural stem and progenitor 
cells (Wicki-Stordeur et al., 2012). Panx1 was also involved in cell migration and neurite extension 
during adult neurogenesis (Wicki-Stordeur and Swayne, 2013). 
In mouse development, Panx1 mRNA expression has been described in late stages (from E13.5 
onwards), whereas no description of Panx1 expression has been reported in early stages of 
neurogenesis (up to E12.5). To determine the role of Panx1 in early development, Panx1 mRNA 
expression was investigated in this study in early embryonic stages (E9.5, E10.5, E11.5 and E12.5) using 
RT-PCR and whole-mount in situ hybridization. These methods revealed that Panx1 was particularly 
expressed in the developing nervous system. This finding has brought attention to investigate the 
temporal and the spatial expression of Panx1 protein. Analysis of Panx1 protein distribution showed 
Panx1 expression in post-mitotic neurons of developing spinal cord and sensory ganglia. In addition, 
Panx1 expression was examined using Panx1-transgenic mice (Panx1tg/tg). 
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In the second part of the study, the profile of Panx1 expression in spinal cord and dorsal root ganglia 
was investigated using the activity of the reporter gene LacZ in Panx1tg/tg transgenic mice. Panx1 
showed a graded distribution in the gray matter of the spinal cord. All sizes of neurons exhibited Panx1 
expression in DRGs. Furthermore, the relative mRNA expression of Panx1 and purinergic receptors of 
P2X3 and P2X7 was comparatively analyzed in spinal cord and sensory ganglia to determine Panx1 
expression in studied regions selected questions were also addressed for Panx2. 
5.1 The temporal expression of pannexin mRNA in mouse 
development 
Panx1 mRNA expression in mouse development has previously been described in late stages (from 
E13.5 onwards) (Baranova et al., 2004, Ray et al., 2005). Quantitative analysis showed an increase in 
the expression level from E14 to E18 in the cortex, cerebellum and eye (Ray et al., 2005). On the other 
hand, pannexin expression has not yet been described in early stages (up to E12.5) of mouse 
development. Thus, the first aim of this study was the analysis of the expression of Panx1 and Panx2 
mRNA in early stages (E9.5, E10.5, E11.5 and E12.5) of mouse development. At E9.5, whole embryos 
were used for analysis, whereas at later stages (E10.5, E11.5 and E12.5), head and body were analyzed 
separately. RT-PCR results revealed that Panx1 and Panx2 are expressed in early stages of mouse 
development.  An equal quantity of cDNA was used of all samples for PCR analysis. This was confirmed 
through detection of the reference gene 18S rRNA. As head and the body still resulted in different 
amplification product intensities, both samples might express Panx1 and Panx2 at different level. These 
results provide the first evidence that Panx1 and Panx2 expression occurs as early as E9.5 and, thus, 
provides hints that pannexins might be involved in early neurogenesis of the nervous system. Based 
on these results, the next aim was to investigate the spatial distribution of Panx1 mRNA.  
5.2 The spatial expression of Panx1 mRNA in mouse 
development 
In previous studies, the earliest description of Panx1 mRNA was in the brain of E13.5 embryos 
(Baranova et al., 2004); in situ hybridization signal was stronger in the CNS than in other tissues. In the 
brain of an E18 mouse embryo, in situ hybridization analysis revealed that Panx1 was strongly 
expressed in the cortical plate and subplate as well as in the hippocampus (Ray et al., 2005). In rat 
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embryo at E14 and E17, radioactive in situ hybridization analysis revealed Panx1 expression in the brain 
and spinal cord (Vogt et al., 2005).  
In this study, the distribution of Panx1 mRNA is described in detail in earlier stages of mouse 
development, particularly at E9.5, E10.5, and E11.5. At these stages, whole mount in situ hybridization 
was successful. However, no hybridization signal was obtained in an E12.5 embryo, although a specific 
signal was observed in the positive control detecting MyoD mRNA at the same age. The purple staining 
of the Panx1 cRNA probe was restricted to cephalic ventricles, whereas no staining was observed in 
the body. This observation did not confirm RT-PCR results, detecting Panx1 expression also in the body. 
In view of the increasing size of the embryo, these results suggest that the Panx1 cRNA probe might 
not have reached its target because of longer diffusion distances. The MyoD probe, in turn, might have 
reached its target within surface muscles more easily. In contrast, the target of Panx1 cRNA probe is 
located inside the embryo and is protected through recently developed tissues which might hinder the 
passage of cRNA probe its target in late stages (from E12.5 onwards). 
On the other hand, the staining obtained with the antisense Panx1 Ct probe was in general much lower 
than that of the antisense MyoD probe. This might either indicate a lower diffusion or binding 
efficiency of the probe, or indicate that the expression level of Panx1 might be lower than the MyoD 
expression. This can be determined by comparing the expression of both genes using quantitative 
analyses e.g. real time qPCR. 
WM-ISH experiments confirmed RT-PCR results in that Panx1 mRNA is expressed in the head and the 
body of most studied stages. The expression level increased clearly during development, based on the 
intensity of the stain. In studied stages, Panx1 is expressed generally in the nervous system as well as 
in regions outside of the nervous system, which will be discussed in detail (see below). 
5.2.1 Panx1 mRNA expression in the telencephalon 
The cerebral hemispheres develop from the wall of the telencephalic vesicle during cortical 
neurogenesis, which occurs from E11 to E17 during mouse development (Vitalis et al., 2013). At E9.5, 
the telencephalic wall consists initially of bipolar neuroepithelial cells, which proliferate intensely 
without entering neurogenesis. Some neuroepithelial cells switch from proliferation to neuron-
generation at E10.5 of mouse development (Iacopetti et al., 1999). At these stages, particularly E9.5, 
a very light hybridization staining was observed in the wall of the telencephalic vesicle. The expression 
became stronger in the E10.5 embryo and the most intense staining of this region appeared in the 
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E11.5 embryo. At this stage, cortical neurogenesis begins in the ventricular zone (VZ) by generating 
radial glial cells and post-mitotic neurons. Newly generated neurons migrate along radial glial cells 
through the subventricular zone to reach their target in the cortical laminae (Sanes et al., 2011). In this 
study, the purple staining of hybridization was observed in vibratome sections on the apical site of the 
ventricle wall, suggesting that Panx1 is expressed in the ventricular zone at the beginning of 
neurogenesis. 
Panx1 expression in the wall of telencephalic vesicle in these stages suggests that Panx1 expression is 
present at the onset of the cortical neurogenesis. Bearing in mind that Panx1 remains expressed in the 
cortex throughout development and reaches the highest level at E18 (Ray et al., 2005), Panx1 is present 
during the whole period of cortical neurogenesis. This suggests that Panx1 might play a role in the 
development of the cortex. 
5.2.2 Panx1 mRNA expression in the mesencephalon 
Panx1 expression has previously been described in many regions of the adult mesencephalon, i.e. in 
the superior and inferior colliculus, substantia nigra as well as in the nucleus of the oculomotor nerve 
(Ray et al., 2005, Zappala et al., 2006). In this study, Panx1 was observed in the roof plate as well as in 
the basal plate of the mesencephalon at E11.5. The expression increases during development and 
appears most clearly in E11.5 embryos. Motor neurons in the oculomotor nucleus (III) originate from 
the basal plate and differentiate between E10 and E12 of mouse development (Wurst and Bally-Cuif, 
2001). This suggests that Panx1 in the mesencephalic basal plate might be expressed in motor neurons 
of cranial nerve (III) at this stage. Therefore, Panx1 might play a role in the development of midbrain. 
5.2.3 Panx1 mRNA expression in the metencephalon 
The cerebellum develops in the anterior part of the hindbrain (metencephalon) from two regions, the 
roof plate of the fourth ventricle (ventricular zone) and the rhombic lip of the first rhombomere. The 
ventricular zone gives rise to all GABAergic inhibitory neurons, including Purkinje cells, Golgi cells, 
stellate cells, and basket cells, as well as Bergmann glia cells. The rhombic lip, in turn, gives rise to all 
excitatory glutamatergic neurons, including progenitor cells of granule cells (Basson and Wingate, 
2013). At E11.5, these progenitor cells migrate tangentially from the rhombic lip over the ventricular 
zone to accumulate in a layer named the external granule cell layer (egl) (Figure 57) (Martinez et al., 
2013). During postnatal cerebellar development, generated granule cells migrate radially inwards 
along fibers of Bergmann glia cells to form the internal granule layer (Xu et al., 2013). On the other 
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hand, cells in the ventricular zone, e.g. Purkinje cells, become post-mitotic between E10 and E13 
(Namba et al., 2011, Hawkes, 2012) and migrate along radial glia cells toward the pial surface. 
 
 
Figure 57. Schematic representation of cerebellum development 
The cerebellum originates from two regions: the ventricular zone and the rhombic lip. The ventricular 
zone (vz) gives rise to all GABAergic neurons including Purkinje cells (pc), which migrate radially 
outward. The rhombic lip (rl) gives rise to glutamatergic neurons of granule cell precursors and neurons 
of the deep cerebellar nucleus (dcn), which migrate tangentially from rl over the vz to form the external 
germinal layer (egl). Postnatal, cells in the egl migrate radially inwards to the internal granule layer 
(igl). Taken from Basson and Wingate (2013) . 
 
Quantitative analysis showed a high expression level of Panx1 in the cerebellum of E16 and E18 
embryos compared to postnatal stages (Ray et al., 2005, Ray et al., 2006). There are, however, no data 
showing the cellular Panx1 distribution in embryonic stages. In the mature cerebellum, Panx1 is 
expressed in Purkinje neurons and Bergmann glia cells as well as in Golgi neurons of the granular cell 
layer (Ray et al., 2006, Zappala et al., 2006, Cone et al., 2013).  
In this study, Panx1 mRNA expression was observed on the lip of the rhombencephalon in E10.5 
embryos. The expression was more clearly visible in E11.5 embryos, not only in the rhombic lip but 
also in the ventricular zone, anterior to the first rhombomere. This suggests that Panx1 is expressed in 
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the early cerebellar neurogenesis in progenitors of both GABAergic and glutamatergic neurons. It 
appears that Panx1 expression in progenitors of glutamatergic neurons is restricted to the progenitors 
of granule cells during embryogenesis, as Panx1 is not observed in mature granule cells (Ray et al., 
2006, Zappala et al., 2006). On the other hand, Panx1 is still expressed in mature GABAergic neurons. 
From the basal plate of the metencephalon originate motor neurons of the trochlear nucleus (IV) 
(Wurst and Bally-Cuif, 2001). Panx1 expression in the basal plate of the metencephalon suggests that 
Panx1 might be expressed in motor neurons of the cranial nerve IV at early stages. Panx1 might play a 
role in the development of this cranial nerve nucleus. 
5.2.4 Panx1 mRNA expression in the myelencephalon 
The segmentation of rhombomeres appears in early hindbrain development (see Chapter 4.3.2). Each 
rhombomere gives rise to motor neurons, which belong to a defined cranial nerve, e.g., progenitor 
cells in rhombomeres r2 and r3 give rise to motor neurons of the trigeminal nerve V, which innervates 
radially muscles (Sanes et al., 2011). 
For various connexin isoforms, characteristic spatiotemporal expression patterns were described in 
hindbrain development. Connexin 31 was the first connexin discovered in hindbrain development 
(Dahl et al., 1997). Cx31 shows a segment-specific expression in a very short developmental window 
between E8 and E11. The expression is restricted to two rhombomeres (r3 and r5) only (Jungbluth et 
al., 2002). Cx43 is also expressed in hindbrain development from E9.5 onward, visible as longitudinal 
stripes in the medial hindbrain from rhombomere 1 onwards. On the other hand, Cx36 expression 
starts later, from E10.5 onwards, and is visible as continuous columns posterior to rhombomere 4  
(Jungbluth et al., 2002).  
In this study, Panx1 was not detectable in the rhombencephalon of E9.5 embryos. Expression was 
firstly detected at E10.5. The spatial expression of Panx1 was very similar to that of Cx36 expression in 
the lip of rhombomeres. However, Panx1 showed a homogenous expression in all rhombomeres of 
E11.5 embryos, not only in posterior rhombomeres as described for Cx36. Interestingly, Cx36 has been 
found to regulate neuronal differentiation of neural progenitor cells in vitro (Hartfield et al., 2011). 
Because of the similar spatial and temporal expression of Cx36 and Panx1, one might hypothesize a 
comparable role in myelencephalic neurogenesis. 
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5.2.5 Panx1 mRNA expression in the spinal cord 
In spinal cord development, spinal progenitor cells in the ependymal layer proliferate and give rise to 
post-mitotic neurons (Arber, 2012). Neurons, which are derived from different progenitor cells, 
migrate radially to their target destination in the mantle layer. Migrated neurons create laminal 
subpopulations in the gray matter of spinal cord. Many connexin isoforms are expressed during spinal 
cord development. Cx36, Cx37, Cx40, Cx43, and Cx45 expression was observed in E15 and E18 rat 
embryos (Chang et al., 1999). These connexins exhibit a different spatial distribution within the dorsal 
and ventral horn. On the other hand, there is to date only one publication stating Panx1 mRNA 
expression in embryonic spinal cord: Panx1 was observed in sagittal sections of E14 and E17 rat 
embryos using radioactive in situ hybridization (Vogt et al., 2005). 
In this study, Panx1 expression was detected firstly in the truncal region of E9.5 embryos. The 
expression increased and spread towards the caudal region of the E10.5 embryo. In E11.5 embryos, 
Panx1 was observed in all spinal segments. Transverse vibratome sections of E11.5 embryos post WM-
ISH showed a very light Panx1 signal in the mantle layer of the ventral horn. No labeling was detectable 
in the ependymal layer. These results were confirmed by β-Gal staining, which appeared in the mantle 
layer of all spinal segments. The absence of Panx1 expression in the ependymal layer gives a hint that 
Panx1 might be not implicated in cell proliferation during spinal cord development, as most cells in the 
mantle layer are already post-mitotic.  
5.2.6 Panx1 mRNA expression in sensory ganglia 
Panx1 expression in sensory ganglia has been firstly noted by Baranova et al. (2004) . Panx1 was 
observed in trigeminal ganglia and DRGs in a sagittal section of an E13.5 embryo using in situ 
hybridization. There are no further descriptions about Panx1 expression in embryonic stages of sensory 
ganglia development. As mentioned above (see Chapter 1.3.1), neural progenitors of trigeminal, 
geniculate, spiral and vestibular ganglia start migrating from their placodes and neural crest at the 
beginning of neurogenesis between E8.5 and E9 to form an accumulation of ganglion tissues. 
In this study, Panx1 mRNA expression was observed in cranial ganglia immediately after the beginning 
of neurogenesis, i.e. in trigeminal ganglion and in the facio-acoustic ganglion complex (VII-VIII) of E9.5 
embryos. The expression increased during development within studied stages, the highest expression 
was observed in E11.5 embryos. This observation was confirmed in vibratome sections, which also 
revealed an additional expression site at the inferior ganglion of the vagus nerve (not shown). This 
ganglion had previously not been observed by photographing whole-mount embryos. Even the 
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expression in DRGs was observed for the first time in vibratome sections as a very light staining of in 
situ hybridization. This signal was also confirmed in paraffin-blocks after β-Gal staining. These results 
are in concordance with other recent studies, showing Panx1 expression in many cranial ganglia of 
adult rodents, e.g. in trigeminal ganglion (Hanstein et al., 2013), in the nodose-petrosal-jugular 
complex (Retamal et al., 2014), in spiral and vestibular ganglia (Tang et al., 2008). 
This study, however, also revealed that Panx1 mRNA is expressed in most sensory ganglia, including 
cranial nerve sensory ganglia and dorsal root ganglia, immediately after the beginning of the 
neurogenesis, and that its expression increases during development. 
5.2.7 Panx1 mRNA expression in the developing eye and ear 
Panx1 showed, in previous studies, a stable expression during cochlea development from E16.5 to P45 
using RT-PCR (Tang et al., 2008). In E16.5 embryos, Panx1 was observed in epithelial cells of the 
developing organ of Corti  (Tang et al., 2008). In this present study, Panx1 expression appeared in the 
inner side of the otic vesicle at E11.5. The otic vesicle gives rise to the cochlear duct (Phippard et al., 
1999), suggesting that Panx1 might play a role in the development of the cochlear duct. In adult 
cochlea, Panx1 is also expressed in the organ of Corti and in further regions e.g. in the spiral limbus as 
well as in inner and outer sulcus cells (Tang et al., 2008, Wang et al., 2009). It is well known, on the 
other hand, that mutations in connexins can cause the deafness in human patients and animal models 
(Sanchez and Verselis, 2014). In the human genome, the location of nonsyndromic sensorineural 
deafness DFNA11 region on loci 11q12.3–q21 overlaps with the Panx1 gene location on chromomsome 
11q14.3 (Wang et al., 2009). Panx1 was shown to be expressed in the inner ear (Wang et al., 2009). 
However, calcium signals showed identical propagation in organotypic cochlear cultures of wildtype 
and Panx1-deficient mice (Anselmi et al., 2008). Thus, the functional role of Panx1 in hearing 
physiology still needs to be elucidated. 
In the optic cup, it was difficult to distinguish the purple staining in WM-ISH from the retinal pigment. 
In contrast, β-Gal staining was easily distinguishable in E11.5 embryos. This staining revealed that 
Panx1 is expressed in the eye of E11.5 embryos. In a previous study, quantitative analysis of Panx1 
expression in the eye showed that Panx1 expression increased during mouse development from E14 
to E18 and declined thereafter sharply in postnatal and adult stages (Ray et al., 2005). The β-Gal signal 
observed in the optic cup indicates Panx1 expression in the retina at early stages. Thereby, Panx1 might 
be involved in the development of the retina. Its function might be comparable to that of Cx43 in 
retinal development (Cook and Becker, 2009). Cx43 has been found to regulate the proliferation of 
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retinal neuronal progenitors in the retinal pigment epithelium of chicken embryos at E5 (Pearson et 
al., 2005). 
5.2.8 Panx1 mRNA expression in the branchial arch and forelimb plate 
Panx1 is clearly expressed in the surface ectoderm of the first branchial arch and in the apical 
ectodermal ridge (AER) of the developing forelimb in E11.5 embryos. Panx1 expression in embryonic 
skin was previously reported in dermis and epidermis of E13.5 mouse embryos (Celetti et al., 2010). 
The expression level of Panx1 was reduced in the adult skin compared to postnatal stages (Celetti et 
al., 2010). In neonatal skin, keratinocytes, fibroblasts and hair follicles exhibit a high expression level 
of Panx1. Panx1 regulates keratinocyte migration and dermal fibroblast proliferation (Penuela et al., 
2014a). Panx1 deletion resulted in dysregulation of keratinocyte migration and increasing proliferation 
of dermal fibroblasts (Penuela et al., 2014a). Moreover, Panx1 was expressed in the AER which directs 
outgrowth of the limb along the proximal axis (Casanova et al., 2011). This expression at the 
ectodermal ridge might provide hints that Panx1 is involved in skin development or that it might guide 
the outgrowth of the apical ridge through the interaction between Panx1 and cytoskeletal proteins β-
actin and arp3 (actin related protein 3) (Wicki-Stordeur and Swayne, 2013). 
5.3 Panx1 protein expression in mouse development 
Panx1 mRNA expression was temporally and spatially investigated in mouse development. To date, 
Panx1 protein expression had not been reported at these early stages (E9.5 – E12.5). A polyclonal 
antibody against Panx1 (antiserum) was generated in the rabbit and used to detect Panx1 protein. 
The antiserum detected multiple protein bands using the method of immunoblotting. The intensity of 
the immunoreactive products was reduced using antiserum pre-absorbed with Panx1-synthetic 
peptides used to generate the antibody. The antiserum required a long pre-incubation time for a 
complete blocking. A forty-times excess of peptides did not block the antiserum completely after a 
short pre-incubation time of two hours, whereas a tenfold excess of peptides was able to block binding 
completely after a prolonged incubation time of 48 hours. However, immunolabeling required more 
peptides (60x) for complete blocking than immunoblotting (10x peptides), as antibody concentrations 
for immunolabeling are generally chosen higher than for immunolabeling. 
The antiserum showed specific detection on cryosections of defined tissues. In the cerebellum, the 
antiserum detected Panx1 protein in Purkinje cells and in cells of the granule cell layer. This confirms 
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the description by Ray et al. (2005) and Zappala et al. (2006). Additional positive cells were also 
detected in the molecular cell layer. These positive cells were also observed using the Mo503 antibody 
(Cone et al., 2011) as recently described by Cone et al. (2013). The antiserum detected Panx1-
immunopositive cells in most retinal layers, which is in agreement with the results published by Ray et 
al. (2005) and Kranz et al. (2013). 
In summary, immunoblotting and immunolabeling analyses demonstrated the specificity of the 
antiserum as based on the comparison to negative controls of preabsorbed antiserum and to PIS.  
5.3.1 The temporal expression of Panx1 protein in mouse development 
Panx1 protein has a molecular mass of 48.07 kDa, but multiple protein bands were exhibited on 
immunoblots of studied stages. Posttranslational modification of Panx1, e.g. glycosylation, can cause 
multiple protein bands on the immunoblot (Boassa et al., 2007, Penuela et al., 2007). This might explain 
the presence of multiple immunoreactive proteins between 46 and 55 kDa observed in the 
immunoblot using the Panx1 antiserum. These proteins were not visible in the negative controls, using 
PIS or preabsorbed antiserum, of body samples, but were visible in all head samples and in the E9.5 
embryo. 
The E9.5 embryo and all body samples exhibited also an immunoreactive product at 32 kDa. This 
product was not detected in the negative control of PIS or by preabsorbed antiserum. It has been 
recently reported that Panx1 can be expressed in three splice variants; Panx1a (48 kDa), Panx1c (40 
kDa), and Panx1d (34 kDa) (Li et al., 2011). However, the protein detected at 32 kDa in the present 
study cannot be the isoform Panx1d (Table 2). This isoform lacks most of the C-terminus (Li et al., 
2011), including the epitope sequence of the peptide used for immunization. Other studies showed 
that the Panx1 sequence includes two caspase cleavage sites (A and B) (Chekeni et al., 2010). Different 
products can be predicted from these two caspase cleavage sites, i.e. proteins of 6, 19, 24, 30, and 42 
kDa (Figure 58). Only the protein products of 6 and 30 kDa can theoretically be detected with the Panx1 
antiserum, as these products include the peptide sequence used for immunization. This suggests that 
the immunoreactive product of 32 kDa might be a cleavage product. No protein product of 6 kDa, on 
the other hand, was detected in the present study.  
On the immunoblot, an immunoraction product was observed at 17 kDa in E9.5 and body samples or 
at 20 kDa in head samples and was not visible in the negative control of PIS or preabsorbed antiserum. 
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This protein, however, is larger than the predicted cleavage product 6 kDa. Therefore, the nature of 
this product is still unknown although it shows Panx1 immunoreactivity.  
Taken together, the data showed that Panx1 protein was expressed in all studied stages in both the 
head and the body. This was also confirmed by RT-PCR results, showing Panx1 mRNA expression in 
these stages. Panx1 protein might be present in different forms during mouse development, e.g. in 
glycosylated and un-glycosylated forms. Penuela et al. (2007) found that glycosylation of Panx1 was 
required for trafficking of the protein from the endoplasmic reticulum into the plasma membrane. This 
suggested that Panx1 might exhibit different subcellular localization, for instance in the cytoplasm and 
in the cell membrane, and these might possibly be associated with different functions during 
development.  
Given that one observed immunoractive product of 32 kDa could present a cleavage product of 
caspase-3, Panx1 might be activated by caspase cleavage (Sandilos et al., 2012). This interaction 
between Panx1 and caspase-3 might also be required during development. Caspase-3 was found to 
play a nonapoptotic function in development (D'Amelio et al., 2010), mediated through regulation of 
neural stem cell differentiation and neurite extention (Fernando et al., 2005). Furthermore, caspase-3 
deficient mice (CPP32-/-) showed a strongly affected nervous system (D'Amelio et al., 2010); E11.5 
embryos of CPP32-/- showed obvious brain aberrations, which were caused by cell number increase. 
These results suggest, that Panx1 might also interact with caspase-3 in nervous system development. 
This hypothesis needs further evaluation. The determination of Panx1 protein distribution in studied 
stages will help understanding Panx1 function during development. 
Figure 58. Predicted caspase cleavage sites in Panx1 protein 
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An illustration of Panx1 indicates the predicted caspase cleavage sites (sites A and B). The predicted 
product of each fragment is shown. CT indicates the epitope of Panx1 antiserum. Modified from 
Chekeni et al. (2010). 
5.3.2 The spatial distribution of Panx1 protein in mouse development 
The spatial distribution of Panx1 protein was investigated in regions of the head and the body of E11.5 
embryos, as Panx1 mRNA was more abundantly expressed at this stage than at E9.5 or E10.5. The 
antiserum detected Panx1 in trigeminal ganglion and in the mantle layer of spinal cord as well as in 
DRGs. No expression was detectable in the dorsal horn and in the ventricular zone as well as in the 
floor plate of spinal cord. This confirmed the distribution of Panx1 mRNA in these regions, and also 
immunoblotting results showing Panx1 protein expression in the head and the body of E11.5 embryos. 
Panx1-positive cells in the mantle layer and in DRGs were co-labeled with the neuronal marker NeuN. 
However, not all NeuN-positive cells in these regions were Panx1-positive. This suggested that Panx1 
protein expression was restricted to a defined cell subpopulation in these regions. The colocalization 
of Panx1 with NeuN indicated that Panx1 is expressed in post-mitotic neurons, which start to 
differentiate into mature neurons. NeuN is expressed in the nucleus and the cytoplasm of neurons at 
the post-mitotic stage (Mullen et al., 1992, Lavezzi et al., 2013). On the other hand, at this stage, the 
ventricular zone represents mitotically active cells, which express the cell cycle protein Ki67 (Battiste 
et al., 2007). In contrast, cells of the mantle layer do not express this protein. This confirmed that Panx1 
is expressed in the region of post-mitotic neurons and is absent in the area of mitotic cells (ventricular 
zone). This is in contrast to the description of Panx1 expression in the developing rat cerebellum. Both, 
proliferating neurons (Ki67-positive cells) and non-proliferating neurons exhibit Panx1 mRNA 
expression (Vogt et al., 2005). This suggests that the role of Panx1 might vary within regions of the 
nervous system during neurogenesis.  
On the other hand, Panx1 might play a role in post-mitotic events of neurogenesis e.g. migration, 
differentiation, or neurite outgrowth. Interestingly, Panx1 shows an influence on cellular behaviors of 
cell migration and neurite extension (Wicki-Stordeur and Swayne, 2013). During postnatal 
neurogenesis, Panx1 regulates negatively neurite outgrowth. Knockdown of Panx1 induces the 
extension of neurites, while Panx1 overexpression inhibits the outgrowth of neurites (Wicki-Stordeur 
and Swayne, 2013). In Neuro-2a cells, Panx1 knockdown reduced cell migration (Wicki-Stordeur and 
Swayne, 2013). This suggests that Panx1 expression in neurons of spinal cord or DRGs during early 
embryogenesis might regulate the extension of neurites or induce migration of neurons to the target 
destination. Other studies showed that connexin hemichannels are involved in spontaneous electrical 
activity, which affects a variety of developmental processes (Moore et al., 2014). The hemichannel 
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blocker carbenoxolone showed a significantly blocked spontaneous activity in the human fetal cortex 
(Moore et al., 2014). Thus, it is of interest to know if Panx1 in post-mitotic neurons contributes also to 
spontaneous electrical activity in spinal cord, which was identified in the motor neuron region at early 
stages of mouse spinal cord development (E11) (Hanson and Landmesser, 2003). This finding requires, 
however, further physiological analysis using a Panx1 blocker, i.e. probenecid. 
5.4 Panx1 expression in transgenic mice 
As described in Chapter 3.2.2, Panx1-transgenic mice (Panx1tg/tg) (Anselmi et al., 2008) and Panx2-
transgenic mice (Panx2tg/tg) (Bargiotas et al., 2011) were generated by inserting the bacterial gene LacZ 
into exon1 of Panx1 and of Panx2 genes via homologous recombination. This insertion is detectable 
by PCR analysis and by β-Gal staining of transgenic tissues. Due to the insertion, mRNA transcription 
of Panx1 and Panx2 is prevented through the insertion of an off-frame stop codon, and, consequently, 
Panx1 mRNA and Panx2 mRNA were not present in Panx1tg/tg and Panx2tg/tg mice, respectively. These 
results confirm the description of Bargiotas et al. (2011) that Panx1tg/tg and Panx2tg/tg express no Panx1 
or Panx2 mRNA, respectively, as determined by real time qPCR and in situ hybridization analyses. 
Panx1 protein expression was not detectable in the retina of Panx1tg/tg mice using immunolabeling 
analysis. This finding confirms that transgenic animals lack Panx1, as immunopositive cells were clearly 
visible in the ganglion cell layer and in the inner nuclear layer of wildtype animals. Thus, these results 
also indicate that the antiserum exhibits a specific signal.  
Using immunoblotting analysis, however, the Panx1 antiserum detected proteins in tissues of 
transgenic animals similar to those observed in wildtype tissues. Proteins with a molecular weight of 
35 and 32 kDa were present in brain and cerebellum lysates of Panx1tg/tg mice, in addition to a protein 
at 14 kDa. Commercial antibodies (Table 2) also detected proteins in Panx1tg/tg similar to those in the 
wildtype. It is difficult to bring these results in line with RT-PCR results of this study or with 
immunoblotting analysis of Bargiotas et al. (2011). 
The sequence of peptides, which were used to generate the Panx1 antiserum, was used in several 
studies (Penuela et al., 2007, Penuela et al., 2009, Bargiotas et al., 2011, Cone et al., 2013, Penuela et 
al., 2014a). Some of these studies used Panx1-deficient animals to examine the specificity of purified 
antibodies. Bargiotas et al. (2011) did not observe immunoractive proteins in brain tissue lysate of 
Panx1tg/tg, using the same animals as in the present study. In other Panx1-deficient animals, described 
by Qu et al. (2011), this purified antibody did not detect any immunoractive proteins in thymus or 
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spleen lysates as described by Penuela et al. (2014a), whereas small protein bands were still detectable 
using brain lysates of these animals (Cone et al., 2013). 
In the study of Cone et al. (2013), the immunoreactivity of several Panx1 antibodies was compared. 
Whereas used antibodies reacted similar by immunolabeling and immunoblotting of cultured cells, 
different immunoreactivities were observed by immunoblotting of brain lysates of knockout and 
control mice. Immunolabeling also showed different subcellular localizations. Dendrites were 
preferably labeled using the antibody against the N-terminus of Panx1, whereas the cell body was 
labeled using antibodies against the C-terminus or the intracellular loop. These differences might be 
due to different subcellular localizations of modified or non-modified Panx1-protein. 
Interestingly, similar results were obtained for Panx2tg/tg animals. Panx2 antibodies displayed a similar 
pattern of immunoreactivity in wildtype and transgenic animals, whereas Panx2 mRNA was not 
present in Panx2tg/tg. These results reflect the finding by Bargiotas et al. (2011), who also found that 
only one generated and purified antibody against Panx2 reacted specifically in transgenic mice, 
whereas two other commercial antibodies reacted unspecifically (Bargiotas et al., 2011). 
Similar data were obtained for Panx1: Numerous antibodies against Panx1 had previously been 
investigated using these transgenic mice (Bargiotas et al., 2011). Six antibodies did not pass the 
immunoblotting test; four of them were commercial antibodies. Only one purified antibody reacted 
specifically. This antibody was directed against the same peptide epitope, which was used for 
immunization in this study. Therefore, it is preferable to purify the antiserum, e.g. using antigen-
specific affinity purification, and analyze the specificity on different tissues from the CNS and other 
organs, e.g. liver or spleen.  
5.4.1 Phenotypic analysis of transgenic spinal cord 
Pannexin mutant animals were used in several studies to determine the role of pannexin in organs or 
diseases. For instance, Panx1 was shown to modulate wound repair upon injury in the neonatal mouse 
skin (Penuela et al., 2014a). Panx1 knockout mice delayed wound healing from dorsal skin (Penuela et 
al., 2014a). In other study, Panx1 appeared to have a pathological role in ischemic retina 
(Dvoriantchikova et al., 2012). Panx1 deletion suppressed the inflammasome and IL-1b production in 
vivo in post-ischemic retinal ganglion cells. Thereby, the loss of retinal ganglion cells was also protected 
by Panx1 deletion (Dvoriantchikova 2012). On the other hand, the role of Panx1 in brain ischemia is 
still not clear (Bargiotas et al., 2011, Cisneros-Mejorado et al., 2015). The propagation of cortical 
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spreading depolarization, which relies on hemichannels or gap junction, was not affected in the 
absence of Panx1 and Panx2 (Bargiotas et al., 2011). In a model of MCAO, however, inhibition or 
deletion of Panx1 significantly decreased the infarct volume and reduced motor symptoms, suggesting 
Panx1 to be a major player in brain damage after ischemia (Cisneros-Mejorado et al., 2015). 
However, Panx1 mutant animals were generally described as viable, and fertile and they did not show 
any obvious developmental or behavioral abnormalities. Histological analyses of neonatal mouse skin 
did not reveal any obvious skin phenotype in Panx1-deficient mice (Penuela et al., 2014a) other than 
changes in the thickness of skin layers. The thickness of epidermal and dermal layers was reduced 
whereas the thickness of hypodermal adipose tissue was increased in Panx1-deficient mice (Penuela 
et al., 2014a).  
Phenotypic analysis of the thoracic region of spinal cord was performed on histological sections. No 
obvious morphologic difference was observed using microscopic analysis on paraffin section after 
Masson Goldner staining. This suggested that in spinal cord, Panx1-deficiency did not result in any 
obvious morphologic phenotype, or that compensatory mechanisms took over, for instance by 
increasing expression of connexin hemichannels.  
5.5 Panx1 gene expression in spinal cord 
Panx1 gene expression in spinal cord was detected indirectly using β-Gal staining. Panx1 distribution 
in spinal cord showed a temporal regulation. The number of Panx1-positive cells was higher in 
postnatal stages (e.g. P12) than in embryonic stages (E18.5) or in adult mice. This expression pattern 
was not identical to the temporal expression of Panx1 mRNA described for cortex and cerebellum 
development (Ray et al., 2005), as the highest level of Panx1 mRNA in these two regions appeared at 
embryonic stage E18 and was reduced from postnatal to adult stages. The reduction of Panx1 
expression from postnatal to adult has also been reported in other regions. In the skin, Panx1 protein 
expression was higher in up to 4-week-old mice than in adult mice (Penuela et al., 2014a). However, 
Panx1 expression was not constant during development and had the lowest level in adult animals. This 
is similar to Cx37 mRNA expression which showed a significant increase in the first two postnatal weeks 
and a reduction in following stages of rat neocortex development (Prime et al., 2000).  
Panx1 was present in all spinal segments of 4-week-old Panx1tg/tg mice. The posterolateral tract 
exhibited intensively the β-Gal staining along the spinal cord. In contrast, Panx1 was not detectable in 
the dorsal funiculus or in the ventral funiculus. 
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Transverse spinal cord sections showed heterogeneous distribution of Panx1 gene expression. Panx1 
showed a graded distribution within the gray matter of studied stages (E18.5, P9, P12, and adult). The 
density of Panx1-β-Gal-positive cells in the dorsal region (laminae I-V) was significantly higher than in 
the ventral region (laminae VII-X) of P12 spinal cord. This was confirmed by the ratio of Panx1-β-Gal-
positive cells to negative cells in these regions. In contrast to the ventral region (lamina VIII and IX), 
the dorsal region (lamina I-III) showed the highest level of Panx1-β-Gal expression according to this 
optical analysis.  
In a previous study, Panx1 protein distribution was immunohistochemically detected only in the 
ventral region of adult spinal cord, i.e. in laminae VII, VIII, and IX (Zappala et al., 2006). Performing β-
Gal staining, however, in this study a positive signal was also detected in dorsal laminae of the spinal 
cord. These differences might be explained by the methodology used. Immunolabeling determines the 
localization of a protein within the cell, whereas β-Gal staining reports the activity of a gene promoter 
without pointing to the localization of the protein. β-Gal staining is generally observed in the cell body 
of positive cells. On the other hand, proteins in the nervous system can be located very distant from 
the cell body e.g. in the periphery of the axon or dendrite. Panx1, for example, exhibits a post-synaptic 
localization in neurons of cortex and hippocampus (Zoidl et al., 2007). This suggests that the Panx1 
protein of dorsal horn neurons might be not located in the cell body but in the periphery outside of 
the spinal cord. This might explain the absence of Panx1 protein in the dorsal horn as reported by 
Zappala et al. (2006), whereas in the ventral horn, Panx1 protein showed a cytoplasmic localization in 
motor neurons (Zappala et al., 2006). Zappala et al. (2006) also provides an alternative explanation for 
the absence of Panx1 protein from the dorsal horn. Panx1 protein in this region might be modified so 
that epitopes for the antibody used are masked and cannot be detected. However, Panx1 protein 
expression in the dorsal horn has been recently reported in lumbar segments of rat spinal cord using 
immunoblotting analysis (Bravo et al., 2014). This finding confirms results in the present study that 
Panx1 is expressed in the dorsal horn of spinal cord. 
Panx1 mRNA and protein are also expressed in non-neuronal cells of the spinal cord. Panx1 
immunoreactivity was detected in cultured astrocytes, which were obtained from postnatal rat spinal 
cord (Garre et al., 2010). Isolated microglia from embryonic spinal cord at E13.5 also exhibited Panx1 
expression (Rigato et al., 2012). In intact animals, microglia seem to be homogeneously distributed in 
both the white and gray matter of spinal cord (Zhang et al., 2008). In the present study, the signal of 
β-Gal staining was restricted to the gray matter; no expression was detected in the white matter of all 
studied stages. Therefore, Panx1 expression in microglia might be very low or absent so that these cells 
are not detectable by β-Gal staining. Generally, β-Gal staining was used for determination of Panx1 
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distribution in spinal cord without defining particular cell types expressing Panx1. As described in 
Chapter 4.6.1, best results of β-Gal staining were obtained using glutardialdehyde fixation. This fixation 
is unsuitable for immunochemical staining, as glutardialdehyde causes an excessive crosslinking of 
proteins and thus antigens will be masked (Renshaw, 2007). Therefore, further analyses of cell types 
expressing Panx1 by double labeling were limited. 
The graded distribution of Panx1 gene expression in spinal cord revealed that the dorsal part of the 
spinal cord exhibited more Panx1-β-Gal-positive cells than the ventral part. This observation, however, 
was not confirmed by the quantitative method of real time qPCR, which revealed that Panx1 mRNA 
expression in the ventral region was significantly higher than in the dorsal region of adult mice. By PCR, 
neural cells of the ventral horn were shown to express more Panx1 mRNA than those of the dorsal 
horn. Thus, the relative expression of Panx1 mRNA is dissimilar to the number of β-Gal-positive cells, 
thereby not allowing the comparison between results. 
In contrast to Panx1 expression, Panx2 exhibited clearly a higher expression in the dorsal region of 
spinal cord than in the ventral region as determined by qPCR analysis. This result revealed that Panx2 
expression in spinal cord shows an expression complementary to Panx1.  
5.5.1 Association of Panx1 and P2X3R and P2X7R in spinal cord 
ATP release is one major role of Panx1 channels (Dahl et al., 2013), and ATP itself is a widespread 
intercellular signaling molecule in the nervous system. This molecule is involved in several 
mechanisms, for instance neurotransmission or regulation of proliferation (Cotrina and Nedergaard, 
2009). On the other hand, Panx1 channels were found being activated via purinergic receptors after 
extracellular stimulation by ATP (Locovei et al., 2006b). P2X7R, a subtype of purinergic receptors, was 
found to be expressed in neurons of the dorsal and ventral horn of rat spinal cord using in situ 
hybridization (Deuchars et al., 2001). The protein of P2X7R showed localization in the presynaptic 
terminal of the intermediolateral cell column of spinal cord (Deuchars et al., 2001). Whereas P2X7R 
has been described to be associated with motor neurons pathways (Deuchars et al., 2001), P2X3R was 
described in association with sensory pathways (Nakatsuka and Gu, 2006). P2X3R protein was 
observed in the superficial laminae (I and II laminae) of the dorsal horn in spinal cord (Novakovic et al., 
1999). 
This led to investigate the association between Panx1 and purinergic receptors in spinal cord. In the 
present study, the relative mRNA expression of P2X3 and P2X7 was compared between the dorsal and 
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the ventral region of spinal cord. Similar patterns were found for the relative expression of both 
receptors P2X3 and P2X7. However, the dorsal region exhibited significantly lower expression levels 
than the ventral region. This expression was similar to the Panx1 mRNA expression pattern in adult 
spinal cord. Bearing in mind that Panx1 was found to be associated with P2X7 receptor in macrophages 
(Pelegrin and Surprenant, 2006), relative mRNA expression results provided hints that Panx1 might be 
also associated with the purinergic receptors P2X3 and P2X7 in adult spinal cord. This association might 
regulate ATP release, which is among other functions involved in peripheral and central nociceptive 
transmissions, including the mechanism of neuropathic pain (Ide et al., 2009).  
In this context, it is of interest that P2X7 receptors were upregulated after peripheral nerve injury. 
P2X7R mRNA and protein were highly expressed in the dorsal horn of spinal cord after peripheral nerve 
injury obtained by transection of the tibial and common peroneal nerves (Kobayashi et al., 2011). The 
intrathecal blockade of P2X7R using a specific antagonist suppressed the development of mechanical 
hypersensitivity for 3 to 7 days after injury (Kobayashi et al., 2011). In a recent study, Panx1 was also 
shown to be involved in the mechanisms underlying central sensitization in neuropathic pain (Bravo et 
al., 2014). The blockade of Panx1 channels in spinal cord through intrathecal injection of 10Panx (a 
mimetic inhibitory peptide of the first extracellular loop blocking Panx1 channels (Pelegrin and 
Surprenant, 2006)), probenecid, or carbenoxolone reduced the spinal C-reflex wind-up reactivity in 
intact animals (Bravo et al., 2014). Furthermore, this blockage reduced also the mechanical 
hyperalgesia in the neuropathic rat for a short time (Bravo et al., 2014).  
The present study revealed that Panx1 is expressed in spinal cord development, in both the dorsal and 
the ventral regions. Panx1 expression is temporally regulated, shows an increase in postnatal and a 
decrease in adult animals, and exhibits a heterogeneous distribution in the gray matter. Panx1 might 
be associated with purinergic receptors of P2X3 and P2X7 in adult spinal cord.   
5.6 Panx1 expression in sensory ganglia 
This study provides the first description of Panx1 distribution in DRGs using β-Gal staining. Panx1 was 
abundantly expressed in all neuronal cell types, i.e. small, intermediate, and large diameter neurons 
of P9 animals. Some satellite glia cells were also β-Gal-positive at this stage (P9). As 40 % ± 10 of all 
neurons were Panx1-positive in each of the neuronal cell types, Panx1 shows a universal expression in 
all cell types of P9 mice. It is unknown, whether Panx1 is still universally expressed or if there is a 
change to the restricted expression in a defined cell type in the adult. For the purinergic receptor 
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P2X3R, expression switches during postnatal development of mice from a universal expression to a 
restricted expression in 47.5 % ± 2.8 of neurons at P14 (Ruan et al., 2004). P2X3R is also expressed in 
small and intermediate neurons (Ruan et al., 2004). Both proteins, Panx1 and P2X3R, show a similar 
ratio of positive neurons in postnatal stages, in addition to their expression in small and intermediate 
neurons. This suggests that Panx1 and P2X3 might be coexpressed in DRGs. This suggestion needs 
further analyses, i.e. immunohistochemistry for both proteins. 
Panx1 expression was observed in all DRGs and trigeminal ganglia of postnatal mice, and Panx1 was 
heterogeneously expressed within these ganglia. Whole mount β-Gal staining of spinal cord with 
attached sensory ganglia showed that all DRGs are β-Gal-positive, as well as the trigeminal ganglion. 
The expression level, however, was significantly higher in thoracic ganglia than in other ganglia. In 
contrast, the trigeminal ganglion showed the lowest expression of Panx1. This expression pattern was 
very similar to the expression pattern of the purinergic receptor P2X3. On the other hand, the 
purinergic receptor P2X7 showed a very different expression pattern within sensory ganglia. The 
expression level of P2X7R was significantly higher in trigeminal ganglion than in DRGs of all regions, 
which showed a graded reduction in P2X7R expression.  
These results revealed that Panx1 is widely expressed is sensory ganglia. In DRGs, Panx1 was universally 
expressed in neurons and very few SGCs were found Panx1-positive. Whereas Panx1 shows an 
association with both purinergic receptors P2X3 and P2X7 in spinal cord, Panx1 in sensory ganglia 
might be associated with P2X3R but not with P2X7R. However, Panx1 expression in the soma provides 
a hint that Panx1 might be involved in the communication between neurons and SGCs, for instance 
through release of second messengers like ATP (Huang et al., 2013).  
Neuronal somata in sensory ganglia are isolated from each other, they are warped completely with 
satellite glial cells (SGCs) forming a structural unit (Hanani, 2005). SGCs communicate with each other 
through gap junctions (Figure 59), which permit electrical and metabolic communication between glial 
cells. On the other hand, no gap junction formation was observed between SGCs and the soma 
surrounded by these cells (Huang et al., 2013). Sensory neurons communicate with associated SGCs 
via the release of transmitters. ATP is the major transmitter in sensory ganglia binding to purinergic 
receptors. P2X7R is the unique subtype of metabotropic receptors expressed in SGCs (Chen et al., 
2012), whereas P2X3R is expressed in small and intermediate sensory neurons (Ruan et al., 2004).  
Released ATP, which serves as a pain mediator (Hamilton and McMahon, 2000), activates P2X7 
receptors in SGCs after painful injury (Zhang et al., 2007). This activation leads to release of tumor 
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necrosis factor-α (TNF-α) from SGCs (Zhang et al., 2007). TNF-α, in turn, binds on receptors on somata 
to increase the excitability of neurons (Ji et al., 2013). Thus, the present study provides hints that ATP 
might also be released from neuronal somata in DRGs via Panx1 channels.  
Further analyses, however, are required to determine the physiological and pathology-associated 
functions of Panx1 in DRGs. It is of interest to determine if Panx1 channels are the main pathway for 
ATP release from neuronal somata in DRGs. If so, the use of Panx1 blockers or the ablation of Panx1 
expression might modulate the neuropathic pain pathway as already demonstrated for the central 
perception of neuropathic pain at spinal cord level (Bravo et al., 2014). This modulation might offer an 
additional opportunity in pain therapy by targeting Panx1 channel activity in dorsal root ganglion 
neurons. 
 
 
Figure 59. Schematic representation of neuronal-glial interaction in DRGs and trigeminal ganglia 
Neuronal somata (blue) are completely surrounded by satellite glial cells (SGCs) (green) forming a 
structural unit. SGCs communicate with each other through gap junctions. There are no gap junctions 
mediating communication between somata and SGCs. ATP is critically involved in neuronal–glial 
communication. A painful injury results in ATP release from somata. ATP activates P2X7 in SGCs and 
leads to release of tumor necrosis factor-α (TNF-α). Persistent nociceptive activity results in matrix 
metalloproteinase-9 (MMP-9) release from primary sensory neurons, which leads to release of 
interleukin-1b (IL-1b) in SGCs. TNF-α and IL-1b bind to receptors on sensory neurons to elicit 
hyperexcitability. Taken from  Ji et al. (2013). 
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6 Conclusion 
The present study revealed that Panx1 mRNA and protein are expressed at early stages of mouse 
development (E9.5, E10.5, E11.5, E12.5). Panx1 mRNA expression increases during development and 
is abundantly distributed in the developing nervous system particularly in the wall of cephalic 
ventricles, cranial nerve ganglia, spinal cord, and dorsal root ganglia. Panx1 protein is mainly expressed 
in post-mitotic neurons of the developing spinal cord and sensory ganglia. This finding suggests that 
Panx1 expression at early stages might contribute to a variety of developmental processes. 
In spinal cord, Panx1 expression is temporally regulated. The highest expression was observed at 
postnatal stages. Panx1 is expressed in all spinal segments and shows a gradational distribution within 
the gray matter. Panx1 mRNA expression is similar to that of purinergic receptors P2X3 and P2X7. An 
association between Panx1 and these purinergic receptors is thought to be of functional importance 
and might be required to induce pannexin channel activation.  
In sensory ganglia, Panx1 mRNA is heterogeneously expressed within DRGs and trigeminal ganglia and 
shows similar expression to that of P2X3R expression but not to P2X7R expression. In postnatal DRGs, 
Panx1 is expressed in all cell types of neuronal somata. Panx1 might mediate purinergic signaling 
between neurons and SGCs by releasing ATP as a peripheral pain mediator. Thus, targeting Panx1 
channels in DRG neurons might be considered in pain research.   
 In conclusion, Panx1 is widely expressed in the developing nervous system during early stages of 
embryogenesis. All segments of adult spinal cord show a graded distribution of Panx1 in the gray 
matter. The newly discovered expression of Panx1 in DRGs requires further functional analysis, 
including its putative involvement in sensory modulation and pain.  
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